<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005">
<channel xmlns:cfi="http://www.microsoft.com/schemas/rss/core/2005/internal" cfi:lastdownloaderror="None">
<title cf:type="text"><![CDATA[Editorial Board of Journal of Pharmaceutical Research -->Clinical Pharmacy]]></title>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[三苯双脒代谢物氨脒和乙酰氨脒人体药代动力学研究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201309021&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:02:31</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[窦学杰<sup>1</sup>,袁桂艳<sup>2</sup>,张蕊<sup>2</sup>,魏春敏<sup>2</sup>,王本杰<sup>2</sup>,郭瑞臣<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>窦学杰<sup>1</sup>,袁桂艳<sup>2</sup>,张蕊<sup>2</sup>,魏春敏<sup>2</sup>,王本杰<sup>2</sup>,郭瑞臣<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201309021&flag=1]]></guid><cfi:id>245</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[玉屏风胶囊治疗过敏性鼻炎随机双盲平行对照多中心临床研究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201309022&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:02:31</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[陈进<sup>1</sup>,魏福荣<sup>1</sup>,聂丽云<sup>1</sup>,谯凤英<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>陈进<sup>1</sup>,魏福荣<sup>1</sup>,聂丽云<sup>1</sup>,谯凤英<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201309022&flag=1]]></guid><cfi:id>244</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[吉诺通辅助治疗儿童重症肺炎临床疗效观察]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201309023&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:02:32</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[路岩莉,孙丹,韩耀巍]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>路岩莉,孙丹,韩耀巍</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201309023&flag=1]]></guid><cfi:id>243</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[富马酸依美斯汀缓释片治疗过敏性鼻炎的有效性和安全性]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201308021&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:02:58</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[庄婕<sup>1</sup>,晁磊<sup>2</sup>,王淑华<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>庄婕<sup>1</sup>,晁磊<sup>2</sup>,王淑华<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201308021&flag=1]]></guid><cfi:id>242</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[卡培他滨联合奥沙利铂治疗结直肠癌的疗效观察]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201308022&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:02:58</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[罗思红]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>罗思红</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201308022&flag=1]]></guid><cfi:id>241</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[质子泵抑制剂的夜间酸突破及治疗对策]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201308023&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:02:58</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[李孝东<sup>1</sup>,陈洪忠<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>李孝东<sup>1</sup>,陈洪忠<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201308023&flag=1]]></guid><cfi:id>240</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[迈之灵片治疗静脉血管疾病临床应用的Meta分析]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201307012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:03:37</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[王俊卿,车欣颖]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>王俊卿,车欣颖</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201307012&flag=1]]></guid><cfi:id>239</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[快律宁治疗阴虚火旺型过早搏动的临床研究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201307013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:03:37</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[于杰<sup>1</sup>,杨传华<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>于杰<sup>1</sup>,杨传华<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201307013&flag=1]]></guid><cfi:id>238</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[《中成药临床应用指导原则》实施前后我院中成药使用情况对比分析]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201307014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:03:37</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[陈翔,陈婉菁]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>陈翔,陈婉菁</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201307014&flag=1]]></guid><cfi:id>237</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[舒利迭联合顺尔宁治疗咳嗽变异型哮喘的疗效观察]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201306019&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:23:01</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[孙超]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>孙超</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201306019&flag=1]]></guid><cfi:id>236</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[植物来源抗肿瘤药联合化疗方案的临床疗效评价]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201306020&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:23:01</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[谢桓<sup>1</sup>,王鸿梅<sup>2</sup>,张鉴<sup>3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>谢桓<sup>1</sup>,王鸿梅<sup>2</sup>,张鉴<sup>3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201306020&flag=1]]></guid><cfi:id>235</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[我院门诊抗高血压药物应用的调查分析]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201306021&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:23:01</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[孙治国]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>孙治国</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201306021&flag=1]]></guid><cfi:id>234</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[缬沙坦联合硝苯地平治疗高血压合并糖尿病的临床观察]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201305024&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:24:14</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[徐光]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>徐光</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201305024&flag=1]]></guid><cfi:id>233</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[霉酚酸酯(MMF)联合中药治疗狼疮肾炎临床观察]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201305025&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:24:14</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[崔明晓,陈彤]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>崔明晓,陈彤</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201305025&flag=1]]></guid><cfi:id>232</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[我院门诊药房处方调剂内部差错的影响因素分析]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201304025&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:25:03</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[陈文珠]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>陈文珠</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201304025&flag=1]]></guid><cfi:id>231</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[单唾液酸四己糖神经节苷脂的临床应用]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201303026&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:25:57</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[段崇英]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>段崇英</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201303026&flag=1]]></guid><cfi:id>230</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[2012年第三季度我院神经内科抗感染药物应用分析]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201302020&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:27:01</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[孙海琼,郑小清,李琼]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>孙海琼,郑小清,李琼</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201302020&flag=1]]></guid><cfi:id>229</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[托烷司琼联合苯海拉明、地塞米松预防肿瘤化疗所致恶心呕吐疗效观察]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201302021&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:27:01</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[宋丽云]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>宋丽云</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201302021&flag=1]]></guid><cfi:id>228</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[专项整治前后Ⅰ类切口围术期抗菌药物使用合理性分析]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201301018&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:29:43</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[王宏虹,毛桂福,黄玉玲,黄金华,谭强]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>王宏虹,毛桂福,黄玉玲,黄金华,谭强</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201301018&flag=1]]></guid><cfi:id>227</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[复方连芩双层缓释药膜辅助治疗小儿手足口病疗效观察]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201301019&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:29:43</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[王风芹,孙迎东,邢树礼,宋征,成文娜,胡丽敏]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>王风芹,孙迎东,邢树礼,宋征,成文娜,胡丽敏</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201301019&flag=1]]></guid><cfi:id>226</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[我院Ⅰ类切口手术患者抗菌药物应用分析]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201312016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:00:20</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[张香菊<sup>1</sup>,龚子东<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>张香菊<sup>1</sup>,龚子东<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201312016&flag=1]]></guid><cfi:id>225</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[2008~2012年我院抗肿瘤药物使用分析]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201312017&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:00:20</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[吴杨,詹三华]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>吴杨,詹三华</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201312017&flag=1]]></guid><cfi:id>224</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[门诊药房用药差错原因分析及应对]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201312018&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:00:20</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[朱增燕]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>朱增燕</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201312018&flag=1]]></guid><cfi:id>223</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[对1例弥漫大B细胞淋巴瘤患者的药学监护]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201312019&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:00:20</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[张欢,张曙光,胡伟]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>张欢,张曙光,胡伟</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201312019&flag=1]]></guid><cfi:id>222</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[我院自制制剂临床使用情况分析]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201312020&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:00:20</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[杜小换]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>杜小换</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201312020&flag=1]]></guid><cfi:id>221</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[我院静脉用药调配中心药品管理体会]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201311023&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:01:00</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[张先明,吴卉,朱文清]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>张先明,吴卉,朱文清</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201311023&flag=1]]></guid><cfi:id>220</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[2012年我院门诊普通处方统计分析]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201311024&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:01:00</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[张玲美,赵济忠]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>张玲美,赵济忠</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201311024&flag=1]]></guid><cfi:id>219</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[提高门诊病人对药学服务满意度的实践与探讨]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201311025&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:01:00</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[刘玉君,李飞,姚文,朱莉]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>刘玉君,李飞,姚文,朱莉</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201311025&flag=1]]></guid><cfi:id>218</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[利用Excel电子表格进行处方点评]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201310019&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:02:00</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[赵雪梅,唐辉,徐波]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>赵雪梅,唐辉,徐波</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201310019&flag=1]]></guid><cfi:id>217</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[氟比洛芬酯复合不同剂量舒芬太尼在骨科术后静脉镇痛的应用]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201310020&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:02:00</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[杨纪英]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>杨纪英</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201310020&flag=1]]></guid><cfi:id>216</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[2010～2012年我院质子泵抑制剂的应用分析]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201310021&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:02:00</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[辛晓玮,柳艳平,李祥鹏,李欣]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>辛晓玮,柳艳平,李祥鹏,李欣</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201310021&flag=1]]></guid><cfi:id>215</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[我院门诊不合格处方分析]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201310022&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:02:00</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[李明慧]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>李明慧</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201310022&flag=1]]></guid><cfi:id>214</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[生血丸治疗放化疗引起的白细胞减少症临床观察]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201409013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/1/11 15:15:50</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[王达,满孝蕊,陈树泉]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>王达,满孝蕊,陈树泉</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201409013&flag=1]]></guid><cfi:id>213</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[消糜阴道泡腾片对大鼠细菌性阴道炎的治疗作用研究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201409014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/1/11 15:15:50</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[姜善玲<sup>1</sup>,王平<sup>2</sup>,李百开<sup>3</sup>,高雁<sup>3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>姜善玲<sup>1</sup>,王平<sup>2</sup>,李百开<sup>3</sup>,高雁<sup>3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201409014&flag=1]]></guid><cfi:id>212</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[右美托咪定对胸腔镜手术患者围拔管期应激反应的影响]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201409015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/1/11 15:15:50</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[张勇<sup>1</sup>,王耀岐<sup>1</sup>,高天勤<sup>2</sup>,静广建<sup>1</sup>,张莉<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>张勇<sup>1</sup>,王耀岐<sup>1</sup>,高天勤<sup>2</sup>,静广建<sup>1</sup>,张莉<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201409015&flag=1]]></guid><cfi:id>211</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[血栓抽吸导管联合冠状动脉内注射替罗非班治疗急性心肌梗死患者的临床研究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201408014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 9:10:29</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[丁晓军<sup>1</sup>,王点<sup>2</sup>,邱林林<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>丁晓军<sup>1</sup>,王点<sup>2</sup>,邱林林<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201408014&flag=1]]></guid><cfi:id>210</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[亚胺培南\西司他丁临床使用药物利用评价分析]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201408015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 9:10:30</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[刘兴]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>刘兴</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201408015&flag=1]]></guid><cfi:id>209</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[通痹胶囊治疗类风湿关节炎临床研究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201408016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 9:10:30</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[车洪勇<sup>1</sup>,车晓青<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>车洪勇<sup>1</sup>,车晓青<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201408016&flag=1]]></guid><cfi:id>208</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[我院静脉药物配置中心不合理用药处方分析]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201408017&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 9:10:30</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[舒卫清]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>舒卫清</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201408017&flag=1]]></guid><cfi:id>207</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[治疗非酒精性脂肪肝复方中药颗粒的临床疗效]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201407015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 10:23:47</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[纪乐军,高希章,赵伏梅,贾晓臣]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>纪乐军,高希章,赵伏梅,贾晓臣</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201407015&flag=1]]></guid><cfi:id>206</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[消糜阴道泡腾片联合达克宁栓治疗阴道炎180例临床观察]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201407016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 10:23:47</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[高雁<sup>1</sup>,葛泉丽<sup>2</sup>,姜善玲<sup>3</sup>,郭绍梅<sup>4</sup>,陶萍<sup>5</sup>,李百开<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>高雁<sup>1</sup>,葛泉丽<sup>2</sup>,姜善玲<sup>3</sup>,郭绍梅<sup>4</sup>,陶萍<sup>5</sup>,李百开<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201407016&flag=1]]></guid><cfi:id>205</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[我院静脉用药集中调配中心常见不合理医嘱分析]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201406018&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 10:18:18</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[顾卫平,时银萍,郑丽媛,程永波]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>顾卫平,时银萍,郑丽媛,程永波</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201406018&flag=1]]></guid><cfi:id>204</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[品管圈活动在提高门诊药房质量管理品质中的应用]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201406019&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 10:18:18</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[宋伟]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>宋伟</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201406019&flag=1]]></guid><cfi:id>203</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[纤维支气管镜下沐舒坦灌洗治疗儿童感染性肺不张疗效观察]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201405019&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 10:12:10</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[刘兰]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>刘兰</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201405019&flag=1]]></guid><cfi:id>202</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[静脉用药调配中心岗位设置方法及应用]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201405020&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 10:12:10</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[赵方允<sup>1</sup>,李娟<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>赵方允<sup>1</sup>,李娟<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201405020&flag=1]]></guid><cfi:id>201</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[长期服用赖诺普利、苯磺酸氨氯地平及厄贝沙坦对高血压病患者心肺功能的影响比较]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201405021&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 10:12:10</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[曲红,王冰]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>曲红,王冰</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201405021&flag=1]]></guid><cfi:id>200</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[常规疗法联合益心酮滴丸治疗冠心病心绞痛的临床研究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201405022&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 10:12:11</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[张华芸<sup>1</sup>,高雁<sup>2</sup>,郭绍梅<sup>3</sup>,陶萍<sup>4</sup>,张昆<sup>5</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>张华芸<sup>1</sup>,高雁<sup>2</sup>,郭绍梅<sup>3</sup>,陶萍<sup>4</sup>,张昆<sup>5</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201405022&flag=1]]></guid><cfi:id>199</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[奥扎格雷钠对脑梗死急性期患者血小板膜糖蛋白表达和临床疗效的影响]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201404015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 10:06:19</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[何来鹏<sup>1</sup>,张远之<sup>1</sup>,王欣<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>何来鹏<sup>1</sup>,张远之<sup>1</sup>,王欣<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201404015&flag=1]]></guid><cfi:id>198</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[应用PASS系统对我院质子泵抑制剂使用情况分析]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201404016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 10:06:20</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[荆俊丽<sup>1</sup>,张想旺<sup>1</sup>,马玉想<sup>2</sup>,马守江<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>荆俊丽<sup>1</sup>,张想旺<sup>1</sup>,马玉想<sup>2</sup>,马守江<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201404016&flag=1]]></guid><cfi:id>197</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[我院2013年1～6月人血白蛋白临床应用分析]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201404017&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 10:06:20</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[胡伟,慈静,崔红霞]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>胡伟,慈静,崔红霞</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201404017&flag=1]]></guid><cfi:id>196</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[静脉输液调配中心环境与自然环境输液调配后不溶性微粒数量对比研究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201403018&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 10:01:00</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[刘兴,李世东]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>刘兴,李世东</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201403018&flag=1]]></guid><cfi:id>195</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[某二甲医院门诊及住院患者抗菌药物超说明书用药情况对比分析研究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201403019&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 10:01:00</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[王鸿梅<sup>1</sup>,张震<sup>2</sup>,李广瑞<sup>3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>王鸿梅<sup>1</sup>,张震<sup>2</sup>,李广瑞<sup>3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201403019&flag=1]]></guid><cfi:id>194</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[卡介菌多糖核酸治疗白癜风68例临床疗效及对免疫调节作用观察]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201403020&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 10:01:00</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[瞿理华]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>瞿理华</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201403020&flag=1]]></guid><cfi:id>193</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[利用抗菌药物信息化管理系统对我院Ⅰ类切口手术预防用抗菌药物干预前后对比分析]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201402019&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 9:54:56</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[官东秀,俸小平,冯祚臻,凌宇兵,李超明]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>官东秀,俸小平,冯祚臻,凌宇兵,李超明</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201402019&flag=1]]></guid><cfi:id>192</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[仙灵骨葆防治糖尿病性骨质疏松症的临床观察]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201402020&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 9:54:56</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[尤煜祺,庒日喜,赵华,谢英才]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>尤煜祺,庒日喜,赵华,谢英才</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201402020&flag=1]]></guid><cfi:id>191</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[330份中成药说明书和标签的规范性问题辨析]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201402021&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 9:54:56</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[李百开<sup>1</sup>,张华芸<sup>2</sup>,张昆<sup>3</sup>,孙士真<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>李百开<sup>1</sup>,张华芸<sup>2</sup>,张昆<sup>3</sup>,孙士真<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201402021&flag=1]]></guid><cfi:id>190</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[抗菌药物信息化管理系统的研发和应用]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201401016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 9:48:22</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[官东秀,杨华,俸小平,李骞,韦并阳,杨双]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>官东秀,杨华,俸小平,李骞,韦并阳,杨双</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201401016&flag=1]]></guid><cfi:id>189</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[我院中心摆药室裸片识别和片剂分劈的实践分析]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201401017&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 9:48:23</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[刘雅丽,王志,王琳,李欣]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>刘雅丽,王志,王琳,李欣</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201401017&flag=1]]></guid><cfi:id>188</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[复方榆树皮软膏的制备及对乳腺癌术后放射性皮肤损伤疗效观察]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201401018&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 9:48:23</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[李世东]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>李世东</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201401018&flag=1]]></guid><cfi:id>187</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[复方芩E乳膏的制备及治疗化妆品皮炎的疗效观察]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201401019&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 9:48:23</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[樊其忠,王玉,王风芹,孙迎东,胡丽敏]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>樊其忠,王玉,王风芹,孙迎东,胡丽敏</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201401019&flag=1]]></guid><cfi:id>186</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[布地奈德联合小剂量阿奇霉素对毛支后小气道病变患儿潮气呼吸肺功能的影响]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201412017&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/9/22 11:06:22</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[张静]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>张静</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201412017&flag=1]]></guid><cfi:id>185</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[乌鸡白凤丸联合化疗治疗复发性卵巢癌的疗效观察]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201412018&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/9/22 11:06:22</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[李文敏]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>李文敏</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201412018&flag=1]]></guid><cfi:id>184</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[2013年我院消化系统口服药物使用状况分析]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201411017&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/9/22 13:16:34</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[李龙昱]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>李龙昱</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201411017&flag=1]]></guid><cfi:id>183</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[临床药师在减少中药不良反应中的作用]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201411018&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/9/22 13:16:34</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[王晨静,李萍,曲海军,朱莉,王志]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>王晨静,李萍,曲海军,朱莉,王志</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201411018&flag=1]]></guid><cfi:id>182</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[临床路径下急性脑梗死药物治疗方案的成本-效果分析]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201410017&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/1/11 14:59:12</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[张香菊<sup>1</sup>,张明艳<sup>2</sup>,龚育杭<sup>3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>张香菊<sup>1</sup>,张明艳<sup>2</sup>,龚育杭<sup>3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201410017&flag=1]]></guid><cfi:id>181</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[281份合理用药调查问卷分析]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201410018&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/1/11 14:59:12</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[高菲,刘丹,成文娜,丁召兴,李燕,丁长玲]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>高菲,刘丹,成文娜,丁召兴,李燕,丁长玲</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201410018&flag=1]]></guid><cfi:id>180</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[康士德联用诺雷德对中晚期前列腺癌患者术后PSA及P540S的影响]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201509018&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/5/10 9:10:27</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[李卓,叶木石,张康妹,唐伟雄,柳建军]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>李卓,叶木石,张康妹,唐伟雄,柳建军</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201509018&flag=1]]></guid><cfi:id>179</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[临床药师参与1例急性弥漫性肺间质病变的药物治疗实践]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201509019&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/5/10 9:10:27</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[郝忻伟<sup>1</sup>,孙铜<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>郝忻伟<sup>1</sup>,孙铜<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201509019&flag=1]]></guid><cfi:id>178</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[2012～2014年某医院麻醉用药合理性分析]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201508017&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/5/10 13:23:03</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[姜佳希<sup>1,3</sup>,李静<sup>2</sup>,曲海军<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>姜佳希<sup>1,3</sup>,李静<sup>2</sup>,曲海军<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201508017&flag=1]]></guid><cfi:id>177</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[1例甲泼尼龙致支气管哮喘患者血糖升高的病例分析]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201508018&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/5/10 13:23:03</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[王冰<sup>1</sup>,高荔<sup>2</sup>,孙明杰<sup>3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>王冰<sup>1</sup>,高荔<sup>2</sup>,孙明杰<sup>3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201508018&flag=1]]></guid><cfi:id>176</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[莫西沙星注射液联合喜炎平注射液治疗社区获得性肺炎的临床疗效观察]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201507018&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/5/13 16:39:44</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[肖斌,贺作玉]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>肖斌,贺作玉</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201507018&flag=1]]></guid><cfi:id>175</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[消糜阴道泡腾片联合红外光治疗宫颈糜烂92例的临床观察]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201506016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/5/16 14:26:03</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[赵莉<sup>1</sup>,宫钦红<sup>1</sup>,高雁<sup>2</sup>,刘志芬<sup>1</sup>,张华芸<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>赵莉<sup>1</sup>,宫钦红<sup>1</sup>,高雁<sup>2</sup>,刘志芬<sup>1</sup>,张华芸<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201506016&flag=1]]></guid><cfi:id>174</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[复合磷酸酯酶肠溶片治疗肝病患者腹胀的疗效分析]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201505016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/9/19 14:07:52</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[牛庆慧<sup>1</sup>,边城<sup>1</sup>,江月萍<sup>2</sup>,杨玉玲<sup>1</sup>,刘培<sup>1</sup>,张凤娟<sup>1</sup>,张晗<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>牛庆慧<sup>1</sup>,边城<sup>1</sup>,江月萍<sup>2</sup>,杨玉玲<sup>1</sup>,刘培<sup>1</sup>,张凤娟<sup>1</sup>,张晗<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201505016&flag=1]]></guid><cfi:id>173</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[盐酸氨溴索治疗分泌性中耳炎的疗效观察]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201505017&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/9/19 14:07:52</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[高文燕]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>高文燕</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201505017&flag=1]]></guid><cfi:id>172</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[坎地沙坦联合曲美他嗪治疗原发性高血压左室肥厚的临床观察]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201505018&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/9/19 14:07:52</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[王春梅,文军,丁润会,刘叶,嵇诚,郭景华,袁志勇]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>王春梅,文军,丁润会,刘叶,嵇诚,郭景华,袁志勇</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201505018&flag=1]]></guid><cfi:id>171</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[羟基喜树碱膀胱灌注联合热疗对浅表性膀胱癌术后复发的影响研究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201504017&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/9/19 14:22:33</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[任启明,李健,郭萍]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>任启明,李健,郭萍</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201504017&flag=1]]></guid><cfi:id>170</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[我院静脉药物调配中心不合理处方分析]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201503016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/9/19 14:33:18</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[周芬,王琳琳,高声传,袁娜,刘美彤,李杨]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>周芬,王琳琳,高声传,袁娜,刘美彤,李杨</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201503016&flag=1]]></guid><cfi:id>169</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Analysis of the effectiveness, safety, and cost-effectiveness of 10 anti ventricular arrhythmia drugs]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201502013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/9/19 0:00:00</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[朱敬玲<sup>1</sup>,李新新<sup>1,2</sup>,劳海燕<sup>1</sup>,王映辉<sup>1</sup>,李桃<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>朱敬玲<sup>1</sup>,李新新<sup>1,2</sup>,劳海燕<sup>1</sup>,王映辉<sup>1</sup>,李桃<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201502013&flag=1]]></guid><cfi:id>168</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[他克莫司应用中的药学服务]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201502014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/9/19 14:43:07</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[高其水<sup>1</sup>,韩淑华<sup>1</sup>,苏乐群<sup>2</sup>,黄欣<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>高其水<sup>1</sup>,韩淑华<sup>1</sup>,苏乐群<sup>2</sup>,黄欣<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201502014&flag=1]]></guid><cfi:id>167</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[自动化药房管理系统在医院药房的应用]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201502015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/9/19 14:43:07</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[汪风芹,高培民,胡丽敏,孙迎东]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>汪风芹,高培民,胡丽敏,孙迎东</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201502015&flag=1]]></guid><cfi:id>166</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[一例四月龄婴儿川崎病的用药分析]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201501013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/9/19 14:58:20</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[赵华<sup>1</sup>,郭胜蓝<sup>1</sup>,罗崇彬<sup>1</sup>,张扬<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>赵华<sup>1</sup>,郭胜蓝<sup>1</sup>,罗崇彬<sup>1</sup>,张扬<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201501013&flag=1]]></guid><cfi:id>165</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[中药润骨通治疗股骨头缺血性坏死临床研究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201501014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/9/19 14:58:20</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[都全荣<sup>1</sup>,魏敬成<sup>2</sup>,谢克明<sup>1</sup>,李立新<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>都全荣<sup>1</sup>,魏敬成<sup>2</sup>,谢克明<sup>1</sup>,李立新<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201501014&flag=1]]></guid><cfi:id>164</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[对1例晚期结肠癌患者的药学监护]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201501015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/9/19 14:58:20</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[王慧丽,王序杰,张欢]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>王慧丽,王序杰,张欢</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201501015&flag=1]]></guid><cfi:id>163</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Clinical study of Thalidomide combined with CIK cells on the treatment of lymphoma]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201512015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To evaluate the effectiveness and security of cytokine-induced killer cells' cure on B-cell lymphoma.<b>Methods</b>  64 cases of lymphoma patients in hospital from Jan.2010 to Jan.2013 were selected and divided into observation group (32 patients) and control group (32 patients) randomly.The observation group was treated by Thalidomide combined with CIK cells,while the control group by CIK cells.The treatment effects,adverse reactions of two groups were recorded and compared.<b>Results</b>  Adverse reaction was not occurred in two groups. The levels of beta-2-microglobulin and LDH were reduced remarkably,especially in the observation group.Clinical symptoms and living quality of all the patients in both groups were improved.The total effective rates of observation group and control group were 84.3%,60%（<i>P</i>＜0.05）,respectively.The PFS rates of observation group and control group in one year were 82.3%,62.7%（<i>P</i>＜0.05）,respectively. The total survival rates of observation group and control group in one year were 96.8%,77.4%（<i>P</i>＜0.05）,respectively.<b>Conclusion</b>  Compared with CIK cells,Thalidomide showed a better performance in improving patient remission rate,extending patient survival without obvious toxic and side effects to be worth for a further research.]]></description>
<pubDate>2016/3/29 9:07:19</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[LI Jing, MENG Di, YANG Lu and YANG Shu]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LI Jing, MENG Di, YANG Lu and YANG Shu</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201512015&flag=1]]></guid><cfi:id>162</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Analysis of the Drug Wastage in PIVAS]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201512016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To analyze the drug consumption in pharmacy intravenous admixture service, to reduce the damage rate to provide the reference and advice.<b>Methods</b>  To analyze the causes of drug wastage, of our hospital in PIVAS from 2013 to 2014, From the drug classification,statistics,variety,the breakage of the special drugs, etc.<b>Results</b>  The drug breakage rate was 0.05% in our PIVAS in 2013～2014.Each link in the work flow had drug wastage.Original damage,drug dispensing damage and improper operation caused damage were the most important three reasons.<b>Conclusion</b>  The breakage rate was low in our PIVAS,the breakage of the drug was inevitable,but it can continue to reduce the damage rate through analysis the reasons and find out the countermeasures.]]></description>
<pubDate>2016/3/29 9:07:19</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[ZHAO Fang-yun<sup>1</sup> and CAI Wen-cai<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHAO Fang-yun<sup>1</sup> and CAI Wen-cai<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201512016&flag=1]]></guid><cfi:id>161</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[The application of anti-hypertension medicine in one second grade class-A hospital]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201511016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To investigate the application of anti-hypertension medicine in outpatients about one second grade class-A hospital.<b>Methods</b>  1 953 outpatient service prescriptions was selected randomly.There was 147 prescriptions using anti-hypertension medicine,accounted for the total 7.53%.And the traditional Chinese medicine application had prescription 15,other 132 were to the western medicine application. These 132 prescriptions were analyzed.<b>Results</b>  The uses of anti-hypertension medicine were 6 categories of 19 varieties.The maximum of use ratio was calcium antagonist(48.48%),next was the blood vessel tense elementⅡacceptor antagonist(21.97%) and β-acceptor retarder(19.7%).In 19 varieties,the amounts of medicine for drug utilization index>1 were 5,and 73.68% belonged to the reasonable medication.<b>Conclusion</b>  The rational use of anti-hypertension medicine can enhance efficacy and reduce side effect.]]></description>
<pubDate>2016/4/25 9:06:02</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[WANG Hongmei<sup>1</sup> and ZHANG Zhen<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WANG Hongmei<sup>1</sup> and ZHANG Zhen<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201511016&flag=1]]></guid><cfi:id>160</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Investigation and analysis on the utilization of narcotic drugs in our hospital from 2012 to 2014]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201511017&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To investigate the utilization of narcotic drugs in our hospital from 2012 to 2014 for references of reasonable utilization of this kind of drugs.<b>Methods</b>  7 017 outpatient prescriptions from 2012 to 2014 were analyzed statistically.The utilization and trends of narcotic drugs was evaluated.<b>Results</b>  There were 10 varieties of narcotic drugs in our hospital.The amount of Morphine Sustained-release Tables,Oxycodone Sustained-release Tablets,Fentanyl Sustained-release Patch was ranked in the top three and there was just a change in the rankings.The amount of Oxycodone Sustained-release Tablets was experienced rapid increase.The amount of Pethidine Injection from 2012 to 2014 was the least and was 130, 59, 42 mL,respectively.<b>Conclusion</b>  The use of narcotic drugs in our hospital was basically rational and some issues remain to be improved.]]></description>
<pubDate>2016/4/25 9:06:02</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[LIU Yujun, LIU Donghua, ZHANG Xiaolei, LIANG Yu, WANG Yue, ZHAO Shanshan, GAO Tongyu and SUN Lu]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LIU Yujun, LIU Donghua, ZHANG Xiaolei, LIANG Yu, WANG Yue, ZHAO Shanshan, GAO Tongyu and SUN Lu</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201511017&flag=1]]></guid><cfi:id>159</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[The point of pharmaceutical intervention for antibiotic-associated diarrhea treatment 
by Clinical pharmacists]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201511018&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objctive</b>  To investigate the point of pharmaceutical intervention for clinical pharmacists providing pharmaceutical care for patient with antibiotic-associated diarrhea.<b>Methods</b>  Clinical pharmacists provided pharmaceutical intervention for two kinds of patients with antibiotic-associated diarrhea in drug treatment, and analyzed the improper methods during in treatment of antibiotic associated diarrhea.<b>Results</b>  There are some unreasonable points in the process of drug treatment of antibiotic-associated diarrhea.<b>Conclusion</b>  In the process of drug treatment for the patients with antibiotic-associated diarrhea,clinical pharmacists should focus on the key content, such as the diagnosis of different types of antibiotic associated diarrhea, the choice of main drugs,drug dose and indications of other auxiliary medication.]]></description>
<pubDate>2016/4/25 9:06:02</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[SONG Zheng, ZHENG Cuicui, GOU Chunxia and GAO Xinfu]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>SONG Zheng, ZHENG Cuicui, GOU Chunxia and GAO Xinfu</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201511018&flag=1]]></guid><cfi:id>158</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[瑞舒伐他汀联合前列地尔治疗糖尿病肾病的临床研究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201510015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/5/9 14:57:57</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[鞠富霞]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>鞠富霞</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201510015&flag=1]]></guid><cfi:id>157</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[临床药师参与1例肺鳞癌伴大咯血的药学实践]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201510016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/5/9 14:57:57</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[闫秀娟<sup>1</sup>,全香花<sup>2</sup>,郭玉竹<sup>3</sup>,王冰<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>闫秀娟<sup>1</sup>,全香花<sup>2</sup>,郭玉竹<sup>3</sup>,王冰<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201510016&flag=1]]></guid><cfi:id>156</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Effects of Mudan Particles combined with irbesartan on the levels of serum transforming growth factor-β1 and homocysteine in patients with early diabetic nephropathy]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201609015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To investigate the effects of Mudan Particles combined with irbesartan on the levels of serum transforming growth factor-β<sub>1</sub> (TGF-β<sub>1</sub>) and homocysteine (Hcy) in patients with early diabetic nephropathy.<b>Methods</b>  Application of prospectively randomized open parallel-controlled methods,a total of 72 patients with early diabetic nephropathy were selected, and were randomly divided into two groups for Mudan Particles combined with irbesartan (combined therapy) or irbesartan treatment, respectively.Changes in urinary albumin excretion rate (UAER),urine β<sub>2</sub>-microglobulin (β<sub>2</sub>-MG), the levels of serum TGF-β<sub>1</sub> and Hcy were measured and compared between two groups at both pre- and post-treatment of 48 weeks.<b>Results</b>  There were no statistically significant difference in the baseline clinical characteristics of study participants between two treatment groups (<i>P</i>>0.05 for all).Comparison of therapy-related differences between groups showed that the combined therapy was better in reducing UAER, urine β<sub>2</sub>-MG and serum TGF-β<sub>1</sub> than the irbesartan group [(-37 12 vs 22 10) μg•min<sup>-1</sup>, (-0.40 0.17 vs -0.24 0.12)mg•L<sup>-1</sup>,(-31 15 vs-14 12)U•L<sup>-1</sup>,respectively,all <i>P</i><0.01].<b>Conclusion</b>  Compared with irbesartan monotherapy,Mudan Particles combined with irbesartan treatment can better reduce serum TGF-β<sub>1</sub> levels,decrease UAER and urine β<sub>2</sub>-MG, and may exert kidney protection effects in patients with early diabetic nephropathy.]]></description>
<pubDate>2016/9/13 8:36:05</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[LI Weihua, DI Huifeng, CHEN Yingying, WANG Debao and LIU Peng]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LI Weihua, DI Huifeng, CHEN Yingying, WANG Debao and LIU Peng</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201609015&flag=1]]></guid><cfi:id>155</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Introduction of the operation mode of temporary medical order in PIVAS under all medical order mode]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201609016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To explore the operation mode of temporary medical order in PIVAS under all medical order mode,and satisfy the needs of clinical medicine.<b>Methods</b>  The influencing factors during the operation of temporary order were analyzed in each link of order receiving,review,distributing infusion batch, check,configuration,and conjoin.<b>Results and Conclusion</b>  PIVAS have configuration standing orders, and simultaneously can undertake the temporary order configuration,the consummate temporary order operation mode is the foundation to ensure the normal operation.]]></description>
<pubDate>2016/9/13 8:36:05</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[YANG Jinbin]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>YANG Jinbin</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201609016&flag=1]]></guid><cfi:id>154</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Analysis of relationship between the resistance rate of <i>Pseudomonas aeruginosa</i> and the doses of antibacterials in our hospital]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201608013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To analyse the relationship between the resistance rate of <i>Pseudomonas aeruginosa</i> and the use frequency of antibacterials within recent 5 years and provide references for the reasonable use of antibacterials.<b>Methods</b>  Collecting,statistics,associativity analytical methods were adopted.The resistance information of <i>Pseudomonas aeruginosa</i> obtained from 2010～2014 in our hospital and the use frequency of 11 antibacterials with resistance activity for Pseudomonas aeruginosa were retrospectively analysed.<b>Results</b>  During the 5 years,1 510 strains of <i>Pseudomonas aeruginosa</i> were separated.The resistance rates of Piperacillin/Tazobactam and Imipenem had positive relationship with the use frequency of Cefotaxime(<i>r</i>＝0.917,<i>P</i>＜0.05;<i>r</i>＝0.880,<i>P</i>＜0.05); The resistance rate of Piperacillin also had positive relationship with the use frequency of Piperacillin and Cefotaxime(<i>r</i>＝0.902,<i>P</i>＜0.05;<i>r</i>＝0.944,<i>P<?i>＜0.05) ;The resistance rate of Ceftazidime also had positive relationship with the use frequency of Cefotaxime and Amikacin(<i>r</i>＝0.904,<i>P</i>＜0.05;<i>r</i>＝0.907,<i>P</i>＜0.05).<b>Conclusion</b>  The resistance rate of <i>Pseudomonas aeruginosa</i> obtained in our hospital had relationship with the use frequency of  antibacterials.The use of antibacterials should be rigorous and standard,initial anti-infective therapeutic schedule should be optimized to reduce the need of antibacterials and their doses,By this way,we could control the drug resistant strains of bacteria.]]></description>
<pubDate>2016/8/8 10:12:09</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[HE Qinghua, DENG Baili, LI Hankun, CAO Kun, YANG Wanxia, GUO Wei and HUANG Yunping]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>HE Qinghua, DENG Baili, LI Hankun, CAO Kun, YANG Wanxia, GUO Wei and HUANG Yunping</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201608013&flag=1]]></guid><cfi:id>153</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Clinical effects of Qidong Yixin Oral Solution for the auxiliary treatment of severe pneumonia complicated heart failure in children]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201608014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To observe the clinical effects of Qidong Yixin Oral Solution for the auxiliary treatment of severe pneumonia complicated heart failure in children.<b>Methods</b>  76 cases of children with severe pneumonia complicated heart failure from 2013 to 2015 were selected,and randomly divided them into the observation group and the control group on average.The control group was treated with strong heart,diuresis,anti-infection,relieving cough and phlegm and other comprehensive treatment by western medicine.On the basis of the above treatment,the oral adjuvant therapy Qidong Yixin Oral Solution was carried out in the observation group.LVEF,LVSF,E/A of two groups of children were determined by color Doppler flow imaging before and after treatment.The changes of NT-proBNP and myocardial enzymes(CK,CK-MB,LDH) were detected.<b>Results</b>  In the aspects of pulmonary rales,correction time of heart failure,breath holding time and average length of stay of children,the observation group were better than the control group,and the differences are statistically significant (<i>P</i><0.05).The observation group were better than the control group in the improvement effect of LVEF,LVDD,E/A after treatment,and the differences were statistically significant (<i>P</i><0.05).Each index of the observation group after treatment was significantly lower than the control group,such as NT-proBNP,myocardial enzyme spectrum,and the difference was statistically significant(<i>P</i><0.05).<b>Conclusion</b>  The method of Qidong Yixin Oral Solution for the auxiliary treatment of severe pneumonia complicated heart failure in children can improve the myocardial contractile force,protect the cardiac muscle cells and improve the cardiac function,which was beneficial to the prognosis of the patients with good clinical effect.]]></description>
<pubDate>2016/8/8 10:12:09</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[WANG Wenjie, ZHU Hongfeng and WANG Jianlong]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WANG Wenjie, ZHU Hongfeng and WANG Jianlong</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201608014&flag=1]]></guid><cfi:id>152</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Applied research of the individual intervention care to prevention of anaphylaxis of Vitamin K<sub>1</sub> Injection]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201607015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To prevent the side effects of the Vitamin K<sub>1</sub> Injection with the individual intervention care to the infant patients administered the injection.<b>Methods</b>  Every infant patient was administered the dilute injection through the intravenous drip and the drug allergy history was registered.107 infant patients administered Vitamin K<sub>1</sub>. Injection during January 1, 2014 to December 31,2014 were chose as the research participants,who were randomly divided into control group (52 cases) and interventional group (55 cases).The patients in control group received the routine treatment of transfusion and careful observation,while the infants who had the first treatment and unclear history in the interventional group cannot get Vitamin K<sub>1</sub> Injection except those who would have the negative results of allergy skin test.<b>Results</b>  3 anaphylactic reactions occurred in control group,whereas no allergy was observed in interventional group（<i>P</i><0.05）.<b>Conclusion</b>  The individual intervention care to the infant patients administered Vitamin K<sub>1</sub> Injection can provide the efficient prevention of anaphylactic reactions and ensure the drug use.Furthermore,the harmonious doctor-patient relationship would come true and there would be much less medical disputes.]]></description>
<pubDate>2016/7/12 14:11:37</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[GAO Junfang<sup>1</sup>, SONG Xinyu<sup>2</sup>, ZHU Meiyu<sup>1</sup> and WANG Jing<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>GAO Junfang<sup>1</sup>, SONG Xinyu<sup>2</sup>, ZHU Meiyu<sup>1</sup> and WANG Jing<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201607015&flag=1]]></guid><cfi:id>151</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[The effects of ibandronate on OST and BAP in hepatic carcinoma with bone metastases patients]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201607016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To investigate the prognosis of OST（osteocalcin） and BAP（bone alkaline phosphatase）for hepatic carcinoma with bone metastases patients and valuation of Ibandronate.<b>Methods</b>  16 patients of hepatic carcinoma with bone metastases,22 patients of hepatic carcinoma without bone metastases and 20 patients of hepatic carcinoma without metastases were collected.The hepatic carcinoma with bone metastases group was treated with Ibandronate.To observe the defferences of the BAP and OST in three groups and treatment or not.<b>Results</b>  The levels of OST and BAP increased significantly in the bone metastasis group（<i>P</i><0.05）.Ibandronate Injection reduced the levels of OST and BAP in hepatic carcinoma with bone metastasis group. <b>Conclusion</b>  The value of BAP and OST were significantly higher in hepatic carcinoma with bone metastases patients,which can be used as reference index of clinical prediction.Ibandronate Injection was effective in the treatment of bone metastases and the mechanism may be related to reduce the levers of OST and BAP.]]></description>
<pubDate>2016/7/12 14:11:37</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[ZHANG Nannan, LI Jing, YANG Shu and CAO Zhongshu]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Nannan, LI Jing, YANG Shu and CAO Zhongshu</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201607016&flag=1]]></guid><cfi:id>150</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Analysis of literatures about drug-induced death caused by cephalosporins from 2005 to 2014]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201606017&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To analyze literatures about drug-induced death caused by cephalosporins,investigate the characteristics of drug-induced deaths by cephalosporins and provide a scientific basis for drug safety.<b>Methods</b>  To retrieve literatures related cephalosporins cause drug-induced death in Chinese Knowledge Reseurce Integrated Database,Wanfang Data and VIP Network,and retrospectively analysis by sex,age,clinical manifestations of adverse drug reactions and cause of death and other information.<b>Results</b>  There were 55 effective documents of 76 cases, 45 males (59.2%),31 females (40.8%),and the ratio was 1.45:1;Patients aged 0.5 to 79 years,the mean age was 46.9±17.9. Patients with primary disease 29 cases of upper respiratory tract infection (38.2%),12 cases of tracheitis(bronchitis) (15.8%),lung infection in 11 patients (14.5%),and other respiratory diseases mainly with intravenous administration of Lord,there were 65 cases (85.5%).ADR occurrence time,mainly within 10 min,there were 48 cases (63.2%);59 cases of anaphylactic shock patients (77.6%) occurred in patients of all ADR,shock symptoms occur after administration time <5 minutes,46 patients (78.0%).Highest third-generation cephalosporin usage,there are 49 cases(64.5%);the most frequently used before 5 cephalosporins were:ceftriaxone,cefazolin,cefoperazone,cefotaxime sodium,cefoperazone-sulbactam.Clinical manifestations of adverse reactions in all patients and cause of death distribution, accounting for up to anaphylactic shock 59 cases (77.6%).<b>Conclusion</b>  The clinical application of antibiotics was widespread,the clinical manifestations of ADR were different, and the main cause of the death of drug was allergic shock,and the use of the third generation of the most important was the highest.In the process of clinical medication,the medical history,allergic history, etc.,should be closely observed to prevent the occurrence of ADR fatal cases.]]></description>
<pubDate>2016/6/21 15:47:29</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[WEI Yiwen and QIU Han]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WEI Yiwen and QIU Han</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201606017&flag=1]]></guid><cfi:id>149</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Analysis of the results of monitoring the prescription in children's hospital using rational drug monitoring system and the recommendations]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201606018&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To assess the role of rational drug monitoring system in the rational drug use of children's hospital and improve the pharmacy service of hospital.<b>Methods</b>  Collected the prescriptions of April 2016 monitored by rational drug monitoring system,to evaluate and analyze the rationality,and propose improvement measures and recommendations.<b>Results</b>  The proportion of unreasonable prescriptions monitored by rational drug monitoring system was 15.58%.The problems were mainly children with caution,drug interactions and repeated drug use.Some of the information was meaningless.<b>Conclusion</b>  Rational drug monitoring system played an important role in improving the pharmacy service of hospital,but there were still some limitations and the system need further improvement.]]></description>
<pubDate>2016/6/21 15:47:29</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[HAO Lina<sup>1</sup> and XIE Qiangsheng<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>HAO Lina<sup>1</sup> and XIE Qiangsheng<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201606018&flag=1]]></guid><cfi:id>148</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Influence of Feiwei Mixture in chemotherapy patients with brain metastasis of lung cancer about sialic acid levels]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201605014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To investigate the effect of Feiwei Mixture in chemotherapy patients with brain metastasis of lung cancer about sialic acid levels.<b>Methods</b>  A total of 87 patients were selected from the hospital from January 2013 to December 2015 with lung cancer brain metastasis, Feiwei Mixture treated patients 41 cases as the observation group, other 46 patients as control group, the changes of two groups of patients with clinical curative effect and sialic acid level were observed. <b>Results</b>  There was no significant difference in pre-chemotherapy, sialic acid levels in the two groups of patients (<i>P</i>>0.05); The two groups of patients after treatment compared with before treatment group, were significantly decreased,there was significant difference (<i>P</i><0.05);After 2 cycles of chemotherapy, comparison between groups were made,the observation group was significantly lower than that of sialic acid in control group,there was significant difference (<i>P</i><0.05). After 2 cycles of chemotherapy, the efficacy of two groups of patients were assessed by WHO criteria, the clinical remission rate of patients in the observation group was significantly higher than that of the patients in the control group, there was statistically significant difference (<i>χ</i><sup>2</sup>=4.370, <i>P</i><0.05). <b>Conclusion</b>  Feiwei Mixture can significantly improve the effect of the treatment of patients with brain metastases from lung cancer,reduce the sialic acid level, satisfactory clinical effect.]]></description>
<pubDate>2016/5/25 10:40:36</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[SONG Zhenmin, JIANG Luxia, MA Yanhong, CHEN Fei and ZAHNG Hongwei]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>SONG Zhenmin, JIANG Luxia, MA Yanhong, CHEN Fei and ZAHNG Hongwei</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201605014&flag=1]]></guid><cfi:id>147</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Analysis of intervention on irrational prescriptions in outpatient pharmacy]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201605015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To regulate prescription management,improve the quality of prescription,promote rational use of drugs,ensure medical safety,pharmacists should review the suitability of the prescription,and carry out timely and effective intervention to prevent the occurrence of errors,and ensure the safety of life and property.<b>Methods</b>  Pharmacists checked prescription strictly, timely intervened the irrational prescription and summaried analysis,secondary  intervention was carried out by rewards and punishments.<b>Results</b>  Doctors paid attention to prescriptions,the overall decline of the irrational prescription was 50%.<b>Conclusion</b>  To strengthen the intervention of pharmacists to prescription,enhance the effective communication between doctors,pharmacists and patients,can improve the level of rational drug use,avoid the occurrence of errors,and protect the safety of life and property.]]></description>
<pubDate>2016/5/25 10:40:36</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[LI Feng]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LI Feng</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201605015&flag=1]]></guid><cfi:id>146</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Effect of Modified Danggui Buxue Decoction on T-lymphocyte subsets and natural killer (NK) cells in patients with lung cancer after radiotherapy]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201604016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To investigate the effect of Modified Danggui Buxue Decoction on T-lymphocyte subsets and natural killer (NK) cells in patients with lung cancer after radiotherapy.<b>Methods</b>  70 cases with lung cancer were randomly divided into treatment group and control group,35 cases in each group.The treatment group patients were treated by Modified Danggui Buxue Decoction,at the same time both groups were treated by radiotherapy.Peripheral blood T-lymphocytes subsets and NK cells ratio of the patients of both groups were detected by flow cytometer before or after medication.<b>Results</b>  After radiotherapy,CD3<sup>+</sup>,CD4<sup>+</sup>,CD8<sup>+</sup>,CD4<sup>+</sup>/CD8<sup>+</sup> and NK cell of treatment group were significantly different compared with those of the control group (<i>P</i>＜0.05).The improvement of peripheral blood lymphocytes subset of treatment group patients was observed more notablely powerful than control group's(<i>P</i>＜0.05).<b>Conclusion</b>  Modified Danggui Buxue Decoction had certain immunoregulation action on lymphocytes and may enhance immunologic functions in patients with lung cancer after radiotherapy．]]></description>
<pubDate>2016/5/5 15:59:03</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[LIU Yucai, ZHANG Huanzhen, YU Fengling and ZHANG Peiliang]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LIU Yucai, ZHANG Huanzhen, YU Fengling and ZHANG Peiliang</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201604016&flag=1]]></guid><cfi:id>145</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[The therapeutic effect of clopidogrel on different weight patients with acute ischemic stroke]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201603015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  Based on normal body mass index,to study the therapeutic effect of clopidogrel on different weight patients with acute ischemic stroke.<b>Methods</b>  A total of 126 normal-weight patients with acute ischemic stroke in department of neurology,Nanjing First Hospital from September 2012 to May 2013 were enrolled and evenly divided by gender and median weight into low and high weight groups.Platelet aggregation was detected before and 7 days later after taking standard clopidogrel antiplatelet therapy,and stroke recurrence rate and adverse event occurrence rate was followed-up for one year.<b>Results</b>  No significant difference in platelet aggregation before (low weight group was 74.1%±13.2% and high weight group was 74.7%±13.6%,<i>P</i>=0.802) while statistical difference 34.4%±9.8% and 39.1%±14.4% respectively,<i>P</i>=0.034) was found 7 days later after taking standard clopidogrel antiplatelet therapy.Two groups of stroke recurrence rate and adverse event occurrence rate showed no significant difference in one year's following up.<b>Conclusion</b>  Within the range of normal BMI,patients with a lower body weight would have a better anti-platelet effect after taking clopidogrel.But further research was needed to see whether such effect would reduce stroke recurrence or increase adverse events.]]></description>
<pubDate>2016/4/7 9:39:54</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[DING Yunlong<sup>1,2</sup>, ZHAO Yanxia<sup>2</sup> and LIU Yan<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>DING Yunlong<sup>1,2</sup>, ZHAO Yanxia<sup>2</sup> and LIU Yan<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201603015&flag=1]]></guid><cfi:id>144</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Clinical observation of Melilotus Extract Tablets combined with Dujiu for treating ankylosing spondylitis]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201603017&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To investigate the effect of Melilotus Extract Tablets (Met) with DuJiu on inflammatory cytokines (TNF-α,IL-2,IL-6) in ankylosing spondylitis with positive HLA-B27, and explore it's mechanism of clinical efficacy.<b>Methods</b>  40 AS patients with positive HLA-B27 were randomly divided into two groups:treatment group received Met,control group received diclofenac.Clinical manifestation and disease activities index were recorded,serum levels of T lymphocyte were determined by Using Flow Cytometry method in the patients of AS.<b>Results</b>  There were no significant difference before therapy between the two groups(<i>P</i>＞0.05) in CRP and ESR and the T lymphocyte,After 4 weeks treatment,all patients had obviously improvement in CRP and ESR,there were no significant difference between the two groups of the number of adverse drug reactions (ADRs) after 4 weeks treatment , but the gastrointestinal tract ADRs in Met group was lower than the diclofenac group(<i>P</i>＜0.05).Comparing the index of inflammatory factors of two groups,the Met group's was better than the diclofenac group's,the improvement of CD3<sup>+</sup> and CD4<sup>+</sup> between the two groups were significant differernce(<i>P</i>＜0.05).<b>Conclusion</b>  The clinical efficacy of Melilotus Extract Tablets with DUjiu was significant,the mechanism may relevant with regulating the levels of T lymphocyte.]]></description>
<pubDate>2016/4/7 9:39:54</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[LIU Wenqi<sup>1</sup> and LU Xiuhua<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LIU Wenqi<sup>1</sup> and LU Xiuhua<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201603017&flag=1]]></guid><cfi:id>143</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Investigation and analysis of prescription in hospital outpatient of liver disease]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201602015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To investigate the clinical application of hepatitis liver drug in hospital outpatient pharmacy and make objective evaluation.<b>Methods</b>  To count the main types of drugs,dosage, amount and medication frequency of prescription drugs in hospital outpatient of liver disease from July to August in 2012.<b>Results</b>  From the pharmacological classification to see,the antiviral drugs usage frequency was highest,protecting liver drop enzymes drug took second place;With single drug analysis,the use frequency of Adefovir Capsules was highest,Lamivudine Tablet took second place.<b>Conclusion</b>  Liver disease was also treated mainly by antiviral drugs,with immune regulation and protecting liver drop enzymes as a combination treatments.]]></description>
<pubDate>2016/3/21 14:56:14</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[JIANG Ganling]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>JIANG Ganling</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201602015&flag=1]]></guid><cfi:id>142</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Comparison of clinical therapeutic effects of Kangshuai Cream in preventing irradiation-induced dermal injury in patients with breast cancer]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201602016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To explore the clinical effects of Kangshuai Cream in preventing irradiation- induced dermal injury in breast cancer patients.<b>Methods</b>  120 patients with breast cancer who received radiotherapy were randomly divided into three groups,40 cases in each group.The patients of group A,B,C with breast cancer who initially received radiotherapy respectively used Kangshuai Cream,Triethanolamine Cream and Superoxide Dismutase (SOD) Spray.The protective effect of irradiation- induced dermal injury after radiation therapy in the three groups was evaluated.<b>Results</b>  The degree of skin damage and serious radioactive skin lesions (＞Ⅱ) in group A and group B was no difference (<i>P</i>＞0.05),the degree of skin damage and serious radioactive skin lesions (＞Ⅱ) in group A and group C was statistically significant (<i>P</i>＜0.05).The degree of skin damage and the incidence rate of severe irradiation-induced dermal injury (＞Ⅱ) in group A were lower than group C.<b>Conclusion</b>  Kangshuai Cream had same effect in preventing the irradiation-induced dermal injury in breast cancer patients,the clinical therapeutic effects of Kangshuai Cream in preventing irradiation-induced dermal injury was better than SOD Spray,and Kangshuai Cream offered better value for money.]]></description>
<pubDate>2016/3/21 14:56:14</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[GAO Xinfu<sup>1</sup>, SONG Zheng<sup>1</sup>, LIU Changmin<sup>2</sup>, LI Lei<sup>2</sup> and GAO Peimin<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>GAO Xinfu<sup>1</sup>, SONG Zheng<sup>1</sup>, LIU Changmin<sup>2</sup>, LI Lei<sup>2</sup> and GAO Peimin<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201602016&flag=1]]></guid><cfi:id>141</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Meta  analysis of Yangxueqingnao Granule in the treatment of vascular cognitive dysfunction]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201601014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To evaluate the therapeutic effect of Yangxue Qingnao Granule on  vascular cognitive impairment.<b>Methods</b>  The randomized controlled trials of Yangxue Qingnao Granule in treating vascular cognitive impairment was collected by computer retrieval tools and manual retrieval,extract data and Meta-analysis was analyzed with Revman 5.2 software released by Cochrane.<b>Results</b>  8 experiments were included (579 patients),all experiments were carried out on the MMSE score,results displayed that Yangxue Qingnao Granule improving MMSE scores was better than the control group [WMD=2.47,95%CI (1.57,3.37)];4 experiments were carried out on the HDS scores,which displayed that Yangxue Qingnao Granule improving HDS was better than the control group [WMD=4.80,95%CI(3.94,5.67)];4 experimental were carried out on the HDL scores,results displayed that Yangxue Qingnao Granule improving ADL scores was better than the control group [WMD=-4.43,95%CI (-5.75,-3.12)];4 experimental was evaluated on efficiency, which indicated that the effect of Yangxue Qingnao granule was better than the control group [OR=2.87, 95%CI (1.67,4.94)];<b>Conclusion</b>  Yangxue Qingnao Granule was efficacious on treating vascular cognitive impairment.]]></description>
<pubDate>2016/3/22 9:43:04</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[LIU Tai, ZENG Peipei and ZHANG Qingping]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LIU Tai, ZENG Peipei and ZHANG Qingping</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201601014&flag=1]]></guid><cfi:id>140</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Clinical curative effect of Compound Phosphatase Enteric Coated Tablets combined with Silibinin Capsules in the treatment of 70 cases of simple alcoholic liver disease]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201601015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To observe the clinical curative effect of Compound Phosphatase Enteric Coated Tablets Combined with Silibinin Capsules in the treatment of  simple  alcoholic liver disease.<b>Methods</b>  70 patients with simple alcoholic liver disease were randomly divided into two groups. The control group using Inosine Tablets and Silibinin Capsules,the treatment group based on the control group  used  Compound Phosphatase Enteric Coated Tablets.ALT/AST/TBIL/GGT of two groups and the improvement of clinical symptoms were observed.<b>Results</b>  It can effectively  reduce transaminase with Compound Phosphatase Enteric Coated Tablets combined with Silibinin Capsules.The total effective rate of improving the symptoms was 100%, the total effective rate of control group was 57.14%.The clinical total effective rate in treatment group was significantly higher than that in control group (<i>P</i><0.05).<b>Conclusion</b>  The clinical curative effect of Compound Phosphatase Enteric Coated Tablets combined with Silibinin Capsules was very good. It was worth to extend in clinical practice.]]></description>
<pubDate>2016/3/22 9:53:43</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[HUANG Xinzao, JI Dan, SAI Jun and KE Wenbing]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>HUANG Xinzao, JI Dan, SAI Jun and KE Wenbing</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201601015&flag=1]]></guid><cfi:id>139</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Analysis of the distribution and drug resistance of pathogenic bacteria of bloodstream infections]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201612012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To get information about bacterial distribution and resistance in bloodstream infection.<b>Methods</b>  Various clinical department blood cultures samples were collected by  BACTEC FX and BACT/ALERT 3D 240. The identification and antimicrobial susceptibility testing were performed with WalkWAY96PLUSand API，Statistical analysis was done with Whonet 5.6.<b>Results</b>  A total of 385 bacterial strains were isolated,and gram negative bacteria accounted for 63.11%,; of which Escherichia coli accounted for 31.69%, followed by Klebsiella pneumonia 8.83%, the gram positive bacteria accounting for 34.55%, of which staphylococcus epidermidis accounted for 8.05% ,followed by staphylococcus aureus accounted for 7.53%.The resistant rates of Staphylococcus 、enterococcus and streptococcus pneumoniae to vancomycin,linezo1id were 0;No imipenem and meropenem resistant Escherichia coli and Klebsiella pneumonia were found.<b>Conclusions</b>  Gram-negative bacilli were the major pathogens of BSI;antibiotic resistance becomes more prevalent in some major pathogens.Rational use of antibiotics is important for the containment of bacterial resistance.]]></description>
<pubDate>2016/12/29 13:59:16</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[JI Bing<sup>1</sup>, FU Mingxia<sup>2</sup>, GAO Meilan<sup>1</sup>, LIU Yongyun<sup>1</sup>, MENG Wei<sup>1</sup> and PENG Xinguo<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>JI Bing<sup>1</sup>, FU Mingxia<sup>2</sup>, GAO Meilan<sup>1</sup>, LIU Yongyun<sup>1</sup>, MENG Wei<sup>1</sup> and PENG Xinguo<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201612012&flag=1]]></guid><cfi:id>138</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Experience of clinical pharmacist participate in septic shock caused by knee joint replacement]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201612013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To explore an approach and method for clinical pharmacist work in pharmaceutical care in secondary hospital.<b>Methods</b>  Providing drug administration regimens and dosage adjustment for septic shock caused by mismanagement after right knee joint replacement.<b>Results</b>  The infection got well control and effective treatment. <b>Conclusion</b>  Clinical pharmacists in secondary hospital need to be developed in multiple disciplines.]]></description>
<pubDate>2016/12/29 13:59:16</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[MAO Yuanbo<sup>1</sup> and GU Yizhu<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>MAO Yuanbo<sup>1</sup> and GU Yizhu<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201612013&flag=1]]></guid><cfi:id>137</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Influence study of pharmaceutical intervention on clinical use of antibacterials in outpatient prescriptions during special rectification]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201612014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To investigate and analyze the influence of pharmaceutical intervention on clinical use of antibacterials in outpatient prescriptions during special rectification.<b>Methods</b>  A retrospective analysis was made,1 200 outpatient prescriptions were randomly selected during 2010,2012 and 2014.The clinical use of antibacterials before,during and after special rectification was compared.<b>Results</b>  After the intervetion during special rectification,the rate of outpatient antibacterials prescription decreased to 18.08% in 2012 and 14.92% in 2014,the rate of intravenous decreased to 11.52% in 2012 and 13.41% in 2014,the rate of combination decreased to 23.04% in 2012 and 14.53% in 2014,the rate of antimicrobial prescription amount decreased to 12.31% in 2012 and 9.96% in 2014.<b>Conclusion</b>  The implementation of special rectification and pharmaceutical intervention improved the use of antibacterials in outpatient prescriptions greatly,and it also improved the level of rational use of drugs in our hospital.]]></description>
<pubDate>2016/12/29 13:59:16</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[WANG Xiaokun, DING Juying and HUANG Xingang]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WANG Xiaokun, DING Juying and HUANG Xingang</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201612014&flag=1]]></guid><cfi:id>136</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Treatment status and economic burden of breast cancer targeted drugs in Fujian Province]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201611013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To explore the current status of breast cancer targeted drug therapy in Fujian Province,and analyze the economic burden of the treatment,so to provide a reference for the establishment of medical insurance policy of major catastrophic disease.<b>Methods</b>  Obtaining the breast cancer patients’ data during 2012 to 2014 from informational system of nine cities’ medical insurance management center in Fujian Province;Operating investigation in Guangxi,Guangzhou Zhuhai,Xiamen and other cities;Holding symposium with experts,scholars and cancer patients.<b>Results</b>  In recent years,the incidence of breast cancer in Fujian Province increased year by year.The incidences in 2012,2013 and 2014 were 51.70,53.76 and 54.26 per 100 000 people,respectively.The incidence for women who aged from 21 to 40 was particularly increased, from 9.13 per 100 000 in 2012 to 10.17 per 100 000 in 2014.The patients' economic burden was heavy,and the cost of targeted drug therapy reached to ￥227 000 per patient.<b>Conclusion</b>  The key to reduce the economic burden of patients with breast cancer and other serious illness is to improve the medical insurance system for major catastrophic disease, and reduce the cost of targeted drugs.]]></description>
<pubDate>2016/11/9 9:59:03</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[LUO Gelian<sup>1</sup>, LIN Jinwen<sup>1</sup>, LIN Yongshun<sup>2</sup> and CHEN Chun<sup>3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LUO Gelian<sup>1</sup>, LIN Jinwen<sup>1</sup>, LIN Yongshun<sup>2</sup> and CHEN Chun<sup>3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201611013&flag=1]]></guid><cfi:id>135</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Clinical application of flurbiprofen axetil combined with lidocaine in elderly patients of modified radical mastectomy]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201611014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To investigate the safety and feasibility of flurbiprofen axetil combined with lidocaine in elderly patients of modified radical mastectomy(MRM).<b>Methods</b>  52 cases of elderly patients that underwent MRM were randomly divided into two groups. All patients were received general anesthesia during operation.The patients in observation group received flurbiprofen axeil 1 mg·kg<sup>-1</sup> i.v. 10 minutes before incision and after operations respectively. After the operations, patients in control group were received patient-controlled intravenous analgesia(PCIA), which containing 100 μg sufentanil and 5 mg tropisetron in a volume of 100 mL;while the PCIA in observation group was containing 75μg sufentanil, 5 mg tropisetron and 100mg flurbiprofen axetil in a volume of 100 mL.The patient's reactive symptoms were observed and the vital signs were recorded. The degree of post-operative pain was accessed with the visual analogue scale(VAS) at extubation time, 4 h, 8 h, 12 h, 24 h and 48 h after surgeries. The safety and adverse drug reaction of the method was also evaluated.<b>Results</b>  The VAS scores of observation group at extubation time, 4 h, 8 h, 12 h and 24 h after surgery were significantly lower than the control group (<i>P</i><0.05); and the incidence of adverse reaction in observation group was significantly lower than the control group (<i>P</i><0.05).<b>Conclusion</b>  Flurbiprofen axetil combined with lidocaine in elderly patients of MRM showed good sedative effect and high safety.]]></description>
<pubDate>2016/11/9 9:59:03</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[LIANG Yanli, ZENG Zhaoxia, YAO Shaohong, YE Zhanqing and HUANG Yuyao]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LIANG Yanli, ZENG Zhaoxia, YAO Shaohong, YE Zhanqing and HUANG Yuyao</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201611014&flag=1]]></guid><cfi:id>134</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Expression of Livin in lung cancer and its correlation with Fas/FasL]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201610014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To study Livin protein expression in lung cancer and its relationship with the expression of Fas and FasL.<b>Methods</b>  Immunohistochemical method was used to detect the expressions of Livin,Fas and FasL in 216 cases of lung cancer,90 cases of adjacent tumor tissues and 45 cases of benign pulmonary disease tissues.<b>Results</b>  The positive rate (53.24%) of Fas in lung cancers was significantly lower than that in adjacent tumor tissues (83.33%) and benign tissues (86.67%).The difference was significant(<i>P</i><0.01).The positive rate of Fas associated with pathological types is differentiation(<i>P</i> <0.05);The positive rate of FasL was related to clinical stage, lymph node metastasis and pathological classing(<i>P</i> <0.05).Conclusion  Our findings suggested that Livin and Fas/FasL may be the apoptosis-related gene involved in the occurrence and development of lung cancer.]]></description>
<pubDate>2016/10/12 14:45:15</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[SU Wenmei, WANG Yan, YE Haiyin, MAI Zongjiong, GUO Kangwen and YANG Zhixiong]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>SU Wenmei, WANG Yan, YE Haiyin, MAI Zongjiong, GUO Kangwen and YANG Zhixiong</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201610014&flag=1]]></guid><cfi:id>133</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Clinical observation on the treatment of congestive heart failure with sodium tanshinone sulfonate combined with meglumine adenosine cyclophosphate]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201610015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To observe the clinical efficacy of sodium tanshinone sulfonate (STS) and meglumine adenosine cyclophosphate (MAC) combined with the treatment of congestive heart failure(CHF).<b>Methods</b>  On the basis of routine treatment for CHF,72 cases of CHF patients were randomly divided into 3 groups.24 cases of STS group,STS 60 mg dissolved in 5% glucose injection 250mL intravenous infusion,1 times daily,14d for 1 courses.24 cases of MAC group,MAC 120 mg in 5% glucose 150 mL intravenous infusion,1 times daily,14 d for 1 courses.24 cases of STS combined with MAC group,the usage and dosage of MAC combined with STS were the same as the two drugs alone.Clinical efficacy of the three groups were observed and compared.<b>Results</b>  The clinical total effective rate of STS combined with MAC group was 95.8%, better than that of MAC group 87.5% and STS group 85.3%,and there was significant difference between the two groups (<i>P</i><0.05).After treatment,STS combined with MAC group, left ventricular diastolic end systolic diameter(LVD),left ventricular end systolic diameter(LVS), left ventricular ejection ejection fraction(LVEF),cardiac output(CO),N-terminal pro-B-type natriuretic titanium (NT-proBNP) concentration improve was superior to that of STS group and MAC group,the difference had statistical significance (<i>P</i><0.05).<b>Conclusion</b>  On the basis of conventional treatment of heart failure, the application of Sodium Tanshinone Sulfonate Injection combined with MAC in the treatment of CHF was effective and worthy of clinical application.]]></description>
<pubDate>2016/10/12 14:45:16</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[WANG Xinhua, LIN Meiping and YUAN Jianhua]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WANG Xinhua, LIN Meiping and YUAN Jianhua</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201610015&flag=1]]></guid><cfi:id>132</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Statistical analysis of unreasonable doctor’s advice in the first quarter of 2017 in PIVAS]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201709014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To strengthen the hospital reasonable application of intravenous transfusion drugs,and ensure the safe and effective for clinical application.<b>Methods</b>  Using retrospective statistical analysis, 382 483 doctor’s advices for infusion received from each nurse station in first season of 2017 in our hospital were reviewed.<b>Results</b>  There were 8 281 unreasonable doctor’s advices,accounting for 2.17% of the total number of doctor’s advices.Types including unreasonable dosing dose,unreasonable dosing frequency,wrong route of administration,unsreasonable solvent selection,incompatibility,unreasonable usage,unsreasonable carrier selection,etc.<b>Conclusion</b>  Pharmacists in Pharmacy Intravenous Admixture Services checked the long-term doctor's advice,can find unreasonable doctor's advice timely and communicate with the clinician and feedback,can effectively reduce the ratio of unreasonable doctor's advice to improve the level of clinical safety medication.]]></description>
<pubDate>2017/9/21 9:45:58</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[LIN Wenxin]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LIN Wenxin</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201709014&flag=1]]></guid><cfi:id>131</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Clinical observation on multipurpose Anziheji in treatment of endometriosis associated infertility of cold stagnation and blood stasis type]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201709015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To observe the effect of multipurpose Anziheji on endometriosis(EMs) associated infertility of cold stagnation and blood stasis syndrome.<b>Methods</b>  60 patients were randomly divided into control group(20 cases) and observation group(40 cases).Patients in control group took Sanjie Zhentong capsule,once 4 capsules,3 times a day,and patients in treatment group took multipurpose Anziheji, 2 times a day,continuing for 12 months.The levels of serum cancer antigen 125(CA125) and CA199,levels of serum matrix metalloproteinase(MMP-3),MMP-9,vascular endothelial growth factor(VEGF) and tumor necrosis factor-α(TNF-α) were detected before and after treatment,and the symptom scores were observed.<b>Results</b>  After therapy,scores of visual analogue scale(VAS),dysmenorrheal,pelvic pain,pelvic tenderness,and sacral ligament tenderness nodules in observation group were significantly lower than those in control group(<i>P</i>＜0.05).After treatment,levels of CA125 and CA199 in observation group were lower than those in control group(<i>P</i>＜0.05),levels of serum MMP-3,MMP-9,VEGF and TNF-α in treatment group were less than those in control group(<i>P</i>＜0.05).The total effective rate in treatment group was superior to that in control group(<i>P</i>＜0.05).The ovarian follicular development in treatment group was obviously improved(<i>P</i>＜0.05),and the ovarian follicular development of multipurpose Anziheji treatment group was better than that of Anziheji treatment group(<i>P</i>＜0.05).<b>Conclusion</b>  Multipurpose Anziheji can obviously improve pain for EMs patients,reduce the inflammatory response,enhance their quality of life,improve the ovarian function of patients,and improve the efficiency of the treatment of infertility.]]></description>
<pubDate>2017/9/21 9:45:58</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[GU Junjie]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>GU Junjie</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201709015&flag=1]]></guid><cfi:id>130</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Regulation of puerarin on vasoactive factors in patients with metabolic syndrome]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201708013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To observe the curative effect and regulation of Puerarin for Injection on the metabolic syndrome and vasoactive factors.<b>Methods</b>  50 cases of patients with metabolic syndrome were randomly divided into control group and experimental group with 25 cases in each group.Two groups were treated with metformin.The experimental group was given Puerarin for Injection for 3 weeks additionally.Blood pressure,blood lipids,plasma glucose,insulin resistance index and the levels of endothelin and nitric oxide were measured before and after treatment.To  compare the difference of the treatment between groups.<b>Results</b>  The systolic blood pressure (SBP),diastolic blood pressure (DBP),total triglyceride (TG),total cholesterol (TC),high density lipoprotein cholesterol (HDL-C),fasting blood glucose (FBG),2 h postprandial blood glucose (PBG), insulin resistance index (HOMA-IR) were statistically significant in the experimental group after treatment.Compared with the control group,the difference of experimental group was significant in SBP,DBP,PBG,FBG(<i>P</i>＜0.05)and statistically significant in TG,TC,HDL-C,HOMA-IR (<i>P</i>＜0.01). ET and NO in the experimental group after the treatment were significantly improved (<i>P</i>＜0.01) and statistical significance compared with the control group(<i>P</i>＜0.05).<b>Conclusion</b>  Puerarin had a significant advantage in the regulation of blood lipid and blood pressure,the mechanism maybe related to improve vascular endothelin and nitric oxide levels.It was one of the important adjuvant therapy for metabolic syndrome.]]></description>
<pubDate>2017/8/30 13:48:11</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[LI Dongjuan, CHU Xueyuan, LI Jing and ZHANG Nannan]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LI Dongjuan, CHU Xueyuan, LI Jing and ZHANG Nannan</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201708013&flag=1]]></guid><cfi:id>129</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Pharmaceutical care for a diabetic patient with urinary tract infection]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201708014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To investigate the effect of drug treatment for one patient with diabetes accompanied with urinary infection.<b>Methods</b>  The clinical pharmacists participated in the treatment of one patient with diabetes accompanied with urinary tract infection,and provided reasonable suggestions for anti-infection treatment. Meanwhile,The clinical pharmacists paid attention to adverse drug reactions during medication.<b>Results</b>  The patient’s blood glucose was effectively controlled,the urinary tract infection was cured,and the adverse drug reaction was disappeared.<b>Conclusion</b>  Clinical pharmacists were involved in the adjustment of the treatment program and provided medication guidances during the clinical treatment,reflecting the professional value of them．]]></description>
<pubDate>2017/8/30 13:48:11</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[WANG Xiao, WANG Weibo<sup>2</sup> and BA Yudong<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WANG Xiao, WANG Weibo<sup>2</sup> and BA Yudong<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201708014&flag=1]]></guid><cfi:id>128</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Observation on the effect of levosimendan in elderly patients with refractory systolic heart failure]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201707014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To analyze the effect of levosimendan on elderly patients with refractory systolic heart failure.<b>Methods</b>  A total of 128 patients with heart failure who met the inclusion criteria were treated with conventional drug eluting therapy for 1 weeks at the initial stage of admission.One week later,38 patients with intractable heart failure were selected.They were divided into control group and treatment group according to the principle of randomization,each with 19 cases.The control group continued to be given conventional treatment,while the treatment group was treated with levosimendan on the basis of conventional treatment.The therapeutic effects of the two groups were compared.<b>Results</b>  Compared with the control group,NYHA,LVEF and NT-proBN of treatment group were significantly improved,and the difference was statistically significant (<i>P</i><0.05).The control group received levosimendan without hypotension,arrhythmia and hypersensitivity, and the patients were well tolerated.<b>Conclusion</b>  Levosimendan was effective in the treatment of elderly patients with refractory systolic heart failure,and had better safety and tolerability.]]></description>
<pubDate>2017/7/21 15:57:15</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[YAN Lixin]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>YAN Lixin</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201707014&flag=1]]></guid><cfi:id>127</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Application of quality control circle in ruducing narcotic drugs batch tracking discrepancy rate]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201707015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To explore the application of quality control circle in ruducing narcotic drugs batch tracking discrepancy rate.<b>Methods</b>  Check the error of narcotic drugs injection batch tracking number error in three months before ctivity(control group).The quality control circle was set up in order to reduce batch tracking discrepancy rate.After the end of the activity,check the error in one month(experimental group),compared two groups of batch tracking situation.<b>Results</b>  Through the continuous quality improvement continuously, narcotics batch tracking discrepancy rate by 2.67/month fell to zero, the difference was statistically significant.<b>Conclusion</b>  Quality management circle activity in reducing hospital narcotics in the batch tracking discrepancy rate effect is remarkable.]]></description>
<pubDate>2017/7/21 15:57:15</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[ZHANG Yuan, TANG Zhenxiang and MIAO Qingyuan]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Yuan, TANG Zhenxiang and MIAO Qingyuan</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201707015&flag=1]]></guid><cfi:id>126</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Participation of clinical pharmacists in analysis of one case of tramadol-warfarin interaction]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201706015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To investigate the significance of clinical pharmacists participate in analysis of one case of tramadol-warfarin interaction.<b>Methods</b>  Clinical pharmacists participated in one case of tramadol-warfarin interaction,and provided suggestions and pharmaceutical cares on the basis of the signs,laboratory examination and disease condition.<b>Results</b>  The condition of patients gradually improved.<b>Conclusion</b>  The participating of clinical pharmacists in clinical therapy can provide suggestions of pharmaceutical using and pharmaceutical care,promote rationality and safety of medication.]]></description>
<pubDate>2017/6/19 13:58:15</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[TANG Hui, ZHANG Yahui, ZOU Dongna and ZHAO Xuemei]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>TANG Hui, ZHANG Yahui, ZOU Dongna and ZHAO Xuemei</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201706015&flag=1]]></guid><cfi:id>125</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Analysis of drug use in 1082 cases of early pregnancy abortion]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201705014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b> Discussion on the drug use in 1082 cases of early pregnancy abortion. <b>Methods</b> Through retrospective investigation，we extract 1082 prescriptions about early pregnancy abortion（medicaments abortion and Vaccum Suction）from one grade class-A hospital for Maternity and Child Care，prescriptions time is from January 18, 2015 to January 18, 2016 .The datas were analyzed statistically through designing table and investigating the use of drug.<b>Results</b> Early pregnancy abortion patients account for 4.29% of the gynaecology patients，the using drugs include antibacterial agents and Intravenous anesthetics and Chinese patent medicine and estrogen，they are 26.00% and 8.08% and 53.71% and 8.16%.<b>Conclusions</b> Antibacterial agents were used arbitrarily in medicaments abortion，medicine can be used prophylactically during perioperative periodin in Vacuum Aspiration，but it often occured at the wrong moment . Chinese patent medicine were over - used other than new biochemical drug，it belonged to unreasonable application，so further research in this field was needed.]]></description>
<pubDate>2017/5/23 16:01:09</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[WANG Hongmei<sup>1</sup>, SUN Jingang<sup>2</sup> and ZHANG Zhen<sup>3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WANG Hongmei<sup>1</sup>, SUN Jingang<sup>2</sup> and ZHANG Zhen<sup>3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201705014&flag=1]]></guid><cfi:id>124</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Clinical progress of Decitabine]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201705015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Decitabine is a nucleoside metabolic inhibitor indicated for treatment of patients with myelodysplastic syndromes (MDS).In September 2012,the European Medicines Agency approved as a treatment for acute myelogenous leukemia.The advancement of Decitabine in current clinic researches are reviewed in this article．]]></description>
<pubDate>2017/5/23 16:01:10</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[YANG Tongjiang, CHEN Yancheng, XIE Lili and SHAN Yanqiang]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>YANG Tongjiang, CHEN Yancheng, XIE Lili and SHAN Yanqiang</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201705015&flag=1]]></guid><cfi:id>123</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Participation of clinical pharmacists in the empirical anti-infective therapy for a case of AECOPD with pulmonary infection]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201704014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To investigate the significance of clinical pharmacists participate in the empirical anti-infective therapy for acute aggravating period of chronic obstructive pulmonary disease (AECOPD).<b>Methods</b>  Clinical pharmacists participated in one case of AECOPD with pulmonary infection and fungal infection,and provided suggestions and pharmaceutical cares during the empirical anti-infective therapy on the basis of the signs,auxiliary examination and disease condition.<b>Results</b>  No serious ADR was found during therapy,the condition of patients gradually improved.<b>Conclusion</b>  The participating of clinical pharmacists in clinical therapy can provide suggestions of pharmaceutical using and pharmaceutical care,promote rationality and safety of medication.]]></description>
<pubDate>2017/5/2 14:32:10</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[MA Shaoxin<sup>1</sup> and KONG Wei<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>MA Shaoxin<sup>1</sup> and KONG Wei<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201704014&flag=1]]></guid><cfi:id>122</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Clinical application of Gefitinib]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201704015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Gefitinib is an EGFR inhibitor. It is only effective in cancers with mutated and overactive EGFR. The CFDA approved gefitinib in 2005 for non-small cell lung cancer (NSCLC). It was approved as monotherapy for the treatment of patients with locally advanced or metastatic NSCLC after failure of both platinum-based and docetaxel chemotherapies.On July 13,2015,FDA approved as a first-line treatment for NSCLC.The advancement of gefitinib in current clinic researches were reviewed in this article．]]></description>
<pubDate>2017/5/2 14:32:10</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[YANG Tongjiang, WANG Quanliang, XIE Lili and SHAN Yanqiang]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>YANG Tongjiang, WANG Quanliang, XIE Lili and SHAN Yanqiang</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201704015&flag=1]]></guid><cfi:id>121</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Analysis of curative effect of Xueshuantong Injection combined with alprostadil and lipoic acid on diabetic foot]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201703014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To observe the clinical therapeutic effect of Xueshuantong Injection combined with alprostadil and lipoic acid on diabetic foot.<b>Methods</b>  62 patients with diabetic foot were randomly divided into two groups,the control group of patients were given the basis of conventional treatment.The treatment group was given Xueshuantong Injection combined with alprostadil and lipoic acid.The therapeutic effect were inspected.<b>Results</b>  The total effective rate of two treatment groups had significant difference (<i>P</i>＜0.05).The Hcy,VB12 and MMP-9 concentration of two groups had significant difference (<i>P</i><0.05).There was no significant difference in biochemical index(<i>P</i>>0.05).<b>Conclusion</b>  Xueshuantong Injection combined with alprostadil and lipoic acid on diabetic foot had distinct curative effect and the cure rate can be improved effectively.]]></description>
<pubDate>2017/4/17 14:20:01</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[LYU Jingyi, GUAN Wujie, HE Yi and CHEN Cong]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LYU Jingyi, GUAN Wujie, HE Yi and CHEN Cong</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201703014&flag=1]]></guid><cfi:id>120</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[The application and experience of auto-dispense machine in our hospital outpatient pharmacy]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201703015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To evaluate changes before and after application of auto-dispense machine in clinic pharmacy.<b>Methods</b>  To observe the changes of outpatient pharmacy drug dispensing process,statistically analyse the time of prescription dispensing and review and prescription dispensing error rate before and after auto-dispense machine used 90 work-days.The outpatient service work before and after using of auto-dispense was estimate.<b>Results</b>  Service quality and work efficiency had obviously improved after auto-dispense machine used.<b>Conclusion</b>  The advantage of auto-dispense machine should be developed,and need to improve the management mode and operating environment.]]></description>
<pubDate>2017/4/17 14:20:01</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[WANG Cunwei]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WANG Cunwei</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201703015&flag=1]]></guid><cfi:id>119</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Analysis of drug use of outpatient in IVF department]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201702014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To investigate the clinical application of drug in IVF department,and provide reference for rational drug use.<b>Methods</b>  The application data of drugs in IVF department such as pharmacological actions,the usage amount,defined daily doses(DDDs),defined daily cost(DDC),the amount sorts/DDDs sorts (B/A) were analyzed with the help of Hospital Information System(HIS).<b>Results</b>  IVF department ovulation induction and sex hormone class medicine were the mainstay in IVF department.The usage amount and DDDs sorts were different.<b>Conclusion</b>  The drugs used in IVF department are reasonable structurally,therapeutic plan can be determined by different condition and economic status of patients.Some ovulation induction and sex hormone class medicine were expensive, it has added to patients'financial burden.]]></description>
<pubDate>2017/3/28 14:39:39</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[WANG Honghong<sup>1</sup>, HUANG Yuling<sup>1</sup>, XU Hongbing<sup>2</sup>, LI Yong<sup>1</sup>, LU Caihong<sup>1</sup> and MAO Guifu<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WANG Honghong<sup>1</sup>, HUANG Yuling<sup>1</sup>, XU Hongbing<sup>2</sup>, LI Yong<sup>1</sup>, LU Caihong<sup>1</sup> and MAO Guifu<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201702014&flag=1]]></guid><cfi:id>118</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Comparison of the efficacy of propofol respectively combined with fentanyl,dezocine and butorphanol for painless gastroscopy]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201702015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To compare the efficacy of propofol respectively combined with fentanyl,dezocine and butorphanol for painless gastroscopy.<b>Methods</b>  114 cases of patients for painless gastroscopy were randomly divided into fentanyl group,dezocine group and butorphanol group,each group had 38 patients.All patients were fasted for 8 h and prohibited drink water for 4 h before examination,had no preanesthetic medication. Patients in fentanyl group were intravenous pushed fentanyl 1 μg·kg<sup>-1</sup>,patients in dezocine group were intravenous pushed dezocine 20 μg·kg<sup>-1</sup>,patients in butorphanol group were intravenous pushed butorphanol tartrate 10 μg·kg<sup>-1</sup>.All patients in 3 groups were intravenous pushed propofol 2 mg·kg<sup>-1</sup> after 5 min.The changes of SBP,DBP,HR,SpO2 were observed,and the conditions of body movement,respiratory depression,wake up time,nausea and vomitting,dizzy were compared.<b>Results</b>  Comparing with before check,each index of all patients on the time of in check were reduced（<i>P</i>＜0.05）.Comparing with fentanyl group,the DBP of fentanyl group and HR of butorphanol group on the time of in check was reduced(<i>P</i>＜0.05）.After check,the HR of butorphanol group was rised（<i>P</i>＜0.05）.The wake up time of butorphanol group was obviously shorter than other two groups.Nausea,vomiting and dizzy were appeared in each group,but the incidence rate in butorphanol group was obviously lower than fentanyl group and dezocine group（<i>P</i>＜0.05）.<b>Conclusion</b>  The anesthesia effect and safety of propofol combined with butorphanol for painless gastroscopy was better than with fentanyl and dezocine.]]></description>
<pubDate>2017/3/28 14:39:39</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[GAO Tianqin<sup>1</sup>, ZHANG Quanyi<sup>1</sup>, MA Yibing<sup>2</sup> and SUN Meijuan<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>GAO Tianqin<sup>1</sup>, ZHANG Quanyi<sup>1</sup>, MA Yibing<sup>2</sup> and SUN Meijuan<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201702015&flag=1]]></guid><cfi:id>117</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Analysis on the application of antimicrobial drug in our hospital from 2013 to 2015]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201701015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To analyze the application of antimicrobial drug in the hospital from 2013 to 2015,evaluate the rationality of antimicrobial application,provide basis for clinical treatment.<b>Methods</b>  Taking out the indications data of rational drug use from the hospital information system,and then to summarize and analyze the data.<b>Results</b>  The application rate of outpatient antimicrobial,the application rate of emergency antimicrobial,the application rate of hospitalization patient antimicrobial,the antimicrobial use density was decreased from 17.86%,35.29%,60.44%,55.00 DDDs to 13.93%,30.69%,56.36%,43.08 DDDs,peroperative antibiotics prophylaxis in Class I incisions was increased from 22.36% to 24.36%, the detection rate of microbiological specimens before therapeutic use of antibiotics was a little up and down.<b>Conclusion</b>  The level of rational application antimicrobial drugs was improved significantly.But monitoring the application of antibiotics to promote clinical rational application antibiotics was urgent.]]></description>
<pubDate>2017/2/27 15:13:06</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[CHEN Jieyan<sup>1</sup>, GUO Shenglan<sup>1</sup>, ZHAO Hua<sup>1</sup>, LUO Chongbin<sup>1</sup>, LI Liping<sup>1</sup> and YU Lei<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>CHEN Jieyan<sup>1</sup>, GUO Shenglan<sup>1</sup>, ZHAO Hua<sup>1</sup>, LUO Chongbin<sup>1</sup>, LI Liping<sup>1</sup> and YU Lei<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201701015&flag=1]]></guid><cfi:id>116</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[To observe the curative effect of thymosin in treatment of liver cirrhosis complicated with spontaneous bacterial peritonitis.]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201701016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To observe the clinical application effect of thymosin treatment of liver cirrhosis complicated with spontaneous bacterial peritonitis.<b>Methods</b>  98 cases of cirrhosis complicated with spontaneous bacterial peritonitis in our hospital were enrolled,and randomly divided into treatment group (<i>n</i>=55) and control group (<i>n</i>=43).Anti-infection of the two groups were given two weeks of treatment (three generation cephalosporins),protecting liver,diuresis,plasma albumin and supportive treatment.On this basis,the treatment group was treated with thymosin alpha l 1.6 mg,subcutaneous injection,once every two days.Observe and record the two groups of patients before and after treatment of ascites PMN count and abdominal circumference size,and the occurrence of adverse reactions during treatment of patients.<b>Results</b>  The treatment group in the cure rate (32.7%vs23.3%,χ<sup>2</sup>=3.914,<i>P</i>=0.043),the total effective rate (85.4%vs72.1%,χ<sup>2</sup>=34.065,<i>P</i>=0.038) were better than the control group,comparison between groups was statistically significant (<i>P</i><0.05);In addition,the treatment group in the ascites decreased PMN count and waist circumference were significantly higher than that the control group of narrow etc. (<i>P</i><0.05 or <i>P</i><0.01).<b>Conclusion</b>  Thymosin good clinical efficacy in the treatment of liver cirrhosis complicated with spontaneous peritonitis, especially had certain clinical value in improving symptoms and disease control ascites.]]></description>
<pubDate>2017/2/27 15:13:06</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[KE Wenbing and CHEN Yansheng]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>KE Wenbing and CHEN Yansheng</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201701016&flag=1]]></guid><cfi:id>115</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[The influences of liquid mass ration on fluid volume changes and the cutantest concentration]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201712014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To research the relationship among the ratio of liquid volume and quality,liquid volume changes and the cutantest concentration calculated in cutantest preparation,and provide references to penicillin and cephalosporin preparation.<b>Methods</b>  35 drugs of penicillin and cephalosporin were selected and the liquid volume changes were recorded after the drugs were dissolved by certain solvent.The results of the ratio of liquid volume and quality,liquid volume changes and concentration of cutantest were analyzed with linear regression.<b>Results</b>  The linear regression equation of liquid mass ratio and fluid change rate was <i>Y</i>=-1.169+66.339/<i>X</i>(3.3≤<i>X</i>≤13.33);The linear regression equation of liquid mass ratio and calculated concentration was ln<i>Z</i>=5.710-0.6/<i>X</i>,(3.3≤<i>X</i>≤13.33).<b>Conclusion</b>  When the Liquid mass ratio was larger,the calculated concentration of cutantest was closer to the theoretical concentration.In order to eliminate the influence of liquid volume changes on the cutantest concentration,the value of of liquid volume changes can be corrected by the above formula.]]></description>
<pubDate>2018/1/4 15:58:19</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[CHEN Min and YANG Min]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>CHEN Min and YANG Min</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201712014&flag=1]]></guid><cfi:id>114</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[The efficacy and superiority of the treatment of primary hypertension with Nifedipine Substained-release Tablets Ⅱ]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201712015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>To evaluate the efficacy and superiority of the treatment of primary hypertension. <b>Methods</b> In this study,140 patients with primary hypertension, who were admitted to the hospital in March, 2016, were randomly divided into control group (68 cases) and observation group (72 cases).The control group was treated with metoprolol, and the observation group was treated with the treatment of Nifuda, which monitored the blood pressure and heart rate changes in the two groups during the treatment, and compared the clinical efficacy and drug safety of the two groups.<b>Results</b> After treatment,the SBP/DBP index level of the observation group (128.56 plus or minus 10.23/84.24, plus or minus 6.02 mmHg) was significantly lower than that in the control group (143.58+11.71/90.47 or 0.47 mmHg), and the difference between groups was significant（P<0.05）.The incidence of adverse reactions (13.89%,10/72) was slightly higher than the control group (11.76%,8/68),but no significant difference wassignificant（P<0.05）.<b>Conclusion</b>Thetreatmentof patients with primary hypertension was reliable,which can effectively improve the effect of blood pressure,improve the heart rate of patients,and be safe and effective in clinical application.]]></description>
<pubDate>2018/1/4 15:58:19</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[FAN Zhenxing]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>FAN Zhenxing</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201712015&flag=1]]></guid><cfi:id>113</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Effects of aspirin combined with folic acid on serum Hcy, CRP, IL-6 and TNF-α levels in elderly hypertensive patients]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201711015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To investigate the effects of aspirin and folic acid on serum levels of Hcy, CRP, IL-6 and TNF-α in elderly patients with H-type hypertension.<b>Methods</b>  The elderly patients with H-type hypertension who were treated in our hospital from January 2015 to June 2016 were randomly divided into control group and observation group. The control group was treated with folic acid (0.8 mg/qd) on the basis of routine treatment.The observation group was treated with aspirin enteric-coated tablets (100 mg/qd) on the control group for 24 weeks. The changes of blood pressure and serum levels of Hcy, CRP,IL-6 and TNF-α were observed and compared before and after treatment.<b>Results</b>  Compared with before treatment, the levels of blood pressure (systolic and diastolic blood pressure) and serum Hcy, CRP, IL-6 and TNF-α in the two groups were significantly decreased (<i>P</i><0.05). In addition, the levels of Hcy, CRP, IL-6 and TNF-α in the serum of the observation group were significantly lower than those in the control group (<i>P</i> <0.05).<b>Conclusion</b>  The combination of aspirin and folic acid can effectively reduce the levels of serum Hcy and related inflammatory factors (CRP, IL-6 and TNF-α) in elderly patients with H-type hypertension.]]></description>
<pubDate>2017/12/7 15:02:27</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[WU Xuefeng, LI Aiguo and LIN Weidong]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WU Xuefeng, LI Aiguo and LIN Weidong</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201711015&flag=1]]></guid><cfi:id>112</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Application of self developed nutrition support software in inpatient department of orthopedics in geriatric hospital]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201711016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>To screen the nutritional risk and to assess the rationality of  the undergoing clinical nutrition strategies in the department of orthopaedics in geriatric hospital,with the software developed by our team.<b>Methods</b>With the self-development of "individualized clinical nutrition support" software,combine the nutritional risk screening (NRS2002) and short-form mini-nutritional assessment（MNA-SF）tools to prospective evaluation nutritional risk profile and rationality review of nutritional therapy of the hospital from October toDecember of2016.<b>Results</b>　Totally,112 patients were included,with a mean age of (81.4±4.7)years.WithNRS2002 and MNA-SF methods,it showed that 67.9%and 51.8%of the patients had nutrition risk, 8.0% of the patients had undernutrition（BMI<18.5kg·m<sup>-2</sup>）.The overall nutrition approval rating was 81.3%,PN and EN support occupied separately 77.4% and 20.4%.There were 2 patients use both EN and PN.76.2% of patients accepted single bottle transfusion and only 23.8% used “3 in1”mixtransfusion.Nutritional support for patients with and without nutritional risk were respectively 82.8%和79.6%.<b>Conclusion</b>The traditional clinical nutrition support scheme still existed irrationality.The clinical application mode of nutritional support software will be conducive to individualized hospital clinical nutrition support and further standardize work.]]></description>
<pubDate>2017/12/7 15:02:27</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[WANG Fei, HUANG Xuhui, HUANG Xin, LIN Kui and LIU Gang]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WANG Fei, HUANG Xuhui, HUANG Xin, LIN Kui and LIU Gang</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201711016&flag=1]]></guid><cfi:id>111</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[TPMT gene polymorphism and 6-MP dividual therapy in children ALL]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201710014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[6-mercaptopurine (6-MP) is a key drug for the maintainable treatment in childhood acute lymphoblastic leukemia (ALL).Thiopurine S-methyltransferase (TPMT) has been confirmed as one of the most distinctive enzymes,its gene polymorphisms and activity are associated with tolerance in ALL children which further affect the incidence of adverse reactions and long-term prognosis of ALL children with 6-MP. In addition,TPMT genotype may also be related to second malignant neoplasm (SMN).So detecting TPMT genotypes may be helpful to predict the severity of adverse reaction with thiopurine drugs, adjustment of the dosage in time, might make a safety and reasonable dividual medicine programs in clinical treatment.This article reviews the effect of TPMT gene polymorphism on the individual treatment of 6-MP in childhood ALL.]]></description>
<pubDate>2017/10/24 9:20:11</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[ZHANG Yichi, ZHAO Xiaolin, WANG Xiaoyan, HAO Lina and WU Xuexin]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Yichi, ZHAO Xiaolin, WANG Xiaoyan, HAO Lina and WU Xuexin</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201710014&flag=1]]></guid><cfi:id>110</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Challenges and opportunities for clinical pharmacists in the context of precision medicine]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201710015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Precision medicine is defined as clinical treatments,medication and services targeted to the needs of individual patients on the basis of genetic,proteomics,biomarker,phenotypic,or psychosocial characteristics that distinguish a given patient from other patients with similar clinical presentations.Inherent in this definition is the goal of improving clinical outcomes for individual patients and minimizing unnecessary side effects for those less likely to have a response to a particular treatment.Clinical pharmacists participated in the diagnosis of clinical diseases and gave individualized treatment,which could promote and improve the healthy development of precision medicine.Precision medicine would change the existing diagnosis,treatment model and bring a change to medical development.Precision medicine not only challenges the traditional medical thinking model,but also offers significant opportunities for clinical pharmacists.]]></description>
<pubDate>2017/10/24 9:20:11</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[NIU Xiaofang]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>NIU Xiaofang</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201710015&flag=1]]></guid><cfi:id>109</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Different brands antihypertensive drugs of Connotation response on 85 hospitalized patients and analysis of influential factors]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201809013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To investigate the influence of antihypertensive drugs brand on the outpatient response to the selection and compliance.<b>Methods</b>  For the drug brand connotation response and medication adherence questionnaire,85 hospitalized patient were included for this study,the score results were statistically analyzed to compare the influence of antihypertensive drugs brand on the outpatient response to the selection and compliance.<b>Results</b>  The patients who have higher income expressed higher recognition on ventures-imported brands drugs than domestic brands,and the difference was statistically significant (<i>P</i><0.05);the age,education level,income level are showing moderate correlation with the antihypertensive drugs brand response degrees;The age and income level were showing moderate correlation with the long-term adherence to medication.<b>Conclusion</b>  The tendency of medication selection and compliance were linking with the educational level,income level,age and gender,medical workers should be targeted to take effective methods and measures to improve patient medication compliance.]]></description>
<pubDate>2018/9/29 14:08:05</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[ZHANG Chenghao]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Chenghao</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201809013&flag=1]]></guid><cfi:id>108</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Efficacy of fluconazole liquid ear bath and clodazole ointment on the treatment of external ear fungal disease]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201807015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To compare the curative effect of fluconazole liquid and clodazole ointment on the treatment of external ear fungal disease.<b>Methods</b>  74 patients were randomly assigned to the observation group and control group of the patients with external ear mycosis,and the observation group used 0.2% fluconazole fluid ear bath,and the control group used clotriazole ointment to coat the ear external ear.After two weeks of treatment and three months of follow-up clinic,the effective treatment of different drugs in two groups were compared.<b>Results</b>  The effective rate of the observation group was 97.3%,and the effective rate of the control group was 70.97%,and there was a significant difference between the two groups (P<0.05).<b>Conclusion</b>  The effect of fluconazole liquid ear bath on the treatment of external ear fungus was better than that of trizole ointment.The former was easier to use and accept,which was worthy of clinical promotion.]]></description>
<pubDate>2018/8/1 16:47:06</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[CHEN Ping<sup>1</sup>, WANG Yuhong<sup>1</sup> and ZHU Lingyun<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>CHEN Ping<sup>1</sup>, WANG Yuhong<sup>1</sup> and ZHU Lingyun<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201807015&flag=1]]></guid><cfi:id>107</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Medication analysis of clinical pharmacists participating in one patient with severe drug-induced thrombocytopenia]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201806015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To investigate the related drugs of severe drug-induced thrombocytopenia in patients with acute myocardial infarction after percutaneous coronary intervention (PCI).<b>Methods</b>  The typical cases participated by clinical pharmacist were shared and analyzed from three aspects of analyzation of drugs that may caused drug-induced thrombocytopenia, formulation of therapeutic regimen and implementation of pharmaceutical care.<b>Results</b>  Tirofiban as a suspect drug for thrombocytopenia was identified. Platelets of the patient gradually returned to normal level with symptomatic treatment.The patient discharged after symptomatic remission.<b>Conclusion</b>  Clinical pharmacists participated in the treatment and monitoring of patients with drug-induced thrombocytopenia,can reduce the occurrence of adverse reactions,to ensure the safety of patients.]]></description>
<pubDate>2018/7/6 16:37:45</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[ZHOU Qingqiu<sup>1</sup> and WU Yun<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHOU Qingqiu<sup>1</sup> and WU Yun<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201806015&flag=1]]></guid><cfi:id>106</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Medication analysis of clinical pharmacists participating in one child patient with severe exfoliative dermatitis]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201805013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To investigate the relationship between anaplastic large cell lymphoma and delayed severe exfoliative dermatitis,in order to explore the role of clinical pharmacists in guiding drug use.<b>Methods</b>  Systematically analyzes the drug administration process,drug combination,and the occurrence and treatment of dermatitis of a case of exfoliative dermatitis.<b>Results</b>  The severe exfoliative dermatitis was resulted by anaplastic large cell lymphoma itself and the drugs used in treatment.<b>Conclusion</b>  Clinical pharmacists participated in the treatment and monitoring of patients with drug-induced thrombocytopenia, can reduce the occurrence of adverse reactions, to ensure the safety of patients.]]></description>
<pubDate>2018/6/13 9:41:48</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[ZHANG Shuping<sup>1</sup>, LENG Jiawei<sup>2</sup> and ZHANG Jing<sup>3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Shuping<sup>1</sup>, LENG Jiawei<sup>2</sup> and ZHANG Jing<sup>3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201805013&flag=1]]></guid><cfi:id>105</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Analysis of narcotic use in inpatients pharmacy of our hospital in 2016]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201804014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To provide reference for the scientific management and the rational usage of narcotic drugs.<b>Methods</b>  The utilization of narcotic drugs for inpatients in our hospital in 2016 were collected from HIS,and analyzed statistically in respects of consumption amount,consumption sum,DDDs,B/A,DDC and consumption amount of the different departments.<b>Results</b>  The consumption amount of Morphine Sulfate Sustained-release Tablets,Codeine Phosphate Tablets and Oxycodone Hydrochloride Prolonged-release Tablets (10 mg) ranked the first 3 places.The consumption sum of Remifentanil Hydrochloride for Injection,Sufentanil Citrate Injection and Oxycodone Hydrochloride Prolonged-release Tablets (10 mg) ranked the first 3 places.Remifentanil Hydrochloride for Injection,Sufentanil Citrate Injection and Morphine Hydrochloride Injection Bucinnazine Hydrochloride Injection steadily occupied the first 3 places in the list of DDDs.B/A value of Remifentanil Hydrochloride for Injection,Sufentanil Citrate Injection and Bucinnazine Hydrochloride  Injection were all equal to 1 and synchronized well,others all had deviation.The DDC of Sufentanil Citrate Injection took up the first place,and Codeine Phosphate Tablets took up the last 1 place.There were 56% departments used narcotic drugs in our hospital,but mainly in the department of oncology and general surgery, accounting for 56%.<b>Conclusion</b>  The variety and dosage form of narcotic drugs could meet the clinical needs and its application was basically reasonable.]]></description>
<pubDate>2018/5/23 17:07:56</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[YIN Ling, ZHANG Xiuzhen, CHEN Wenwen, LIU Yanlin, GENG Tao and DANG Heqin]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>YIN Ling, ZHANG Xiuzhen, CHEN Wenwen, LIU Yanlin, GENG Tao and DANG Heqin</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201804014&flag=1]]></guid><cfi:id>104</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[The effectiveness analysis of clinical pharmacists intervention in patients with severe renal insufficiency]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201803013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  Investigating the effect of clinical pharmacists intervention in patients with severe renal insufficiency, to provide reference for clinical pharmacists to carry out clinical work in depth.<b>Methods</b>  Review the inpatient order from January 2016 to December 2016 in patients with severe renal insufficiency, give suggestions and optimize the unreasonable medical orders.<b>Results</b>  A total of 243 clinical pharmacists intervention carried out and successfully intervened 195 times,with a total success rate of 80.25%,including 54.36% drugs dosage adjusted; The success rate of antibiotic drugs was 90.12%.Through adjusted dose of medication in 106 patients,the average daily cost reduced about (45.2±10.8)RMB;Through replaced the clinical medication of 57 patients,a total cost of 3 668.9 RMB for patients was saved.<b>Conclusion</b>  By intervening on drug selection and dosage in patients with renal insufficiency, clinical clinicists can significantly reduce the incidence of unreasonable medical order and improve their medication habits to ensure the medication safety of patients.]]></description>
<pubDate>2018/4/19 15:28:05</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[SHAO Yuping]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>SHAO Yuping</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201803013&flag=1]]></guid><cfi:id>103</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Participation of clinical pharmacist in analysis of one case of severe gastrointestinal adverse reactions caused by mycophenolate mofetil （MMF）of an nephrotic syndrome（NS）child]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201802015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To explore the role of clinical pharmacists in the treatment of children with nephrotic syndrome (NS) in MMF administration.<b>Methods</b>  The clinical pharmacists participated in 1 case therapy of children with NS in the early treatment of MMF administration with severe gastrointestinal discomfort to provide reasonable suggestions.Meanwhile,pharmaceutical monitoring was provided for the children in the process of the drug administration.<b>Results</b>  Since urinary protein control was poor after taking tacrolimus,tacrolimu was successfully replaced by MMF for nephrotic syndrome (NS) in this treatment and eventually result in severe gastrointestinal adverse reactions,which may be related to the gastrointestinal adverse reactions common in MMF.<b>Conclusion</b>  Clinical pharmacists participated in the adjustment of treatment program and provided medication guidances and individualized monitoring during the clinical treatment,it was indicated that the majority of patients can gradually tolerant the MMF gastrointestinal adverse reaction according to some references,therefore it was recommended to continue taking MMF after the gastrointestinal symptoms was improved.Meanwhile,the pharmaceutical care for the children in the process of administration indicated their professional value.]]></description>
<pubDate>2018/3/26 15:43:50</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[JI Bo<sup>1</sup>, ZHANG Yong<sup>2</sup> and SHEN Yan<sup>3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>JI Bo<sup>1</sup>, ZHANG Yong<sup>2</sup> and SHEN Yan<sup>3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201802015&flag=1]]></guid><cfi:id>102</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[The medication analysis of folic acid in four cases of children with renal failure and anemia]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201801014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To analyze the use of folic acid in the children with renal failure and anemia,which indicated the role of the clinical pharmacist in the therapeutic process and provided the reasonable medication guidelines.<b>Methods</b>  4 children with renal failure and anemia treated with folic acid were monitoring, and the medication of folic acid administration in children was controlled by determining the level of folic acid.<b>Results</b> Children with renal failure didn’t recommend giving routine folic acid supplement, which due to the highly abnormal cardiac function caused by folic acid.It was recommended that we should take into account the folate levels and Methylene Tetrahydrofolate Reductase (MTHFR) metabolism to administrate folic acid pertinently in order to lower the high hyperhomocysteinemia (HHcy) level in the children with renal failure. <b>Conclusion</b>  Clinical pharmacists were involved in the adjustment of treatment program, meanwhile, the use of folic acid in children with renal failure and anemia was analyzed to reduce the occurance of short and long-term adverse reactions indicating the their professional value.]]></description>
<pubDate>2018/2/7 9:32:16</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[JI Bo<sup>1</sup>, SHEN Yan<sup>2</sup> and ZHANG Yong<sup>3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>JI Bo<sup>1</sup>, SHEN Yan<sup>2</sup> and ZHANG Yong<sup>3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201801014&flag=1]]></guid><cfi:id>101</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Analysis of typical cases of unstable angina in the treatment of Yangxinshi Tablets]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201907013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  This article explored the possible mechanism of Yangxinshi Tablet (YXST) 's treatment of coronary heart disease by observing the effect of YXST's on the phenotype and function of peripheral blood mononuclear cells in patients with unstable angina pectoris of coronary heart disease.<b>Methods</b>  One typical patient with unstable angina pectoris of coronary heart disease was selected. The basic information, blood lipid, liver function, kidney function and serum cystatin C were recorded. Monocytes were extracted from peripheral venous blood, and the expression of CD163, CD206, IL-10 and IL-12 in monocytes was detected by flow cytometry. The levels of IL-10, IL-12 and TNF-alpha in serum were measured by ELISA. The patients were assessed by comprehensive quality of life scale: Seattle Angina Questionnaire (SAQ), General Anxiety Self-Rating Scale (GAD-7), and 9-item Patient Health Questionnaire (PHQ-9).<b>Results</b>  After YXST combination of conventional drugs treatment, the expression of CD14<sup>+</sup>CD163<sup>+</sup>CD206<sup>+</sup> in monocytes was up-regulated, while the expression of CD14<sup>+</sup>CD163<sup>-</sup>CD206<sup>-</sup>was down-regulated.The expression of pro-inflammatory factors IL-12 and TNF-alpha decreased, while the expression of anti-inflammatory factor IL-10 increased compared with before treatment.The Seattle Scale score was improved,and the scores of GAD-7 General Anxiety Scale and Depression Scale were decreased.<b>Conclusion</b>  YXST play an anti-atherosclerosis role by may promoting the phenotype transformation of macrophages, changing the inflammatory state of patients with coronary heart disease.YXST have the effect of double heart treatment.]]></description>
<pubDate>2019/7/26 10:27:48</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[WANG Mingyu<sup>1,2</sup>, YANG Lina<sup>1,3</sup>, TONG Yaqi<sup>1,2</sup> and DING Yanchun<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WANG Mingyu<sup>1,2</sup>, YANG Lina<sup>1,3</sup>, TONG Yaqi<sup>1,2</sup> and DING Yanchun<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201907013&flag=1]]></guid><cfi:id>100</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Effectiveness research in immunologic function of immunomodulator on measles children]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201906013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To evaluate the effectiveness of immunologic function of Thymopetidum Injection on children with measles.<b>Methods</b>  Children with measles were divided into experimental group and control group.Experimental group were given Thymopetidum Injection by intravenous drip;Control group only given general treatment.Lymphocytes cells counting in the groups were tests after treatment.Control group was tested before treatment.The clinical efficacy was evaluated,and adverse reaction observed.<b>Results</b>  As the extension of time,Thymopetidum could balance T-lymphocytes subgroup,promote CD19+,NK lymphocytes to normal range.The time to defervescence,the number of complications and the cure time of measles between two groups were different.No significant adverse reaction was found in four groups.<b>Conclusion</b>  Thymopetidum can raise cell-immunologic function on measles patients,reduce inflammation activity,and improve the prognosis ultimately.]]></description>
<pubDate>2019/6/27 10:49:44</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[LI Sanni and ZHANG Guying]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LI Sanni and ZHANG Guying</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201906013&flag=1]]></guid><cfi:id>99</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Analysis of one case of Yangxinshi Tablets combined with enhangce external counter pulsation (EECP) on patients with asthenia and shortness of breath after DCB]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201904013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To observe the clinical efficacy of Yangxinshi Tablets combine with enhanced external counter pulsation (EECP) in improving exercise tolerance after DCB.<b>Methods</b>  On the basis of standardized medical treatment of western medicine, Yangxinshi Tablets combine with enhanced external counter pulsation (EECP) were used to treat patients with DCB, and observe the changes of TCM symptom scores and metabolic equivalents (METs).<b>Results</b>  After treatment, patients with DCB had a quality of life score of 7 and exercise tolerance of 6.8 METs.<b>Conclusion</b>  Yangxin Tablet combined with enhanced external counter pulsation improves the symptoms of fatigue and shortness of breath after DCB, improves exercise tolerance and improves quality of life.it has positive and effective clinical effects.]]></description>
<pubDate>2019/5/10 16:54:54</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[GUO Caijie<sup>1</sup>, ZHONG Xiaozheng<sup>1</sup> and GONG Lihong<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>GUO Caijie<sup>1</sup>, ZHONG Xiaozheng<sup>1</sup> and GONG Lihong<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201904013&flag=1]]></guid><cfi:id>98</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Literature analysis of 59 cases of drug-induced pancreatitis]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201903012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To investigate characteristics of drug-induced pancreatitis, supplying evidences for rational drug use in clinical practice.<b>Methods</b>  Related literatures of drug-induced pancreatitis published on CNKI database from 1987 to 2018 were collected and analyzed.<b>Results</b>  A total of 56 articles were included, involving 59 cases. Anticancer drugs, anti-infective drugs and hormone drugs were associated with high occurrence rate (28.81%,23.73% and 15.25%,respectively). Patients aged less than 10 years old appear to have highest occurrence rate (22%). Of 59 cases, 31cases (52.54%) occurred within one week, 54 cases (91.53%) were cured, 4 cases (6.78%) were died and 1 cases (1.69%) was unclear.<b>Conclusion</b>  L-asparaginase,tegacycline, rifampicin and prednisone can easily induce drug-induced pancreatitis so patients' symptoms should be paid close attention to in the clinical application of the above drugs.]]></description>
<pubDate>2019/4/12 10:55:30</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[ZHANG Xu, DANG Heqin, LIU Yanlin and CHEN Wenwen]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Xu, DANG Heqin, LIU Yanlin and CHEN Wenwen</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201903012&flag=1]]></guid><cfi:id>97</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Analysis of drug therapy in patients with oral sedation hypnotic drug poisoning]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201902013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To compare the efficacy of two drugs in the treatment of sedative hypnotic drug poisoning.<b>Methods</b>  The date of 59 patients with sedative hypnotic drug poisoning treated in emergency department of our hospital from January 2016 to December 2018 were selected according to the different treatment regimen and divided into two groups: naloxone and flumazenil combined treatment group (group A) ,Xingnaojing and Flumazenil combined treatment group (group B).GCS (Glasgow Coma Score), recovery time，hospitalization time and adverse reactions were compared. <b>Results</b>  The results of GCS (Glasgow Coma Score), recovery time and hospital stay significantly became better than before treatment. The therapeutic effect of B group was better than A group (<i>P</i><0.05).<b>Conclusion</b>  Xingnaojing combined with Flumacini in the treatment of sedative hypnotic drug poisoning can significantly shorten the hospital stay and the effect is better than naloxone and flumacini.]]></description>
<pubDate>2019/3/29 12:07:30</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[MA Shasha<sup>1</sup>, HAN Haixia<sup>2</sup>, GAO Tianqin<sup>2</sup> and LIU Li<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>MA Shasha<sup>1</sup>, HAN Haixia<sup>2</sup>, GAO Tianqin<sup>2</sup> and LIU Li<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201902013&flag=1]]></guid><cfi:id>96</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Medication analysis of clinical pharmacists participating in anti-infective treatment regimen on a patient with biliary tract infection and secondary peritonitis]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201901014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To investigate the role of clinical pharmacists in drug treatment according to the consultation and retrospective analysis of a clinical case.<b>Methods</b>  Through the analysis and summary about the treatment of a patient with biliary tract infection and secondary peritonitis by the clinical pharmacists,to explore the evaluation of experienced treatment, drug selection for targeted treatment, and medication monitoring points.<b>Results</b>  Clinical pharmacists applied the professional knowledge of pharmacy to assist physicians in adjusting drug treatment,monitor possible adverse drug reactions,and ensure patients’ safety of drug use.<B>Conclusion</b>  Clinical pharmacists participate in the formulation of individualized treatment to improve the efficacy and safety of patients’ clinical medications.]]></description>
<pubDate>2019/3/1 11:18:20</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[LIANG Yu<sup>1</sup>, MENG Zhen<sup>2</sup>, LI Xiangpeng<sup>1</sup>, CANG Huaiqin<sup>1</sup> and SUI Zhongguo<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LIANG Yu<sup>1</sup>, MENG Zhen<sup>2</sup>, LI Xiangpeng<sup>1</sup>, CANG Huaiqin<sup>1</sup> and SUI Zhongguo<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201901014&flag=1]]></guid><cfi:id>95</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[ADCY9基因介导吉西他滨肺腺癌耐药的系统生物学研究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201912011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2020/1/16 10:21:56</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[王桂平<sup>1</sup>,梁杰聪<sup>2</sup>,张彦焘<sup>1</sup>,李智斌<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>王桂平<sup>1</sup>,梁杰聪<sup>2</sup>,张彦焘<sup>1</sup>,李智斌<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201912011&flag=1]]></guid><cfi:id>94</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[养心氏片对急性ST段抬高型心肌梗死患者预后影响典型病例分析]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201912012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2020/1/16 10:21:56</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[范晓艳<sup>1</sup>,郭彩杰<sup>2</sup>,李彦<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>范晓艳<sup>1</sup>,郭彩杰<sup>2</sup>,李彦<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201912012&flag=1]]></guid><cfi:id>93</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Effect of the quality control circle activities on reducing repeated communication times between the Pharmacy Intravenous Admixture Services and clinical departments]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201911012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b> Through the quality control circle activities, the number of the repeated communication between the Pharmacy Intravenous Admixture Services (PIVAS) and the clinical department can be reduced, while the workload can be reduced, and the quality of pharmaceutical care can be improved.<b>Methods</b> In the    form of voluntary registration, a group of eight people was formed. According to the ten steps of quality control circle activities and the 80/20 Rule, the main contents of the repeated communication were found. The cause analysis was carried out through the fish bone map. The policy is implemented and the effect is finally confirmed. <b>Results</b> The number of repeated communication decreased from 1264 /15 days before the activity to 717 /15 days after the activity, and the target reaching rate was 104.6%. <b>Conclusion</b> The quality control circle activity is an effective and scientific management tool to reduce repeated communication between PIVAS and clinical departments.]]></description>
<pubDate>2019/12/2 15:14:04</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[ZHANG Xianming, ZHOU Lifang and XUE Jin]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Xianming, ZHOU Lifang and XUE Jin</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201911012&flag=1]]></guid><cfi:id>92</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Efficacy and safety of active vitamin D in the treatment of type 2 diabetic nephropathy: A meta-analysis]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201911013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To evaluate the efficacy of active vitamin D in the treatment of type 2 diabetic nephropathy.Evaluating the safety of active vitamin D in the treatment of type 2 diabetic nephropathy.<b>Methods</b>  We retrieved the Cochrane library,Pubmed,Embase databases and other relevant literatures. Meta-analysis was performed using RevMan5.2 software.<b>Results</b>  Meta-analysis outcomes showed that vitamin D treatment group significantly reduced 24-hour urine protein [OR=0.28, 95%CI(0.24,0.33),<i>P</i><0.00001]. There was statistical difference in high calcium blood [OR=4.86, 95%CI (1.09,21.56),<i>P</i>=0.04].<b>Conclusion</b>  In this meta-analysis, the use of active vitamin D in the treatment of type 2 diabetic  nephropathy can significantly reduce 24-hour urinary protein,but increase the risk of hypercalcemia.]]></description>
<pubDate>2019/12/2 15:14:04</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[ZHANG Xin<sup>1,2</sup> and CHENG Gang<sup>3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Xin<sup>1,2</sup> and CHENG Gang<sup>3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201911013&flag=1]]></guid><cfi:id>91</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Clinical effect of oral polysaccharide iron complex combined with EPO on anemia in hemodialysis patients]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202009011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b> To observe the clinical effect of oral polysaccharide iron complex (Hong-yuan-da) combined with erythropoietin (EPO) on maintenance hemodialysis patients.<b>Methods</b> A total of 40 hemodialysis patients admitted to zhaoyuan people's hospital from January to December 2016 were selected as research objects. Patients were given polysaccharide iron complex (Hong-yuan-da®) while using EPO. Patients were sampled three times in March, July and November to collect the required information.<b>Results</b>  ①In combination with the EPO intervention, the hemoglobin compliance rate of hemodialysis patients was 30%, 63%, 72.5%, and Hb≥110 g·L<sup>-1</sup> increased by 42.5% in 6 months, from 30% in March to 72.5% in November.②After the intervention of oral polysaccharide iron complex combined with EPO, the proportion of serum ferritin in 100~500 μg·L<sup>-1</sup> of hemodialysis patients remained at 17.5%, 25%, 25% for three times, and the proportion of SF>500 mg·L<sup>-1</sup> patients decreased from 5% to 0%.<b>Conclusion</b> Oral polysaccharide iron complex (Hong-yuan-da) combined with EPO in the treatment of patients with maintenance hemodialysis can significantly increase the hemoglobin compliance rate, which is worthy of clinical application.]]></description>
<pubDate>2020/9/30 14:34:46</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[CHEN Jiejun<sup>1</sup>, DU Miaomiao<sup>1</sup>, SHAO Xiaoming<sup>2</sup>, YANG Hongrong<sup>2</sup>, LIU Chunmei<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>CHEN Jiejun<sup>1</sup>, DU Miaomiao<sup>1</sup>, SHAO Xiaoming<sup>2</sup>, YANG Hongrong<sup>2</sup>, LIU Chunmei<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202009011&flag=1]]></guid><cfi:id>90</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Observation of the clinical efficacy of Modified Tuohua Decoction in the treatment of medical abortion for early pregnancy]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202008013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To observe the clinical efficacy of Modified Tuohua Decoction combined with Mifepristone and Misoprostol in the treatment of medical abortion for early pregnancy.<b>Methods</b>  600 cases of early pregnancy with medial abortion from July 2017 to July 2019 were recruited in this study. According to the random number table method, it was divided into observation group and control group, 300 cases in each group．In the control group, Mifepristone and Misoprostol were given for abortion, while in the observation group, Modified Tuohua Decoction was used for abortion more than the control group. The rate of abortion, the discharge time of gestational sac, the time of vaginal bleeding, the remnant of pregnancy sac tissue in the uterus and adverse reactions were compared in two groups.Results  The total abortion rate of the observation group (98.3%) was significantly higher than that of the control group (93.7%);The discharge time of pregnancy sac in the observation group (median 3 h) was significantly less than that in the control group (median 5 h) (<i>P</i><0.05);The time of vaginal bleeding after abortion in the observation group (median 6 days) was significantly shorter than that in the control group (median 11 days) (<i>P</i><0.05);At the time of color doppler ultrasound review 15 days after abortion,intrauterine tissue residue in the observation group was significantly less than that in the control group (<i>P</i><0.05);There was no statistically significant difference in the incidence of adverse reactions between the two groups (<i>P</i>>0.05).<b>Conclusion</b>  Modified Tuohua Decoction is used in the treatment of medical abortion for early pregnancy, which can promote the expulsion of pregnancy sac, facilitate the apoptosis of pregnancy trophoblast cells, reduce vaginal bleeding and embryo residue, and promote uterine rejuvenation.Thus the risk of second palace clearing and the infection after abortion can be reduced, which is worthy of clinical promotion.]]></description>
<pubDate>2020/8/26 16:19:33</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[KANG Yihua<sup>1</sup>, MA Hongyang<sup>2</sup>, CHEN Xing<sup>1</sup> and WANG Tianhua<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>KANG Yihua<sup>1</sup>, MA Hongyang<sup>2</sup>, CHEN Xing<sup>1</sup> and WANG Tianhua<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202008013&flag=1]]></guid><cfi:id>89</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[The clinical analysis of dessicabine combined with CAG in the treatment of senile acute myeloid leukemia]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202008014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To explore the different treatment methods and curative effects of elderly patients with myelogenous leukemia.<b>Methods</b>  A one-year study was carried out in January 2018. During the study, the leukemia patients in our hospital were randomly selected as cases to explore the best treatment. All the patients were diagnosed as myeloid leukemia. At the same time, the patients were included in the experimental group and the conventional group. The conventional group was treated with CAG alone, and the experimental group was treated with dessicabine combined with CAG. The effects of rehabilitation, adverse reactions and quality of life were compared.<b>Results</b>  The curative effect of the experimental group was significantly better than that of the conventional group (P Standard, <i>P</i><0.05;The average survival rate, disease and event-related survival data of the experimental group were significantly better than those of the conventional group, and the difference between the data was significant, <i>P</i><0.05.<b>Conclusion</b>  The combination of CAG and dessicabine for patients with myeloid leukemia has a significant intervention effect, which can effectively improve the clinical symptoms, prolong the survival time and improve the quality of life of patients. It is worth popularizing.]]></description>
<pubDate>2020/8/26 16:19:34</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[XU Zhilong, CHEN Yina, WU Mei, DU Feng and MA Yanyan]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>XU Zhilong, CHEN Yina, WU Mei, DU Feng and MA Yanyan</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202008014&flag=1]]></guid><cfi:id>88</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Analysis of drugs used in male outpatient department of reproductive and urological in our hospital]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202007013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To analyze the drug use in male reproductive and urological outpatient department of our hospital so as to provide reference for comprehensive evaluation of drug use and clinical rational drug use.<b>Methods</b>  Retrospective investigation is adopted to statistically analyze the drug use in reproductive and urological male outpatient department from 2018 to 2019 according to pharmacological classification of sales amount,DDDs and evidence-based basis of drug use.<b>Results</b>  The top three categories of drug sales in 2018 and 2019 were Chinese patent medicine (78.42% and 69.74%), cardiovascular system drugs (9.09% and 18.6%), gonadotropins (6.45% and 7.25%), and the above three categories occupied the dominant position in male medicine, accounting for 93.96% and 95.59% respectively. The ranking of sales amount of the drugs mentioned is relatively stable, while the ranking of DDDs changes partially.Shengjing Tablets,Dragon Deer Pill and Pancreatic Kininogenase Enteric-coated Tablets are all listed in the top three in sales within the 2 years. The top three drug use frequencies were Letrozole Tablets,Shengjing Tablets and Pancreatic Kininogenase Enteric-coated Tablets in 2018.In 2019,Pancreatic Kininogenase Enteric-coated Tablets,Dragon Deer Pill and Four-dimensional Zinc Gluconate Capsules rank the top three.<b>Conclusions</b>  The pregnancy rate of male infertility in Shanda Reproductive Hospital is the highest in China, in which the adjuvant therapy of drugs has played a positive role. Drug evaluation analysis shows that the overall drug structure basically conforms to the clinical diagnosis and treatment direction of reproductive and urological andrology department in our hospital.However, the treatment cycle of Chinese patent medicine is long and the curative effect lacks high-level evidence-based basis needs further comprehensive evaluation and clinical research. In addition, it is necessary to strengthen the clinical supervision of adjuvant drugs and improve the level of rational drug use.]]></description>
<pubDate>2020/7/31 15:58:37</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[SUN Yalin<sup>1</sup>, YIN Xiaoli<sup>1</sup>, HUANG Min<sup>1</sup> and HOU Ning<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>SUN Yalin<sup>1</sup>, YIN Xiaoli<sup>1</sup>, HUANG Min<sup>1</sup> and HOU Ning<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202007013&flag=1]]></guid><cfi:id>87</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Monitoring results of Carbamazepine blood concentration in 118 epilepsy patients and analysis of influencing factors]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202007014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>   To investigate the factors that were affected concentration of Carbamazepine, provide foundation for clinical rational use.<b>Methods</b>  118 epileptic patients who regularly took CBZ were selected as study subjects.The blood concentration of was detected by high performance liquid chromatography (HPLC), we analyzed the factors which were affecting the blood concentration of carbamazepine.<b>Results</b>  The concentration of 75.42% patients was between 4 and 12 μg·mL<sup>-1</sup>. Gender and age had no significant effect on blood concentration of CBZ (<i>P</i>>0.05). When combined with other antiepileptics, the proportion of  ineffective concentration was higher, had significant effect on blood concentration of CBZ (<i>P</i><0.05).<b>Conclusion</b>  There was a great difference in CBZ blood concentration among  patients who was taking CBZ, especially among those patients who was using other epilepsy drugs at the same time. Therefore, combination should be avoided, drug concentration should be actively monitored, so as to promote safty use.]]></description>
<pubDate>2020/7/31 15:58:37</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[DUAN Zhouping<sup>1</sup>, LIU Hong<sup>2</sup>, FANG Xin<sup>1</sup>, WEI Xiaohua<sup>1</sup> and ZHOU Jian<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>DUAN Zhouping<sup>1</sup>, LIU Hong<sup>2</sup>, FANG Xin<sup>1</sup>, WEI Xiaohua<sup>1</sup> and ZHOU Jian<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202007014&flag=1]]></guid><cfi:id>86</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Observation of curactive effect of oral iron and intravenous iron sucrosein renal anemia]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202006012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  Comparison of oral iron polysaccharide iron complex (red source of), intravenous iron sucrose iron (iron can) respectively with recombinant human erythropoietin (EPO) joint use, treatment of maintenance hemodialysis patients with renal anemia clinical effectiveness. <b>Methods</b>  The cases were from the 144 patients who received kidney disease from June 2016 to April 2017 at the people's hospital of puyang. The 144 patients were divided into oral and intravenous groups; Oral group (76) patients were given a polysaccharide complex,150mg per day, two times a day; 1 h or 2h after meal. Total treatment for 8 weeks. Venous group (68) : dilute 100mg of sucrose iron into 100 ml of saline water, 2 times per week in the first 4 weeks, 100mg per week; Once a week, 100 mg per time.<b>Results</b>  According to the chi 2 test analysis, there was no statistical difference between the oral group and the vein group, <i>P</i>>0.05.By two independent sample t-test, age, weight, EPO dose, hemoglobin, red blood cells deposited, ferritin in no statistically significant differences between the two groups, <i>P</i>>0.05).Before the treatment, the differences between the two groups were statistically significant (both <i>P</i>>0.05).After three months of treatment, both groups were significantly improved in Hb, HCT, MCV, MCH, MCHC, and FER, respectively compared to the treatment before treatment.After 3 months of treatment, there was no significant difference between the HCT, MCV, MCH, MCHC and the oral group (all <i>P</i>>0.05).The Hb and FER levels were significantly higher than the oral group, but their value was in the normal range, and the difference was not statistically significant (both <i>P</i>>0.05).<b>Conclusion</b>  Oral polysaccharide iron complex and venous iron sucrose iron are effective in correcting renal anemia in dialysis patients.]]></description>
<pubDate>2020/7/3 13:44:30</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[SHOU Xianjin and SHEN Xianshi]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>SHOU Xianjin and SHEN Xianshi</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202006012&flag=1]]></guid><cfi:id>85</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Cultivation and standardization of work skills of clinical pharmacists in county hospitals]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202006013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To discuss the index of cultivation and standardization of work skills of clinical pharmacists in county hospitals.<b>Methods</b>  the importance of the knowledge structure of county-level clinical pharmacists and the necessity of assessing the working index in detail were analyzed by encouraging clinical pharmacist to participate in clinical drug therapy.<b>Results</b>  Pharmaceutical care and guidance,knowledge transformation is a prerequisite. Implementing standardized assessment is the guarantee for in-depth clinical pharmacy work and continuous improvement of the quality of pharmaceutical services.<b>Conclusion</b>  Clinical pharmacists in county hospitals need to participate in clinical multidisciplinary pharmacy services, enrich clinical knowledge in practice, and continuously improve the quality of work in the implementation of assessment indicators.]]></description>
<pubDate>2020/7/3 13:44:30</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[FENG Chunxiang<sup>1</sup>, LIN Mengmeng<sup>2</sup> and WANG Yuanming<sup>3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>FENG Chunxiang<sup>1</sup>, LIN Mengmeng<sup>2</sup> and WANG Yuanming<sup>3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202006013&flag=1]]></guid><cfi:id>84</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Analysis of multi-drug resistant infection in neonatology of a hospital from 2016 to 2018]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202005012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To understand the strains and drug resistance of multi-drug resistant strains in neonatology in our hospital, and to guide the rational application of antibiotics in neonatology.<b>Methods</b>  A total of 315 neonatal bacterial surveillance results of multi-drug resistant infections from 2016 to 2018 in the neonatology department of our hospital were analyzed.<b>Results</b>  A total of 351 multi-drug resistant strains and 273 Gram-negative bacteria were detected, accounting for 77.8%. Among them, 179 strains of Klebsiella pneumoniae ranked first, while strains producing extended-spectrum β-lactamase (ESBL) strain were 97 strains, accounting for 27.6%; Klebsiella pneumoniae resistance to cefazolin, cefuroxime, ceftriaxone, ceftazidime is higher, and is increasing year by year, the resistance rate to cefotaxime, cefepime. The trend of declining year by year; the resistance rate of Escherichia coli to cefazolin, cefuroxime, ceftriaxone, cefotaxime, cefepime decreased, but the overall resistance rate still reached more than 50%. There were 78 Gram-positive bacteria, accounting for 22.2%. The top three were Staphylococcus epidermidis, Staphylococcus aureus and Staphylococcus aureus.Gram-positive bacteria resistant to ampicillin/sulbactam, amoxicillin/clavulanic acid, penicillin, ampicillin, oxacillin, ceftriaxone 100%, to vancomycin, linezolid lizolamide, mo Xishaxing, quinupristin/dalofopidine, and daptomycin are highly sensitive. 351 multi-drug resistant strains were resistant to 3-10 antibiotics.<b>Conclusion</b>  The pathogens of multidrug-resistant bacteria in the neonatology department of our hospital are mainly Gram-negative bacteria, which are resistant to most antibiotics.]]></description>
<pubDate>2020/5/28 11:25:46</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[ZHAO Hua<sup>1</sup>, GUO Shenglan<sup>1</sup>, HUANG Nuanchao<sup>2</sup>, GONG Zhanchao<sup>2</sup>, CHEN Bo<sup>3</sup>, CHEN Junhu<sup>4</sup> and LUO Chongbin<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHAO Hua<sup>1</sup>, GUO Shenglan<sup>1</sup>, HUANG Nuanchao<sup>2</sup>, GONG Zhanchao<sup>2</sup>, CHEN Bo<sup>3</sup>, CHEN Junhu<sup>4</sup> and LUO Chongbin<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202005012&flag=1]]></guid><cfi:id>83</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Analysis and intervention of the off label use of safflor yellow injection in elderly inpatients]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202005013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To analyze and intervene the off-label use of safflor yellow injection in elderly inpatients, and to reduce the risk of drug use and promote its appropriate use.<b>Methods</b>  The current situation of the off-label use of safflor yellow injection in elderly inpatients was analyzed. Clinical researches and literature reviews on off-label use of safflor yellow injection were searched and evaluated systematically, and then its reasonable medication rules were developed. To evaluate and intervene the drug use by using a rational drug use software management system audit automatically and clinical pharmacist audit manually. A total of 480 cases of inpatients of safflor yellow injection used from January-June in 2018 (before intervention) and from July-December in 2018 (after intervention) was taken randomly to evaluated the intervention effect on its off-label use.<b>Results</b>  Off-label use of safflor yellow injection was serious. The types of off-label use were mainly focused on over indication, over solvent, contraindication and over precaution, after intervention, the situation of off-label use decreased significantly, the proportion of off-label use decreased from 56.61% before intervention to 16.21%, and the number of adverse reactions reported decreased from 8 cases before intervention to 3 cases after intervention.<b>Conclusion</b>  Although off-label use of safflor yellow injection was serious, the complementary way of rational drug use software informatized real-time monitoring and clinical pharmacist audited manually may be utilized to reduce the phenomenon.]]></description>
<pubDate>2020/5/28 11:25:46</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[CHEN Hui<sup>1</sup>, QIU Lili<sup>2</sup> and DING Juying<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>CHEN Hui<sup>1</sup>, QIU Lili<sup>2</sup> and DING Juying<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202005013&flag=1]]></guid><cfi:id>82</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Efficacy and safety of Ixekizumab for Moderate to Severe Plaque Psoriasis: A Systematic Review]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202004011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To evaluate the efficacy and safety of Ixekizumab for the treatment of plaque psoriasis by systematic review.<b>Methods</b>  PubMed, Clinical Trials, Web of Science, Cochrane Library, EMBASE, Ovid, Google Scholar, WHO ICTRP, Chinese Clinical Trial Registry were searched to collect randomized controlled trials (RCTs) about the efficacy and safety of Ixekizumab for the treatment of plaque psoriasis. According to the predefined inclusion and exclusion criteria, we screened the retrieved studies, evaluated the quality of included studies, and performed systematic review by using Cochrane Collaboration’s RevMan 5.3 software, and more than two studies were conduct meta-analyses.<b>Results</b>  Four RCTs involving 3 866 patients with moderate to severe plaque psoriasis were included and assessed. The proportion of patients reaching up to 75%, 90% and 100% psoriasis area and severity index (PASI 75, PASI 90 and PASI 100）and Static Physician’s Global Assessment (sPGA) of 0 and/or 0/1 were therapeutic Indicators. At week 12, response rates for PASI 75, PASI 90, PASI 100, sPGA 0 and sPGA 0/1 were significantly higher for Ixekizumab-treated group (160 mg starting dose, then 80mg every 2 or 4 weeks) than for placebo group and etanercept-treated group (50mg every 2 weeks). Further comparison between subgroups of Ixekizumab treatment showed that response rates for PASI 75, PASI 90, PASI 100, sPGA 0 and sPGA 0/1 were obviously higher for 80 mg every 2 weeks subgroup than 80 mg every 4 weeks subgroup. Moreover, response rates for PASI 90 and PASI 100 were distinctly increased for Ixekizumab treatment at week 60 compared with Ixekizumab treatment at week 12. In terms of safety, at week 12, the incidence of infection and injection site reaction in Ixekizumab-treated group was higher than those in placebo group, while the two groups did not differ with regard to overall incidences of any adverse events and serious adverse events. The incidence of injection site reaction in 80mg every 2 weeks group was higher than those in 80mg every 4 weeks group, while the two groups did not differ with other adverse events.<b>Conclusion</b> The present evidence indicates that Ixekizumab is efficient and safe in short-term for the treatment of moderate-to-severe plaque psoriasis, and its long-term safety is deserved to explore.]]></description>
<pubDate>2020/5/6 16:00:47</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[LI Xinxin<sup>1</sup>, WANG Yanqin<sup>1</sup>, XING Xiaoyun<sup>1</sup>, PAN Lei<sup>2</sup> and MA Lei<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LI Xinxin<sup>1</sup>, WANG Yanqin<sup>1</sup>, XING Xiaoyun<sup>1</sup>, PAN Lei<sup>2</sup> and MA Lei<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202004011&flag=1]]></guid><cfi:id>81</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[合并多种疾病的老年糖尿病患者中成药口服制剂使用分析]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202003013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2020/4/20 13:55:10</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[胡美芳,牛祥菊,高玉霞]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>胡美芳,牛祥菊,高玉霞</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202003013&flag=1]]></guid><cfi:id>80</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[基于药物治疗管理的慢病医疗数据平台的探索研究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202002013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2020/3/30 0:00:00</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[赵蕾,钟丽红,崔晶,刘梦玉洁,徐莉,王辰洋]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>赵蕾,钟丽红,崔晶,刘梦玉洁,徐莉,王辰洋</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202002013&flag=1]]></guid><cfi:id>79</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[养心氏片治疗微血管性心绞痛典型病例分析]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202002014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2020/3/30 0:00:00</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[范晓艳<sup>1</sup>,张振伟<sup>2</sup>,王辉<sup>3</sup>,郭彩杰<sup>3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>范晓艳<sup>1</sup>,张振伟<sup>2</sup>,王辉<sup>3</sup>,郭彩杰<sup>3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202002014&flag=1]]></guid><cfi:id>78</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[PDCA循环法在抗肿瘤药物及其辅助用药规范化管理中的应用及效果评价]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202001012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2020/3/10 15:53:27</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[苏凤云,李振山,尹玲,刘燕琳,党和勤]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>苏凤云,李振山,尹玲,刘燕琳,党和勤</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202001012&flag=1]]></guid><cfi:id>77</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Analysis of one case of Yangxinshi Tablets combined with Western medicine standardization treatment on patients with recurrent heart failure after PCI]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202011013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To explore the efficacy of Yangxinshi Tablets combined with western medicine standardization treatment on patients with recurrent heart failure after PCI.<b>Methods</b>  On the basis of standardized medical treatment of western medicine,Yangxinshi Tablets were used to treat patients with the patients with recurrent heart failure after PCI, and observe the changes of the heart rate, blood pressure, premature ventricular contractions,electrolyte and renal function, exercise tolerance.<b>Results</b>  After treatment, the patient's heart rate decreased, blood pressure was normal, ventricular premature beats decreased,electrolyte and renal function changes were normal, and exercise tolerance increased.<b>Conclusion</b>  Yangxinshi Tablets can improve the clinical symptoms and improve the exercise tolerance of patients with repeated heart failure after PCI. It is worthy of clinical application.]]></description>
<pubDate>2020/12/7 15:11:54</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[范晓艳<sup>1</sup>，张振伟<sup>2</sup>，郭彩杰<sup>3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>范晓艳<sup>1</sup>，张振伟<sup>2</sup>，郭彩杰<sup>3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202011013&flag=1]]></guid><cfi:id>76</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Mechanism analysis of <i>Salviae Miltiorrhiza</i> and Ligustrazine Hydrochloride Injection into the blood components treatment of cerebral infarction based on network pharmacology]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202010013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  Network pharmacology method to study the salvia miltiorrhiza and ligustrazine injection into the blood composition mechanism for the treatment of cerebral infarction.<b>Methods</b>  Through literature mining is to determine the composition of the salvia miltiorrhiza ligustrazine injection into the bloodstream, in TCMSP, Swiss Target Prediction database retrieval into the blood components targets, through Gene Cards database to collect cerebral infarction targets, both targets sieve weight to get into the blood composition for the treatment of cerebral infarction targets, with the help of Cytoscape software built into the blood components - treatment of cerebral infarction Target network; Application of STRING platform built into the blood components target protein interaction networks, and import the Cytoscape software to calculate the topological parameters, screening of key targets; The enrichment analysis of KEGG pathway was carried out using DAVID database.<b>Results</b>  There are 14 components of tanshinol、salvianolic acid B、Ligustrazine Hydrochloride in salvia miltiorrhiza ligustrazine injection acted on key targets such as VEGFA、IL4、IL2、F2、NOS3, regulating PI3K-Akt signal pathway, VEGF signal pathway,TNF signal pathway, Estrogen signal pathway, platelet activation, etc.<b>Conclusion</b>  Salvia miltiorrhiza ligustrazine injection can effectively treat cerebral infarction by improving microcirculation, anticoagulation and protecting vascular endothelial cells.]]></description>
<pubDate>2020/11/13 13:56:47</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[DUAN Kaixuan<sup>1</sup>, LIU Zhiqiang<sup>2</sup>, WANG Bolong<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>DUAN Kaixuan<sup>1</sup>, LIU Zhiqiang<sup>2</sup>, WANG Bolong<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202010013&flag=1]]></guid><cfi:id>75</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Clinical efficacy and economic evaluation of Cefoperazone and Sulbactam Sodium injection using micro-pumps for 3 hours]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202010014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  Explore the difference antibacterial effect of  Cefoperazone and Sulbactam Sodium in the same dose and different administration schemes.<b>Methods</b>  The terminal drug concentration(c) of cefoperazone sodium and its pharmacokinetic and pharmacodynamic(PK/PD)% (T>MIC) were calculated after 0.5 h intravenous infusion and delayed administration (2 h, 3 h), and the clinical efficacy and pharmacoeconomic cost were evaluated.<b>Results</b>  ① the 3-hour end-point drug concentration: the same dose (1g), delayed 2 h and 3 h groups were 140.3% (40.0/28.5) and 179.2% (51.1/28.5) of the 0.5 h group. ②The increase of antibacterial strength (T > MIC) was as follows: a. the same dose and different administration interval were given intravenously for 0.5h: Q8H and q6h groups increased by 50% and 100% compared with q12h group;b.At the same dose, different administration interval and different administration time: q12h group: delay time (2 h, 3 h), increased by 14%; 11.7%; Q8H group: increased by 13.8% and 20.9%；c.(q6h) (delay 2 h, 3 h) was 207% and 234.9% higher than that of Q12 h and 0.5 h, respectively;d.The same day dose (4.0 g) (%T > MIC) value: (1.0 g, q6h, delayed 2 h, 3 h), compared with (2.0g, q12 h, 0.5), increased by 50%-70%. ③The cost of medicine decreased by1/3: (1.0 g, 8 h, 2.0 h) (%T> MIC) = 61.2, compared with (2G, q12h, 0.5h), the daily dose of 4.0 g (% T>MIC = 60.0) was reduced by 1/3.<b>Conclusion</b>  When increased the number of administration, combined with delayed administration of Cefoperazone and Sulbactam Sodium for 3 h, it can improved the antibacterial strength and saved the cost of medicine. It provided the theoretical basis of PKPD for patients with severe infection and off label medication.]]></description>
<pubDate>2020/11/13 13:56:47</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[XIN Dongyi<sup>1</sup>, YU Xuhong<sup>2</sup>, FANG Fang<sup>3</sup>, XIN Xuejun<sup>4</sup>, XIE Juexing<sup>1</sup>, ZHU Qibing<sup>4</sup>, LIN Feng<sup>1</sup>, JIANG Neng<sup>5</sup>, DUAN Darong<sup>6</sup>, DING Ruliang<sup>1</sup>, ZHANG Zhijian<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>XIN Dongyi<sup>1</sup>, YU Xuhong<sup>2</sup>, FANG Fang<sup>3</sup>, XIN Xuejun<sup>4</sup>, XIE Juexing<sup>1</sup>, ZHU Qibing<sup>4</sup>, LIN Feng<sup>1</sup>, JIANG Neng<sup>5</sup>, DUAN Darong<sup>6</sup>, DING Ruliang<sup>1</sup>, ZHANG Zhijian<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202010014&flag=1]]></guid><cfi:id>74</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[基层卫生服务中心中成药不合理用药情况分析]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202109014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2021/10/22 16:02:40</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[张剑<sup>1</sup>，孙铜<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>张剑<sup>1</sup>，孙铜<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202109014&flag=1]]></guid><cfi:id>73</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[1例临床药师参与阿奇霉素治疗胃排空障碍的病例实践]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202106013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2021/7/22 14:32:19</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[刘群<sup>1</sup>，刘杰<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>刘群<sup>1</sup>，刘杰<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202106013&flag=1]]></guid><cfi:id>72</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[1例曲马多治疗疱疹后神经痛发生严重恶心呕吐的病例分析]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202106014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2021/7/22 14:32:19</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[郑祝华<sup>1</sup>，孙金刚<sup>2</sup>，谢春红<sup>3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>郑祝华<sup>1</sup>，孙金刚<sup>2</sup>，谢春红<sup>3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202106014&flag=1]]></guid><cfi:id>71</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Correlation of liver function abnormality and plasma concentration of high dose methotrexate in patients with osteosarcoma]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202105012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To analyze the characteristics of abnormal liver function and the distribution of plasma concentration of high dose methotrexate in patients with osteosarcoma, and to explore the correlation between abnormal liver function and plasma concentration of methotrexate.<b>Methods</b>  The liver function and plasma concentration of methotrexate at 0, 24, 48 and 72 h of 30 patients with osteosarcoma treated with high dose methotrexate were collected retrospectively. The correlation of liver function abnormality and plasma concentration of methotrexate at different time points were statistically analyzed.<b>Results</b>  The total incidence of liver function abnormality after high dose methotrexate chemotherapy was 84.62%, including 44.23% of grade II and above. ALT and AST were positively correlated with plasma concentration of methotrexate at 0 h and 24 h after chemotherapy, but not correlated with plasma concentration of methotrexate at 48 h and 72 h.<b>Conclusion</b>  The incidence of liver function abnormality induced after high dose methotrexate chemotherapy is very high. The plasma concentration of methotrexate at 0 h and 24 h was significantly correlated to liver function abnormality induced by high dose methotrexate chemotherapy.]]></description>
<pubDate>2021/6/23 9:41:41</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[YUAN Guiyan, LIU Huanjun, LI Rong, GUO Ruichen]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>YUAN Guiyan, LIU Huanjun, LI Rong, GUO Ruichen</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202105012&flag=1]]></guid><cfi:id>70</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Analysis of cancer pain medication in a patient with opioid tolerance]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202105013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Through the introduction and analysis of a case of cancer pain combined with neuropathic pain in a patient with opioid tolerance for advanced ampullary carcinoma, this paper explored how to adjust the analgesic drug treatment according to the patient's pain control situation, and solve the problems in time, so as to effectively control the pain and improve the quality of life of the patient.]]></description>
<pubDate>2021/6/23 9:41:41</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[LI Jing<sup>1</sup>, XIE Chunhong<sup>2</sup>, DU Lili<sup>3</sup>, CAO Zhongshu<sup>4</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LI Jing<sup>1</sup>, XIE Chunhong<sup>2</sup>, DU Lili<sup>3</sup>, CAO Zhongshu<sup>4</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202105013&flag=1]]></guid><cfi:id>69</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Determination of serum vancomycin in ICU patients by UHPLC and its clinical application]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202104015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To develop a rapid ultra-performance liquid chromatographic (UHPLC) method for determination of vancomycin in serum from ICU patients,and investigate the relationship between serum peak-to-valley concentrations of vancomycin and its efficacy and safety.<b>Methods</b>  Serum samples were precipitated with 10% perchloric acid, and subsequently analyzed via gradient elution. The mobile phase consisted of acetonitrile and 0.005 mol·L<sup>-1</sup> KH<sub>2</sub>PO<sub>4</sub> buffer.<b>Results</b>  The chromatographic peaks of vancomycin was not interfered by endogenous matrixes. The linearity of vancomycin was satisfactory. The precision, recovery rate, precision and stability of vancomycin all met the requirement of biological samples analysis. In ICU patients, the vancomycin serum peak and trough concentration were 15.42~89.12 mg·L<sup>-1</sup> and 7.30~55.46 mg·L<sup>-1</sup>, respectively. Spearman correlation analysis showed that there was a weak correlation between serum valley concentration and nephrotoxicity (correlation coefficient <i>r</i>=0.377 2, <i>P</i><0.05). Nephrotoxicity readily occurred when the serum valley concentration exceeded 24 mg·L<sup>-1.<b>Conclusion</b>  The rapid UHPLC method with high efficiency was suitable for the therapeutic drug monitoring (TDM) of vancomycin.]]></description>
<pubDate>2021/5/25 19:40:52</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[FANG Fang<sup>1</sup>, LI Ning<sup>2</sup>, XU Chunli<sup>1</sup>, YANG Jihong<sup>1</sup>, ZHENG Zhichang<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>FANG Fang<sup>1</sup>, LI Ning<sup>2</sup>, XU Chunli<sup>1</sup>, YANG Jihong<sup>1</sup>, ZHENG Zhichang<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202104015&flag=1]]></guid><cfi:id>68</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[临床药师参与1例带状疱疹后神经痛治疗方案分析]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202103014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[带状疱疹后神经痛(postherpetic neuralgia，PHN)为带状疱疹皮疹愈合后由病毒侵入神经所诱发的神经病理性疼痛，是临床中该疾病治疗最常发生且难以控制的并发症。本文中，临床药师对1例带状疱疹后神经痛患者的治疗方案进行分析，从药物使用、联用的角度讨论治疗方案的合理性，体现了临床药师在指导临床诊疗过程中的重要作用。]]></description>
<pubDate>2021/4/19 9:34:30</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[ZHANG Jue]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Jue</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202103014&flag=1]]></guid><cfi:id>67</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Efficacy and safety of Febuxostat and Allopurinol in hyperuricemia after renal transplantation]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202103015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To analyze the patients with hyperuricemia after renal transplantation with different drugs, to compare the efficacy and safety of febuxostat and allopurinol in the treatment of hyperuricemia after renal transplantation.<b>Methods</b>  Review the treatment of hyperuricemia after renal transplantation, according to the use of different antiuricemic drugs, the patients were divided into two groups: febuxostat group and allopurinol group. The control level of uric acid was analyzed and the differences between the two groups were compared. <b>Results</b>  The level of uric acid in the febuxostat group was much lower than that in the allopurinol group, and the difference between the two groups was statistically significant (<i>P</i><0.05). <b>Conclusion</b>  The control of uric acid level in the febuxostat group was better than that in the allopurinol group in the patients with hyperuricemia after renal transplantation. At the same time, according to a large number of literature data, we should closely monitor the relevant indicators and adverse reactions of patients during the application of febuxostat or any other antiduricemic drugs, especially for patients after renal transplantation.]]></description>
<pubDate>2021/4/19 9:34:30</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[XU Junjun, ZENG Caifang]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>XU Junjun, ZENG Caifang</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202103015&flag=1]]></guid><cfi:id>66</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[The effect of type 2 diabetes mellitus and metformin treatment on the prognosis of breast cancer patients]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202102013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To explore the relationship between type 2 diabetes and breast cancer, and the effect of metformin treatment on the prognosis of breast cancer patients with type 2 diabetes.<b>Methods</b>  102 breast cancer patients with type 2 diabetes were enrolled into this study in our hospital from January 2014 to December 2015 as the type 2 diabetes group, and 106 breast cancer patients without type 2 diabetes in the same period as the control group. The type 2 diabetes group was divided into metformin group and non-metformin group according to the treatment plan using metformin for sub-group. The general information, clinical stage, histological grade, molecular classification and prognosis were compared. The survival curve was used to analyze the effect of metformin treatment on the prognosis.<b>Results</b>  Compared with the control group, the breast cancer patients in the type 2 diabetes group were older, and the proportion of postmenopausal patients was higher, both were statistically significant (<i>P</i>＜0.05), but there was no statistical difference in body weight and family history between the two groups (<i>P</i>＞0.05); Compared with the control group, the type 2 diabetes group has a later clinical stage and a higher histological grade, and the molecular type Basal-like type is more common , these are statistically significant (<i>P</i><0.05);the type 2 diabetes group compared with the control group, the proportion of patients with local recurrence, lymph node and distant metastasis was higher, but it was not statistically significant (<i>P</i>>0.05). The 5-year survival rate of patients in the type 2 diabetes group was lower than that of the control group, and the difference was statistically significant (<i>P</i><0.05). There was no statistically significant difference between the metformin group and the non-metformin group in general conditions, clinical stage, histological grade, and molecular typing (<i>P</i>>0.05). There was no significant difference in the occurrence of local recurrence and distant metastasis after metformin treatment compared with the non-metformin group (<i>P</i>>0.05), and the overall survival rate and survival rate removing other causes of death in the metformin group were higher (<i>P</i><0.05). <b>Conclusion</b>  Type 2 diabetes may be one of the risk factors affecting the development and prognosis of breast cancer. It reduces the 5-year survival rate of breast cancer patients, especially in postmenopausal women. The use of metformin can improve the survival of patients with type 2 diabetes and breast cancer and improve the prognosis.]]></description>
<pubDate>2021/3/26 16:41:53</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[YAN Xiaolu<sup>1</sup>, GAO Zhe<sup>1</sup>, DU Liyan<sup>2</sup>, LI Qingxia<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>YAN Xiaolu<sup>1</sup>, GAO Zhe<sup>1</sup>, DU Liyan<sup>2</sup>, LI Qingxia<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202102013&flag=1]]></guid><cfi:id>65</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Analysis of one case of subcutaneous self-control analgesia management in patients with severe cancer pain]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202102014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  According to the consultation and retrospective analysis of a clinical case, to discuss the selection and adjustment of analgesia program for cancer pain patients.<b>Methods</b>  To analyze the treatment plan of a case of subcutaneous self-control analgesia with severe cancer pain, and discusses the choice of drug and the monitoring point of drug use.<b>Results and Conclusion</b>  The clinical analgesic medication of this patient was not very reasonable.Individualized analgesic drug regimen should be developed for each patient according to the specific situation.]]></description>
<pubDate>2021/3/26 16:41:53</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[LI Jing, LIU Fang, LIU Yunxia, CAO Zhongshu]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LI Jing, LIU Fang, LIU Yunxia, CAO Zhongshu</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202102014&flag=1]]></guid><cfi:id>64</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Clinical observation of PEG-rhG-CSF secondary prevention on hematological toxicity caused by whole brain and spinal cord radiotherapy]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202101011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>The primary goal of this study is to observe the effect brought by secondary prevention with pegylated recombinant human granulocyte-colony stimulating factor (PEG-rhG-CSF) on hematological toxicity and therapy period in whole brain and whole bone marrow radiotherapy.<b>Methods</b>We did a rhetorical analysis on 15 patients with tumors on the central neural system (CNS),who were treated with PEG-rhG-CSF for secondary prevention during whole brain and whole bone marrow radiotherapy, to study the effects of such substance on hematological toxicity.Furthermore, we compared the variance in toxicity based on differences in gender,age as well as diagnostic results.Finally,we discussed the outcomes using PEG-rhG-CSF on the radiotherapy during secondary prevention.<b>Results</b>We found that all the 15 patients suffered different degrees of myelosuppression. The corresponding number of patients were 3 (20.0%), 8 (53.3%), 2 (13.3%), 2 (13.3%) for degree I, II, III and IV, respectively. Among the 15 patients, 10 exhibited a decrease in platelet count, where 5 (33.3%), 3 (20%), 2 (13.3%) showed a degree I, II, III decline, respectively. None of them exhibited a degree IV decline in platelets.Additionally,5 of the total 15 patients demonstrated a drop in hemoglobin levels, where 3 of them were degree I and 2 were degree II, with no one suffering degree III decline.Patients showing myelosuppression at degree III or IV as revealed through decreased leukocyte, platelet and hemoglobin levels consisted of 26.7%,13.3% and 0.0% of the total number,respectively.2 patients (13.3%) experienced an interruption, which lasted for 7-8 days, in their treatment due to severe hematological toxicity.Secondary prevention by the application of PEG-rhG-CSF can reduce the interruption resulted from hematological toxicity during radiotherapy.<b>Conclusion</b>In a word,it is quite common for patients undergoing whole brain and whole bone marrow radiotherapy to exhibit hematological toxicity. With the help of PEG-rhG-CSF during secondary prevention, myelosuppression at degree III or IV is significantly reduced among the majority of such patients, shortening the radiotherapy period and ensuring their completion of the therapy. Therefore, the introduction of PEG-rhG-CSF in secondary prevention is worthy to be further studied and spread for a wider range of applications.]]></description>
<pubDate>2021/3/1 14:21:04</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[FENG Hui, GAO Feng, WANG Haoming, WANG Wenhua, LIU Lianhua, LIU Qingtao, HUANG Bingjian]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>FENG Hui, GAO Feng, WANG Haoming, WANG Wenhua, LIU Lianhua, LIU Qingtao, HUANG Bingjian</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202101011&flag=1]]></guid><cfi:id>63</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Clinical efficacy of Xinmailong Injection combined with western medicine in the treatment of patients with coronary heart disease and heart failure and the effect of plasma NT-proBNP]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202101012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To explore the effect of western medicine plus Xinmailong Injection on plasma NT-proBNP and clinical efficacy in patients with coronary heart disease and heart failure.<b>Methods</b>  This study randomly selected 70 patients with coronary heart disease and heart failure who came to hospital for treatment within one year (February 2019 to February 2020) and divided them into 35 basic groups and 35 experimental groups according to different treatment methods. Western medicine was used to treat 35 patients in the basic group and western medicine+Xinmailong injection was used to treat 35 patients in the experimental group. The changes of plasma NT-proBNP level and clinical efficacy of the two groups were compared before and after treatment respectively.<b>Results</b>  Compared with the experimental group, the plasma NT-proBNP level in the reference group was significantly higher (p &lt; 0.05). Compared with the experimental group after treatment, the total effective rate in the reference group was significantly lower (P&lt;0.05).<b>Conclusion</b>  The combination of plasma NT-proBNP level and clinical treatment for patients with coronary heart disease and heart failure can significantly improve the overall clinical efficacy and improve the plasma NT-proBNP level of patients.]]></description>
<pubDate>2021/3/1 14:21:04</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[CAO Bin<sup>1</sup>, BI Jianjie<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>CAO Bin<sup>1</sup>, BI Jianjie<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202101012&flag=1]]></guid><cfi:id>62</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[妊娠晚期妇女B族链球菌检出情况与药敏分析]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202111014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2021/12/10 9:23:29</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[WU Weiwei<sup>1</sup>, JIAO Jin<sup>1</sup>, ZHAO Heyong<sup>1</sup>, SHEN Feng<sup>1</sup>, ZHOU Huiru<sup>1</sup>, FAN Gang<sup>1,2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WU Weiwei<sup>1</sup>, JIAO Jin<sup>1</sup>, ZHAO Heyong<sup>1</sup>, SHEN Feng<sup>1</sup>, ZHOU Huiru<sup>1</sup>, FAN Gang<sup>1,2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202111014&flag=1]]></guid><cfi:id>61</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[头孢曲松钠致胆囊结石的相关临床机制研究和相应CT表现]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202111015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2021/12/10 9:23:30</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[ZHENG Lei]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHENG Lei</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202111015&flag=1]]></guid><cfi:id>60</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Clinical efficacy of Shah Glenn Dean combined with metformin hydrochloride in the treatment of diabetes and analysis of the protective effect of islet β cells of and target rate of HbA<sub>1c</sub>]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202209011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To investigate the clinical efficacy of Shah Glenn Dean combined with metformin hydrochloride in the treatment of diabetes and analysis of the protective effect of islet β cells of and target rate of HbA1c. <b>Methods</b>  137 diabetic patients in our hospital from June 2018 to June 2021 were divided into groups. According to the simple random number table method, the patients were divided into control group (<i>n</i>=68) and observation group (<i>n</i>=69). The control group was treated with metformin hydrochloride and the observation group was treated with Shah Glenn Dean based on the control group. The clinical efficacy, serum insulin (INS), C-peptide, 2-hour postprandial blood glucose (PBG), fasting blood glucose (FBG) and glycosylated hemoglobin of the two groups were evaluated.<b>Results</b>  The total effective rate of the observation group was 95.65%, higher than 83.82% of the control group (<i>P</i><0.05); compared with before treatment, the levels of Ins and C-peptide in the observation group were higher than those in the control group (<i>P</i><0.05); Compared with before treatment, the levels of PBG, FBG and HbA1c in the observation group were lower than those in the control group.There was no significant difference in the incidence of adverse reactions between the two groups (<i>P</i>>0.05).<b>Conclusion</b>  The clinical efficacy of Shah Glenn Dean combined with metformin hydrochloride in the treatment of diabetic patients can improve the levels of Ins and C peptide, reduce the levels of PBG, FBG and HbA1c, and to pancreatic islet β cells play a protective role, patients have less probability of adverse reactions, and the medication is safe and reliable.]]></description>
<pubDate>2022/10/10 9:39:46</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[XIANG Xiaomei<sup>1</sup>, LYU Xiaofang<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>XIANG Xiaomei<sup>1</sup>, LYU Xiaofang<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202209011&flag=1]]></guid><cfi:id>59</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Investigation and analysis of public awareness of safe use of antibiotics]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202206014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  The dosage of antibiotics is large, which is essential for the protection of human life and health. However, there are great safety risks in their use. The abuse of antibiotics will lead to serious consequences, including drug resistance. Since the implementation of the Measures for the Management of Clinical Application of Antibiotics in 2012, China has issued and implemented a series of supporting policies and guidelines to curb the abuse of antibiotics, which has played a good role in limiting the use permission and usage of antibiotics prescribed by doctors. In order to further fully cooperate with the implementation of national policies, and to reflect the effect of policy implementation, the public awareness of safe use of antibiotics was investigated and analyzed.<b>Methods</b>  Questionnaire survey and literature research were used to establish a systematic three-level evaluation index system, and the public awareness of safe drug use of antibiotics was analyzed from three aspects, involving basic cognition, access to antibiotics and the situation of taking antibiotics.<b>Results</b>  Due to the deep-rooted concept of using antibiotics for both "serious and minor diseases" formed by the general public for a long time, their awareness of antibiotic resistance and the awareness of antibiotic resistance caused by the abuse of antibiotics need to be further improved. <b>Conclusion</b>  Through investigation and analysis, it is expected to provide some reference for the further standardization of rational use of antibiotics and the implementation of national policies.]]></description>
<pubDate>2022/7/19 16:37:42</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[SHAO Tianyi, GUO Hong]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>SHAO Tianyi, GUO Hong</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202206014&flag=1]]></guid><cfi:id>58</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Pharmaceutical practice of a patient with leukopenia, thrombocytopenia and liver function damage caused by carbamazepine]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202205013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective  To explore the role of clinical pharmacists by participating in the whole process of the treatment of a case of leukopenia, thrombocytopenia and liver function damage caused by carbamazepine.<b>Methods</b>  The clinical pharmacist participated in the analysis and adjustment of the treatment process of a case of leukopenia, thrombocytopenia and liver function damage caused by carbamazepine, so as to provide individualized pharmaceutical care for the patient. <b>Results</b>  The suggestions of clinical pharmacists were adopted. After systematic treatment and individualized pharmaceutical care, the levels of leukocytes and platelets and liver function returned to normal, and satisfactory clinical treatment results were obtained. <b>Conclusion</b>  It is very necessary for clinical pharmacists to carry out pharmaceutical care for patients using carbamazepine to ensure drug safety.]]></description>
<pubDate>2022/6/8 14:30:16</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[ZHI Xiaohui<sup>1</sup>, WANG Xiaogang<sup>2</sup>, SHAO Wandi<sup>3</sup>, ZHOU Tao<sup>3</sup>, YANG Luoning<sup>3</sup>, LIU Huaxue<sup>3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHI Xiaohui<sup>1</sup>, WANG Xiaogang<sup>2</sup>, SHAO Wandi<sup>3</sup>, ZHOU Tao<sup>3</sup>, YANG Luoning<sup>3</sup>, LIU Huaxue<sup>3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202205013&flag=1]]></guid><cfi:id>57</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Analysis of typical cases of double heart treatment based on Yangxinshi Tablet]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202205014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To investigate the curative effect of combined Yangxinshi Tablet in the treatment of double heart disease.<b>Methods</b>  The patients with heart disease and severe depression were treated with basic treatment combined with Yangxinshi Tablet, and the changes of TCM symptoms, Hamilton depression scale and the use of psychiatric drugs were observed.<b>Results</b>  After 2 months of medication, the emotional stability and depression scores of the patients were reduced, and the symptoms of mood-adjusting drugs and chest tightness and fatigue were improved.<b>Conclusion</b>  Yangxinshi Tablet can significantly improve the changes of Chinese medicine syndrome in patients with heart disease accompanied by severe depression, reduce the score of Hamilton Depression Scale, and reduce the use of psychiatric drugs. It has positive clinical effects, and is worthy of further clinical promotion.]]></description>
<pubDate>2022/6/8 14:30:16</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[ZHANG Yan, WANG Mingzhen, ZHAO Yuping]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Yan, WANG Mingzhen, ZHAO Yuping</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202205014&flag=1]]></guid><cfi:id>56</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[The effect of Continuous Subcutaneous Insulin Infusion combined with metformin on complications after total knee arthroplasty (2) in patients with type 2 diabetes mellitus]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202204013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To observe the effect of Continuous Subcutaneous Insulin Infusion (CS2) combined with metformin on complications after total knee arthroplasty (2) in patients with type 2 diabetes mellitus.<b>Methods</b>  From June 2016 to February 2021, 78 patients with osteoarthritis of type 2 diabetes mellitus were treated with total knee arthroplasty. They were randomly divided into Continuous Subcutaneous Insulin Infusion,CS2 (group A) and CS2 combined with metformin (group B), including 38 cases in group A and 40 cases in group B. The recovering time of FBG, 2hBG and BG before and after treatment and their effects on acute perioperative complications 4 weeks after operation were compared between the two groups. <b>Results</b>  The reaching times of FBG and 2hBG in group A and B had statistically significant (<i>P</i><0.05); The dosage of insulin was (29.80 ± 5.02) and (19.16 ± 5.13) U·d<sup>-1</sup>, respectively (<i>P</i><0.01), the difference was statistically significant (<i>P</i><0.01). In group A, there were 1 case of deep venous thrombosis (DVT) and 1 case of superficial surgical site infection (SSI). There was 1 case of lower respiratory tract infection (LRTI) in group B.<b>Conclusion</b>  CS2 combined with metformin can shorten the perioperative time before knee arthroplasty than CS2 alone. Both CS2 and CS2 combined with metformin can effectively reduce the acute perioperative complications after knee arthroplasty.]]></description>
<pubDate>2022/5/10 10:37:37</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[AN Xinrong, GAO Tianqin, CUI Jingjing, ZHAO Yanmin, WANG Wenna, AN Ranran, MA Shasha]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>AN Xinrong, GAO Tianqin, CUI Jingjing, ZHAO Yanmin, WANG Wenna, AN Ranran, MA Shasha</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202204013&flag=1]]></guid><cfi:id>55</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Clinical observation of Yangxin Shengmai Granules combined with western medicine in the treatment of coronary heart disease and angina pectoris]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202204014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To investigate the clinical efficacy of Yangxin Shengmai Granules combined with western medicine in the treatment of coronary heart disease and angina pectoris. <b>Methods</b>  A total of 86 patients with angina pectoris of coronary heart disease admitted to our hospital from July 2019 to June 2021 were selected, patients were randomly divided into observation group and control group, 43 cases in each group. The control group was given routine western medicine treatment, and the observation group was given Yangxin Shengmai Granules treatment on the basis of the control group. Patients in two groups were treated for 3 weeks. After treatment, the clinical efficacy and incidence of adverse drug reactions were observed between the two groups, and the frequency and duration of angina pectoris in two groups before and after treatment were compared.<b>Results</b>  After the treatment，the total effective rate of the observation group and the control group were 95.35% and 79.07%,respectively，the differences between the two groups were statistically significant (<i>P</i>＜0.05).After the treatment，The frequency and duration of angina pectoris in two groups was significantly decreased(<i>P</i>＜0.05), and were lower in the observation group than those in the control group(<i>P</i>＜0.05). There was no significant difference in the incidence of adverse reactions between groups. <b>Conclusion</b>  Yangxin Shengmai Granules combined with western medicine in the treatment of coronary heart disease and angina pectoris has good clinical efficacy，can effectively reduce the frequency and duration of angina pectoris，which is higher safe，and worthy of clinical application.]]></description>
<pubDate>2022/5/10 10:37:37</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[LI Xiufeng, YAO Zongqin]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LI Xiufeng, YAO Zongqin</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202204014&flag=1]]></guid><cfi:id>54</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Pharmaceutical Care for a hemodialysis patient with enterococcus faecium pneumonia]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202203014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To explore the optimization of vancomycin dosage based on blood concentration monitoring and the role of clinical pharmacists in anti -infection treatment for hemodialysis patients.<b>Methods</b>  According to the etiology，laboratory and imaging examination results and patient’s condition changes，clinical pharmacist participated in the anti-infective drug treatment of a hemodialysis patient with pneumonia infected by enterococcus faecium, assisted physician to formulate and adjust the regimen, and explored the treatment of how to formulate an individualized dosing plan based on the monitoring results of vancomycin blood concentration for hemodialysis patients.<b>Results</b>  The doctor fully adopted the clinical pharmacist's recommendations for antibiotic drug changes and dose adjustments, After the treatment, the patient's infection index decreased, and he was discharged smoothly.<b>Conclusion</b>  Vancomycin blood concentration monitoring is very necessary for hemodialysis patients with infection, and The involvement of clinical pharmacists in the treatment process of patients can promote the rational clinical medication．]]></description>
<pubDate>2022/4/14 14:57:06</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[MEI Qian, TANG Cailin, SHENG Changcheng]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>MEI Qian, TANG Cailin, SHENG Changcheng</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202203014&flag=1]]></guid><cfi:id>53</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Pharmaceutical care practice and analysis of a case of drug-induced liver injury caused by dandelion in a chemotherapy patient]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202203015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To investigate the role of pharmaceutical care in the judgment and treatment of drug-induced liver injury caused by traditional Chinese medicine dandelion in a chemotherapy patient.<b>Methods</b>  A case of drug-induced liver injury in chemotherapy patient was discovered through pharmaceutical care. The causes of the patient’s adverse reactions were judged and intervened and then patient was given medication suggestions by combining related pharmaceutical knowledge with clinical practice.<b>Results</b>  The doctor adopted the pharmacist’s suggestions and stopped using dandelion. The patient’s adverse reactions were improved, and follow-up treatment was completed smoothly.<b>Conclusion</b>  Pharmaceutical care can play an important role in the prevention, discovery and treatment of adverse reactions, which reflects the value of clinical pharmaceutical care.]]></description>
<pubDate>2022/4/14 14:57:06</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[LUAN Xiaoyi<sup>1</sup>, WANG Hui<sup>2</sup>, XIE Fei<sup>3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LUAN Xiaoyi<sup>1</sup>, WANG Hui<sup>2</sup>, XIE Fei<sup>3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202203015&flag=1]]></guid><cfi:id>52</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Clinical observation on the effect of Simiao Powder on coagulation index in the treatment of acute gouty arthritis]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202202013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  This study was to investigate the effect of Simiao Power on coagulation index in the treatment of acute gouty arthritis.<b>Methods</b>  Select 32 cases of acute gouty arthritis with damp heat accumulation syndrome, which were divided into the treatment group with 17 cases and the control group with 15 cases. At the same time, 12 cases in interlude of gouty arthritis were selected as the intermittent control group. Three groups were with low purine food. While the control group were given etoricoxib and Qing peng ointment. The intermittent control group had no drug treatment. Before and after treatment, the treatment group and the control group were both tested PLT, MPR, PPR, FBG, D-D, CRP and ESR in venous blood, while the intermittent control group were also tested the above items only once. After treatment, the relief time and treatment effect of joint swelling and pain were evaluated in the treatment group and the control group.  SPSS statistical software was used for all statistical analysis, and <i>P</i>＜0.05 was considered statistically significant.<b>Results</b>  Before treatment of acute gouty arthritis, there were statistically significant differences in PLT, MPR, FBG, D-D, CRP and ESR in the treatment group and the control group compared with the intermittent control group (<i>P</i>＜0.01).After treatment, there were statistically significant differences in PLT, MPR and FBG between the control group and the treatment group (<i>P</i>＜0.01), and there were also statistically significant differences in the relief time of joint swelling and pain between the two groups (<i>P</i>＜0.05).<b>Conclusion</b>  FBG, D-D, PLT, MPR, PPR and other coagulation indicators have a significant role in acute gout arthritis. The supplemented formule of Simiao Powder can reduce PLT, MPR, FBG and other coagulation indicators, and it can also shorten the relief time of joint swelling and pain. Acute gout arthritis can use this prescription for the treatment.]]></description>
<pubDate>2022/3/16 16:00:23</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[JING Rongyue, XU Lei, XU Chengsong, XU Meimei, GUO Liang, CHEN Yueyue]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>JING Rongyue, XU Lei, XU Chengsong, XU Meimei, GUO Liang, CHEN Yueyue</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202202013&flag=1]]></guid><cfi:id>51</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Application of subject-achieving quality control circle in improving pharmaceutical care for patients with chronic hepatitis B]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202202014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b> To explore the application effect of QCC in improving the pharmaceutical care system for patients with chronic hepatitis B, and to provide theoretical support for the management of patients with chronic hepatitis B.<b>Methods</b> Select the theme of "Improving Pharmaceutical Services for Patients with Chronic Hepatitis B" as the theme of this quality control circle and carry out activities in accordance with the ten steps of the quality control circle of the subject-achieving quality control circle. Before and after the evaluation Tangible fruit and intangible fruit. Analyze the causes of insufficient pharmaceutical services for patients with chronic hepatitis B through QCC activities, and formulate strategies to improve the quality of pharmaceutical services such as reorganizing the management team, multi-dimensional pharmaceutical services, and clinical research to serve patients with chronic hepatitis B. <b>Results</b> After the QCC activities were carried out, in the management of chronic hepatitis B patients, the percentage of abnormal liver function among the selected people who used centralized purchase of entecavir decreased from 18.75% before improvement to 7.14%, and the rate of liver function ALT reversion increased from 81.25% before improvement To 88.39% after improvement, the HBV-DNA conversion rate increased from 86.61% before improvement to 98.21%.  Circle members' sense of honor, sense of responsibility, self-confidence, QCC techniques, communication and coordination and team cohesion and other activities have been significantly improved. <b>Conclusion</b> The project-achieving quality control circle activities are suitable for more complex subjects such as improving the pharmaceutical care of chronic hepatitis B patients, and can effectively improve work efficiency. The development of QCC activities has improved the pharmacy services for patients with chronic hepatitis B, reflects the professional service level of clinical pharmacists, and is of significant significance for improving the quality of hospital pharmacy services.]]></description>
<pubDate>2022/3/16 16:00:23</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[GONG Yinhua, ZHANG Ping, HONG Xiao, CHEN Rong, XU Wenjie, ZHU Jianguo]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>GONG Yinhua, ZHANG Ping, HONG Xiao, CHEN Rong, XU Wenjie, ZHU Jianguo</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202202014&flag=1]]></guid><cfi:id>50</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Exploration and practice of standardized management on donated medicines in a designated medical institution for public health emergencies]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202212012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Obiective</b>  Analyze the working process of donated medicines during the COVID-19. To provide an emergency administration mode of donated medicines for public health emergencies in medical institutions. <b>Methods</b>  Combined with the work situation of the selection, reception, acceptance, storage, delivery, use and supervision of donated medicines accepted by our hospital, a practical and feasible management system was developed. According to the use and management of donated medicines, the management process of donated medicines will be continuously optimized. <b>Results</b>  The "Donated medicines Management System" is legal, reasonable and practical. The selection of donated medicines meets the needs of COVID-19 prevention. Acceptance, storage to achieve strict quality control and establish a special account to achieve source traceability. Standardize the approval process for the use of donated medicines and make the whereabouts traceable. <b>Conclusion</b>  The implementation of "Donated medicines Management System" has been formulated, which has improved the efficiency of the management of donated medicines and ensures the quality and rational use of drugs.]]></description>
<pubDate>2023/1/17 13:57:59</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[DING Jing<sup>1</sup>, WANG Hefei<sup>2</sup>, ZHANG Han<sup>1</sup>, CHEN Wenwen<sup>1</sup>, DANG Heqin<sup>1</sup>, LIU Yanlin<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>DING Jing<sup>1</sup>, WANG Hefei<sup>2</sup>, ZHANG Han<sup>1</sup>, CHEN Wenwen<sup>1</sup>, DANG Heqin<sup>1</sup>, LIU Yanlin<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202212012&flag=1]]></guid><cfi:id>49</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Practice of administration of strong narcotics and psychotropic drugs]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202212013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To establish a regional consensus on the management and use of narcotic drugs and psychotropic drugs in order to ensure their rational use and prevent them from flowing into illegal channels. <b>Methods</b>  To supervise and inspect the management and use of narcotic drugs and class I psychotropic drugs in regional medical institutions, to form regional expert management consensus and to train and implement. <b>Results</b>  Through the introduction of expert consensus, the management and use of narcotic drugs and class I psychotropic drugs in the city reached "standardization, homogeneity and simplification". <b>Conclusion</b>  The management and use of narcotic drugs and class I psychotropic drugs reach "three memorization", which can ensure their standardized management, rational use and prevent them from flowing into illegal channels.]]></description>
<pubDate>2023/1/17 13:57:59</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[CHU Jianshe<sup>1</sup>, XIE Fadong<sup>1</sup>, ZOU Zongqiang<sup>2</sup>, ZOU Huiqi<sup>1</sup>, ZHAO Dongkun<sup>1</sup>, ZHANG Xia<sup>1</sup>, WANG Hongmei<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>CHU Jianshe<sup>1</sup>, XIE Fadong<sup>1</sup>, ZOU Zongqiang<sup>2</sup>, ZOU Huiqi<sup>1</sup>, ZHAO Dongkun<sup>1</sup>, ZHANG Xia<sup>1</sup>, WANG Hongmei<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202212013&flag=1]]></guid><cfi:id>48</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Analysis of drug therapy for stump pain with phantom pain]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202211013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To investigate the role of pharmaceutical care in drug therapy of stump pain with phantom pain in 1 case.<b>Methods</b>  The treatment plan of the patient was discussed with the thinking of evidence-based pharmacy, and the specific medication of the patient was analyzed.<b>Results</b>  It was unreasonable to use carbamazepine and non-steroidal anti-inflammatory drugs to treat phantom limb pain.<b>Conclusion</b>  Clinical thinking of evidence-based pharmacy plays an important role in the process of drug treatment, which helps to improve the level of pharmaceutical care of clinical pharmacists and promote rational drug use.]]></description>
<pubDate>2022/12/12 13:59:59</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[QIAN Limin<sup>1</sup>, ZHANG Yingying<sup>1</sup>, LENG Jiawei<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>QIAN Limin<sup>1</sup>, ZHANG Yingying<sup>1</sup>, LENG Jiawei<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202211013&flag=1]]></guid><cfi:id>47</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Pharmaceutical care of a patient with acute lymphoblastic leukemia in combination with imatinib and voriconazole]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202210012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To provide ideas for adjusting the dosage of imatinib and voriconazole in combination.<b>Methods</b>  The treatment of 1 case of Philadelphia chromosome positive acute lymphoblastic leukemia participated by clinical pharmacists were analyzed. The patient was diagnosed for fungal infection during imatinib treatment. Considering the metabolic characteristics and safety of the drug, the clinical pharmacist recommended voriconazole combined with imatinib for treatment, but the dose of imatinib should be adjusted.The dose of imatinib was adjusted to 200 mg per day,and then increased to 300 mg per day.During the combination medication period, the blood concentration of imatinib was measured,and the adverse drug reactions were evaluated and monitored. <b>Results</b> Physicians adopted the recommendations of clinical pharmacists.During the combination therapy of voriconazole and imatinib, the patient's infection was well controlled. The blood concentration of imatinib showed 1372.08ng/mL, and the patient's liver function and blood routine were normal, and  the condition was stable.the condition was stable. <b>Conclusion</b>  The clinical pharmacist participated in the treatment process of this patient, formulated an individualized treatment plan and achieved good results, and provided ideas for the adjustment of drug dosage for the combination of imatinib and voriconazole.]]></description>
<pubDate>2022/11/11 10:33:32</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[CHEN Chen<sup>1</sup>, LI Xia<sup>2</sup>, DONG Yan<sup>1</sup>, WANG Yongjing<sup>3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>CHEN Chen<sup>1</sup>, LI Xia<sup>2</sup>, DONG Yan<sup>1</sup>, WANG Yongjing<sup>3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202210012&flag=1]]></guid><cfi:id>46</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Thoughts on improving the quality of pharmaceutical services in outpatient pharmacies]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202210013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[The outpatient western pharmacy is a part of the pharmacy department and is an important external window in the hospital. Therefore, the pharmaceutical service level of outpatient western pharmacies will directly affect the image of the hospital. As for how to improve the quality of pharmacy services in outpatient western pharmacies, it is necessary to first find out the problems in outpatient western pharmacies, then analyze and formulate appropriate improvement measures to improve the quality. This article mainly explains the measures to improve the quality of pharmaceutical services in outpatient western pharmacies.]]></description>
<pubDate>2022/11/11 10:33:32</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[SHI Rongjun]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>SHI Rongjun</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202210013&flag=1]]></guid><cfi:id>45</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[养阴清肺膏治疗肺肾阴虚型稳定期慢性阻塞性肺病的临床疗效]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202309015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2023/10/11 15:57:17</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[文高艳<sup>1</sup>，张玲玲<sup>1</sup>，王星<sup>2</sup>，朱珠<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>文高艳<sup>1</sup>，张玲玲<sup>1</sup>，王星<sup>2</sup>，朱珠<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202309015&flag=1]]></guid><cfi:id>44</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[口服托拉塞米与吠塞米在心力衰竭维持治疗中疗效的比较]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202309016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2023/10/11 15:57:17</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[高林<sup>1</sup>，王美蓉<sup>2</sup>，陈付成<sup>3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>高林<sup>1</sup>，王美蓉<sup>2</sup>，陈付成<sup>3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202309016&flag=1]]></guid><cfi:id>43</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Analysis on compatible principles of prescriptions for nephropathic proteinuria by traditional chinese medicine inheritance assistant system]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202308015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  Based on traditional Chinese medicine inheritance assistant system (TCMIAS), the medication rules of Professor Bai Zhijun in treatment of nephrotic proteinuria were analyzed in order to provide basis for the clinical prescription and new drug development.<b>Methods</b>  The Chinese medicine prescriptions of Professor Bai Zhijun in treatment of nephrotic proteinuria were collected from January 2018 to December 2020 (includes outpatient and inpatient prescriptions), and the compatibility rule of them were analyzed using TCMIAS and Microsoft Office Excel software.<b>Results</b>  A total of 110 compliant prescriptions including 139 traditional Chinese herbs were collected, among them, the frequency of Astragalus, Oldenlandia, Scutellaria barbata, Cogongrass rhizome Codonopsis pilosula, Glycyrrhiza uralensis and Poria cocos, et al. were highest sequentially. The herbs is mainly sweet and bitter in taste with cold and flat in nature mostly, and attribute to stomach, lung, spleen and liver meridians mostly. The herbs combinations with high frequency are Astragalus+Oldenlandia, Scutellaria barbata+Oldenlandia, Scutellaria barbata+Astragalus, Scutellaria barbata+ Astragalus+Oldenlandia,Cogongrass rhizome+Astragalus, et al; and five new prescriptions  are obtained by entropy hierarchical cluster analysis.<b>Conclusion</b>  The pathogenesis of nephrotic proteinuria is asthenia in origin and asthenia in superficiality. Asthenia in origin is mainly due to  spleen and kidney deficiency, and qi-yin deficiency; Asthenia in superficiality is marked by blood stasis, heat toxin and water dampness. The therapeutically principle is to strengthen the spleen, kidney and invigorate Qi, with emphasis on heat-clearing and detoxifying always activating blood circulation to dissipate blood stasis.]]></description>
<pubDate>2023/9/11 16:16:03</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[LI Ni, ZHANG Qian, LI Fang, WANG Jilei, CHEN Lijing, ZHANG Hongyan]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LI Ni, ZHANG Qian, LI Fang, WANG Jilei, CHEN Lijing, ZHANG Hongyan</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202308015&flag=1]]></guid><cfi:id>42</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Status quo of management and systematic review in drug storage in China]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202308016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To systematically evaluate the status quo of management in drug storage，and to provide basis for improving the quality of drug storage management.<b>Methods</b>  Retrieved the literatures related to drug storage management published in CNKI，VIP database ,CBM and Wanfang database from Jan.2000 to Dec.2022. The descriptive analysis was conducted for drug storage management mode，infection to hospital. <b>Results</b>  A total of 14 literatures were included，involving 10 before and after control studies, 4 experience sharing studies. According to the analysis of the included literature, the management of hospital drug storage in China can be roughly divided into three aspects, including local zero inventory mode to reduce hospital operating costs; With the help of quality control circle and other management tools, fine internal management of the drug storage; Using the information management method, with the help of the special platform system to improve the efficiency and accuracy of the drug storage. <b>Conclusion</b>  Zero-inventory management of drug storage is inevitably restricted by many aspects, such as manufacturing enterprises and distribution businesses, and should not be pursued by hospitals. Making full use of modern information management methods is of great positive significance to the quality management of drug storage.]]></description>
<pubDate>2023/9/11 16:16:03</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[REN Shouyan<sup>1</sup>, HE Shuang<sup>2</sup>, HOU Fei<sup>3</sup>, ZHU Li<sup>3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>REN Shouyan<sup>1</sup>, HE Shuang<sup>2</sup>, HOU Fei<sup>3</sup>, ZHU Li<sup>3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202308016&flag=1]]></guid><cfi:id>41</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Efficacy Analysis of Tripterygium Polyglycosides combined with Dapagliflozin in Treatment of Diabetic Kidney Disease]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202306012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To investigate the clinical effect of Tripterygium wilfordii polyglycosides combined with Dapagliflozin in the treatment of diabetic kidney disease. <b>Methods</b>  A total of 120 patients with diabetic kidney disease admitted from January 2020 to June 2021 were divided into control group and observation group by random number table method, with 60 cases in each group. Both groups received routine treatment. On this basis, the control group was treated with Dapagliflozin, and the observation group was treated with Tripterygium wilfordii polyglycosides combined with Dapagliflozin. The clinical therapeutic effects of the two groups were compared, including renal function indexes and metabolic indexes before and after treatment, and the adverse reactions during the treatment were recorded at the same time. <b>Results</b>  In terms of therapeutic effect, the decrease of serum creatinine and 24-hour urinary protein quantification in the observation group was significantly higher than that in the control group, and the difference was statistically significant (<i>P</i>＜0.05). The increase of serum albumin in the observation group was higher than that in the control group. The levels of fasting blood glucose,glycosylated hemoglobin and blood uric acid level in the two groups were significantly lower than those before treatment, but there was no statistical difference between the two groups (<i>P</i>＞0.05). In terms of adverse reactions, the incidence of adverse reactions in the observation group and the control group after treatment was 8.33% and 6.67%, respectively, and the difference was not statistically significant (<i>P</i>＞0.05). <b>Conclusion</b>  In the treatment of diabetic kidney disease, Tripterygium wilfordii polyglycosides combined with Dapagliflozin can effectively reduce the levels of serum creatinine and urinary protein, increase serum albumin, and improve the renal prognosis of patients, without significant increase in adverse reactions. The overall clinical effect is ideal.]]></description>
<pubDate>2023/7/25 13:23:05</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[LIU Yanyan<sup>1</sup>, MU Shouhan<sup>1</sup>, YIN Yanzhi<sup>1</sup>, ZHANG Jiayu<sup>2</sup>, LYU Congkui<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LIU Yanyan<sup>1</sup>, MU Shouhan<sup>1</sup>, YIN Yanzhi<sup>1</sup>, ZHANG Jiayu<sup>2</sup>, LYU Congkui<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202306012&flag=1]]></guid><cfi:id>40</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Correlation of ERCC1, hMSH2 expression with pathological characteristics and platinum resistance in cervical cancer]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202306013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To investigate the correlation between the expression of nucleotide excision repair cross complementary gene 1 (ERCC1), mismatch repair gene 2 (hMSH2) and the pathological characteristics and platinum resistance in cervical cancer. <b>Methods</b>  The pathological tissues of 86 patients with cervical cancer in our hospital from January 2019 to March 2022 were collected as the observation group, and the normal cervical tissues of 72 patients with myoma of uterus removed during the same period were collected as the control group. Compare the expression of ERCC1 and hMSH2 in the two groups, analyze the correlation between the expression of ERCC1 and hMSH2 in cancer tissues and pathological characteristics, analyze the pathological characteristics, ERCC1 and hMSH2 expression in patients with platinum resistance, and analyze the multifactor analysis of platinum resistance, and analyze the predictive value of ERCC1 and hMSH2 expression in platinum resistance. <b>Results</b>  The positive rates of ERCC1 and hMSH2 in the observation group were higher than those in the control group (<i>P</i><0.05); The expression of ERCC1 and hMSH2 in cancer tissues was related to the depth of muscle invasion, stage and lymph node metastasis (<i>P</i><0.05); Patients with platinum resistance were related to the depth of muscle invasion, stage, degree of differentiation, lymph node metastasis, ERCC1, hMSH2 positive (<i>P</i><0.05); Logistic regression equation analysis showed that positive ERCC1 and hMSH2 in cancer tissues were still risk factors for platinum resistance in cervical cancer patients after controlling the depth of muscle invasion, stage, degree of differentiation and lymph node metastasis (<i>P</i><0.05); ROC showed that the AUC value of ERCC1 and hMSH2 positive combined prediction of platinum resistance was the largest, 0.702. <b>Conclusion</b>  ERCC1 and hMSH2 are highly expressed in cervical cancer tissues, and are related to pathological characteristics and platinum resistance. Both of them can be used to predict platinum drug reactivity and guide clinical treatment.]]></description>
<pubDate>2023/7/25 13:23:05</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[WU Peipei<sup>1</sup>, SHI Zhenshan<sup>2</sup>, LI Dongpeng<sup>3</sup>, MA Jiaqin<sup>2</sup>, ZHAI Fan<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WU Peipei<sup>1</sup>, SHI Zhenshan<sup>2</sup>, LI Dongpeng<sup>3</sup>, MA Jiaqin<sup>2</sup>, ZHAI Fan<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202306013&flag=1]]></guid><cfi:id>39</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Evaluation of the efficacy of TACE combined with rivatinib combined with MWA in the treatment of advanced large hepatocellular carcinoma]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202305011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To evaluate the clinical efficacy of transcatheter arterial chemoembolization (TACE) combined with rivatinib and microwave ablation (MWA) in the treatment of advanced large hepatocellular carcinoma.<b>Methods</b>  Select 73 patients with advanced large hepatocellular carcinoma admitted to the Peking Union Medical College, Chinese Academy of Medical Sciences and the Second Hospital of Beijing from January 2018 to December 2021. 36 patients were treated with TACE combined with rivatinib and MWA, were set as observation group; 37 patients were treated with TACE combined with rivatinib were set as  the control group. The short-term efficacy, progression-free survival, total survival rate and complications of the two groups were compared.<b>Results</b>  The effective remission rates of the disease in the observation group and the control group after 4 months were 72.2% and 40.5% respectively, with a significant difference (<i>P</i><0.05). The median progression-free survival was 18 months in the observation group and 10 months in the control group. There was a significant difference between the two groups (<i>P</i><0.05). The total survival rates at 6, 12, 18, 24 and 36 months in the observation group were 97.2%, 82.7%, 70.1%, 54.1% and 22.3%, respectively, and the total survival rates at 6, 12, 18, 24 and 36 months in the control group were 94.6%, 66.9%, 35.4%, 32.2% and 9.7% respectively. The total survival rate of the observation group was significantly higher than that of the control group (<i>P</i><0.05). There was no significant difference in the incidence of postoperative complications between the two groups (<i>P</i>>0.05).<b>Conclusion</b>  TACE combined with rivatinib combined with MWA in the treatment of middle and advanced large liver cancer can strengthen the curative effect and effectively prolong the survival time of patients.]]></description>
<pubDate>2023/6/26 13:41:42</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[ZHOU Xuetao<sup>1</sup>, JIANG Wenhao<sup>1</sup>, HAN Yue<sup>2</sup>, FENG Weijing<sup>1</sup>, ZENG Wei<sup>1</sup>, CHEN Chen<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHOU Xuetao<sup>1</sup>, JIANG Wenhao<sup>1</sup>, HAN Yue<sup>2</sup>, FENG Weijing<sup>1</sup>, ZENG Wei<sup>1</sup>, CHEN Chen<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202305011&flag=1]]></guid><cfi:id>38</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Clinical efficacy of Guanxinning combined with isosorbide mononitrate in the treatment of patients with chronic heart failure and its influence on cardiac function]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202305012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To observe the clinical efficacy of Guanxinning combined with isosorbide mononitrate in treating patients with chronic heart failure (CHF) and its influence on cardiac function. <b>Methods</b>  102 patients with CHF who were treated in Fuyang Cancer Hospital, Anhui Province from January 2019 to December 2021 were divided into control group (<i>n</i>=51, isosorbide mononitrate treatment) and observation group (<i>n</i>=51, isosorbide mononitrate + Guanxinning treatment) according to the random number table method. The clinical efficacy as well as echocardiographic parameters [left ventricular end-systolic diameter (LVESD), left ventricular end-diastolic diameter (LVEDD), left ventricular ejection fraction (LVEF)], serum myocardial enzymes [lactate dehydrogenase (LDH), aspartate aminotransferase (AST), creatine phosphokinase (CK), creatine phosphokinase isoenzyme (CK-MB)] and serum troponin I (TnI), brain natriuretic peptide (BNP) and homocysteine (Hcy) before and after treatment were compared between the two groups, and the adverse reactions in the two groups were counted during treatment. <b>Results</b>  The total effective rate in observation group (94.12%) was significantly higher than that in control group (80.39%) (<i>P</i><0.05). After treatment, LVESD and LVEDD in the two groups were reduced compared with those before treatment, and the two indicators in observation group were significantly lower than those in control group, and the LVEF was enhanced compared with that before treatment in the two groups, and the LVEF in observation group was significantly higher compared to control group (<i>P</i><0.05). After treatment, the levels of LDH, AST, CK and CK-MB in both groups were lower than those before treatment, and the levels in observation group were significantly lower than those in control group (<i>P</i><0.05). The levels of TnI, BNP and Hcy in the two groups after treatment were lower than those before treatment, and the above levels in observation group were significantly lower than those in control group (<i>P</i><0.05). During treatment, there were no obvious adverse reactions in the two groups. <b>Conclusion</b>  Guanxinning combined with isosorbide mononitrate can effectively improve the clinical efficacy, enhance the cardiac function and improve the myocardial enzymes in the treatment of patients with CHF, and it has good safety and is worthy of application.]]></description>
<pubDate>2023/6/26 13:41:42</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[ZHAO Zhihui, SONG Yu, WU Dongbin, WANG Jiaojiao]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHAO Zhihui, SONG Yu, WU Dongbin, WANG Jiaojiao</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202305012&flag=1]]></guid><cfi:id>37</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Clinical medication analysis and pharmaceutical care of a case of colon cancer with venous thrombosis]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202304013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To explore the role of clinical pharmacists in the treatment of patient with colon cancer combined with venous thrombosis in individualized pharmaceutical care.<b>Methods</b>  Clinical pharmacists participate in patients' anticoagulation treatment through clinical pharmacy rounds, detailed pharmacy consultations, consultations, literature review and exchanges and discussions, etc., and analyze the use of low molecular weight heparin (LMWH) in the perioperative period and the causes of postoperative bleeding, provide treatment suggestions and provide medication education to patients. <b>Results</b>  The treatment and perioperative management of patients with colon cancer complicated with venous thrombosis should be individualized, and the bleeding adverse reactions caused by LMWH should be vigilant.<b>Conclusion</b>  Clinical pharmacists actively and efficiently participate in the treatment process of patients, provide individualized pharmaceutical services, and assist physicians in formulating treatment plans to facilitate the rational and safe use of anticoagulant drugs.]]></description>
<pubDate>2023/5/31 10:08:19</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[LIN Jie<sup>1</sup>, WANG Feng<sup>2</sup>, LIU Weijing<sup>1</sup>, WANG Liqing<sup>3</sup>, ZOU Liyi<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LIN Jie<sup>1</sup>, WANG Feng<sup>2</sup>, LIU Weijing<sup>1</sup>, WANG Liqing<sup>3</sup>, ZOU Liyi<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202304013&flag=1]]></guid><cfi:id>36</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Application of quality control circle in improving work efficiency of automated pharmacy]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202304014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b> To improve the work efficiency of hospital automated pharmacy. <b>Methods</b> We set up a quality control circle team and implemented various activities in accordance with the ten steps of the quality control circle, analyzed the main reasons for the low work efficiency of automated pharmacies, explored and implemented countermeasures to solve problems, and evaluated the effects before and after the activities.<b>Results</b> The improvement of the work efficiency of the automated pharmacy is mainly reflected in that the automation rate of the dispensing volume of the dispensing machine has increased from 60.95% to 71.13%, the average dispensing time has decreased from 30s to 18s, the average patient collection time has decreased from 218s to 87s, Patient satisfaction increased from 80% to 96.01%;the enthusiasm, sense of responsibility and quality control skills of circle members have been greatly improved.<b>Conclusion</b> Through the activities of quality control circle, the work efficiency of automated pharmacy has been effectively improved, the enthusiasm and enthusiasm of employees have been improved, and the cohesion of the team has been enhanced, which is worthy of promotion.]]></description>
<pubDate>2023/5/31 10:08:19</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[WU Yubao<sup>1</sup>, ZHENG Lei<sup>1</sup>, SONG Chao<sup>1</sup>, CHANG Tao<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WU Yubao<sup>1</sup>, ZHENG Lei<sup>1</sup>, SONG Chao<sup>1</sup>, CHANG Tao<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202304014&flag=1]]></guid><cfi:id>35</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[氨甲环酸两种给药方法对减少全膝关节置换术出血量的对比分析]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202312015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2024/1/10 16:01:45</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[赵想<sup>1</sup>，戚大春<sup>2</sup>，安新荣<sup>2</sup>，高天勤<sup>2</sup>，徐闯<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>赵想<sup>1</sup>，戚大春<sup>2</sup>，安新荣<sup>2</sup>，高天勤<sup>2</sup>，徐闯<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202312015&flag=1]]></guid><cfi:id>34</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[我国社区药学服务现状及发展建议]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202312016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2024/1/10 16:01:45</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[杨异卉，李畅，秦文秀，甘春丽]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>杨异卉，李畅，秦文秀，甘春丽</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202312016&flag=1]]></guid><cfi:id>33</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Expression and significance of programmed death receptor-1 in peripheral blood of patients with primary hepatocellular carcinoma]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202409014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To investigate the expression and significance of programmed death receptor-1 in primary hepatocellular carcinoma. <b>Methods</b>  A retrospective analysis was performed on 70 patients with HCC treated at the 980th (Baiqiu'en International Peace) Hospital of the Joint Security Force from May 2020 to May 2022. All specimens were sectioned, and the expression of PD-1 in the specimens was measured by immunohistochemistry and Western Blot; the expression of PD-1 in cancer tissues, paraneoplastic tissues and HCC with different degrees of differentiation was analyzed; the influence of different pathological characteristics (age, gender, TNM stage, tumor size, HBV positivity, metastasis or not, combined with ascites or not) on the expression of PD-1 was analyzed.<b>Results</b>  PD-1 expression level in cancer tissues was significantly higher than that in paraneoplastic tissues, and the differences were all statistically significant (<i>P</i><0.05); PD-1 expression level in moderately differentiated HCC was significantly higher than that in highly differentiated and hypodifferentiated HCC, and the differences were all statistically significant (<i>P</i><0.05); the differences were not statistically significant (<i>P</i>>0.05) when comparing the highly differentiated type with the hypodifferentiated type; PD-1 positive The difference was not statistically significant (<i>P</i>>0.05); PD-1 positive expression was related to TNM stage, tumor size, whether the tumor was metastatic or not, and the presence of ascites (<i>P</i><0.05); and patients with TNM stage III-IV, tumor diameter >6cm, tumor metastasis and combined ascites The PD-1 positive expression rate was higher in HCC patients with TNM stage III-IV, tumor diameter >6 cm, metastasis and combined ascites.In addition, PD-1 expression was found to be higher in stage III-IV hepatocellular carcinoma than in stage I-II hepatocellular carcinoma as determined by qPCR and Western Blot. <b>Conclusion</b>  PD-1 was expressed at a higher level in cancer tissues and in moderately differentiated HCC; and the higher the tumour stage, the larger the diameter, the combination of metastasis and ascites, the higher the level of PD-1 expression. Therefore, PD-1 is expected to be one of the indicators to determine the stage and prognosis of HCC, providing new strategies for the diagnosis and treatment of HCC.]]></description>
<pubDate>2024/10/9 16:27:01</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[LI Suyan, AN Liyun, ZHANG Huifeng, WANG Fukun]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LI Suyan, AN Liyun, ZHANG Huifeng, WANG Fukun</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202409014&flag=1]]></guid><cfi:id>32</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Construction and practice of full-course pharmaceutical care model for prevention of venous thromboembolism after major orthopedic surgery]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202409015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To establish a full-course pharmaceutical care model and working method to prevent venous thromboembolism (VTE) in patients after major orthopedic surgery, and explore its practical effect.<b>Methods</b>  216 patients who underwent major orthopedic surgery were collected from joint surgery in our hospital during Dec. 2019 – Dec. 2020, and then divided into control group (108 cases) and intervention group (108 cases) according to random number table. Patients in the control group only received traditional medical services provided by doctors and nurses. Patients in the intervention group, besides the basis of the control group, clinical pharmacists participated in the clinical pathway for VTE prevention, and provided standardized pharmaceutical services, and the patients were followed up 35 days after discharge.The incidence of VTE,bleeding,medication compliance,satisfaction, medication deviation, and awareness of adverse drug events (ADE) after discharge were compared between the two groups.<b>Results</b>  The incidence of VTE in the intervention group was 5.55%, which was lower than 19.44% in the control group (<i>P</i><0.01), and the incidence of bleeding in the intervention group was 4.60%, which was lower than 13.89% in the control group (<i>P</i><0.05). The medication compliance rate, medication guidance satisfaction and ADE awareness rate of the patients in the intervention group were significantly higher than those in the control group; the medication deviation of the patients in the intervention group was significantly lower than that in the control group.<b>Conclusions</b>  The full-course  pharmaceutical care model and work method for prevention of VTE in patients undergoing major orthopedic surgery is conducive to improving patient medication compliance and reducing the incidence of VTE, which is worth popularizing.]]></description>
<pubDate>2024/10/9 16:27:01</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[ZHANG Liping<sup>1</sup>, YANG Chunyan<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Liping<sup>1</sup>, YANG Chunyan<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202409015&flag=1]]></guid><cfi:id>31</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[1例利多卡因治疗未成年人复杂性区域性疼痛综合征的用药分析]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202408016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2024/9/11 10:05:17</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[任倩，郭琳]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>任倩，郭琳</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202408016&flag=1]]></guid><cfi:id>30</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[孕妇生殖毒性药品暴露及知信行现状调查]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202408017&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2024/9/11 10:05:17</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[龙凤<sup>1</sup>，潘国军<sup>2</sup>，罗素芳<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>龙凤<sup>1</sup>，潘国军<sup>2</sup>，罗素芳<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202408017&flag=1]]></guid><cfi:id>29</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Analysis of biospecimen management problems in drug clinical trials]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202407014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b> To analyze the problems existing in the management of biological samples in drug clinical trials, and to propose corresponding measures to ensure the quality of clinical trials.<b>Methods</b>  The violation protocol reports submitted to the ethics committee from May 2019 to May 2023 were downloaded from the drug clinical trial management system of our hospital, and the biospecimen management-related violations were retrospectively analyzed, including the type, quantity, responsible subject, distribution of common violation regimen types in different clinical trial stages, comparison of violation types before and after the implementation of the new version of drug clinical trial quality management standards, and the impact of violation of the protocol. <b>Results</b>  A total of 76 cases of violations related to biological samples were included in the 304 protocol violation reports, and the most common types of protocol violations were sample storage over-temperature (22 cases, accounting for 28.95%), collection over-window (14 cases, accounting for 18.42%), and centrifugation time over-window (8 cases, accounting for 10.53%). <b>Conclusion</b>  Improve the quality management system of biological samples, strengthen the training of investigators' GCP regulations and protocols, improve the awareness and ability of investigators' GCP, generate high-quality biological samples, and facilitate the research and development of new drugs.]]></description>
<pubDate>2024/8/13 9:35:34</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[LIANG Xin<sup>1</sup>, XIAO Yan<sup>2</sup>, ZHANG Mengqi<sup>1</sup>, XIA Rui<sup>1</sup>, ZHANG Yatong<sup>3</sup>, GENG Xiaokun<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LIANG Xin<sup>1</sup>, XIAO Yan<sup>2</sup>, ZHANG Mengqi<sup>1</sup>, XIA Rui<sup>1</sup>, ZHANG Yatong<sup>3</sup>, GENG Xiaokun<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202407014&flag=1]]></guid><cfi:id>28</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Literature case analysis of acute generalized exanthematous pustulosis in pregnancy induced by drugs]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202407015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To explore the characteristics of drugs inducing acute generalized exanthematous pustulosis during pregnancy,and the clinical features,disease course and outcomes of the disease.<b>Methods</b>  The relevant databases including PubMed, Embase, Web of Science and four Chinese native databases were searched and literature on AGEP in pregnancy were reviewed. The information of patients [nationality, age, gestational course, history of allergy, history of psoriasis, causes, usage (drugs), time of onset, clinical manifestations and examinations, treatments and outcomes, skin biopsy results] were collected and descriptively analyzed. <b>Results</b>  A total of 14 patients from 11 countries and regions were included, 2 in the first trimester, 4 in the second trimester and 8 in the third trimester. The mean age was 32 years old (from 23 to 39 years old). Apart from 1 case was triggered by vaccine, the other 13 cases were all considered to be caused by drugs [7 (53.85%) for antibiotics and 1 (7.69%) for each of mifepristone, labetalol, omeprazole, hydroxychloroquine, acetaminophen, phloroglucinol]. The onset time ranged from hours to dozens of days, with 2 cases within 24 hours, 9 cases within 1 to 3 days, 1 case within 18 days, 1 case within 6 weeks, and 1 case not mentioned in the literature. After exposure to the triggers ceased, 4 cases improved without medication interference, 2 cases received symptomatic or supportive treatments, and 8 cases were treated with systematic steroids including 1 case was treated with infliximab after steroids not working. All patients were cured after 2-15 days. There’re no statistical differences in onset time or recovery duration among different stages of pregnancy or routes of administration（<i>P</i>＞0.05）.<b>Conclusion</b>  AGEP in pregnancy could be induced by drugs in very common use, and mostly triggered within 3 days with typical clinical manifestations. With histological results and AGEP score system for diagnosis, suspected drugs should be stopped while symptomatic/supportive treatments, steroids or monoclonal antibodies could be chosen according to different situations of the patients and the recovery was always good.]]></description>
<pubDate>2024/8/13 9:35:34</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[JIAO Ping, CHEN Wei, LI Guohui]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>JIAO Ping, CHEN Wei, LI Guohui</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202407015&flag=1]]></guid><cfi:id>27</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A genotypes and serotonin reuptake inhibitor antidepressants: interpretation of the 2023 CPIC guideline]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202405014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[The Clinical Pharmacogenetics Implementation Consortium (CPIC) updated and expanded the 2015 guideline for CYP2D6 and CYP2C19 genotypes and selective serotonin reuptake inhibitors (SSRIs) in July 2023, adding CYP2B6, SLC6A4, HTR2A, SNRIs, and 5-HT modulators with SSRI-like activity in the sections related to genotype and drugs. The new guideline also updated the application recommendations for serotonin reuptake inhibitors based on gene polymorphism. This article interprets the relevant content of the guideline, in order to provide reference for the individualized treatment of 5-HT reuptake inhibitors in China.]]></description>
<pubDate>2024/6/11 10:53:53</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[ZHOU Changkai, YU Hongxia, CAO Mingchen, SHI Yunyan, LIU Donghua, JI Hongyan, XING Xiaomin, WANG Xinyi, LI Jing, JING Fanbo]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHOU Changkai, YU Hongxia, CAO Mingchen, SHI Yunyan, LIU Donghua, JI Hongyan, XING Xiaomin, WANG Xinyi, LI Jing, JING Fanbo</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202405014&flag=1]]></guid><cfi:id>26</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Efficacy and safety of infliximab in the treatment of ulcerative colitis in children]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202405015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b> To evaluate the efficacy and safety of infliximab (IFX) in children with ulcerative colitis (UC). <b>Methods</b>  The clinical data of 21 children with ulcerative colitis who received IFX at Jinan Children's Hospital from January 2018 to December 2022 were analyzed retrospectively.The pediatric ulcerative colitis activity index(PUCAI)、ulcerative colitis endoscopic index of severity and laboratory findings were compared to assess the efficacy and safety of IFX. <b>Results</b>  There were 12 males and 9 females among 21 children with UC. IFX efficacy analysis showed that the clinical response rate at week 14 was 76.2% (16/21) and the clinical response rate was 66.7% (14/21). The clinical response rate in maintained remission at week 30 was 76.4% (13/17) and the sustained response rate was 58.5% (10/17). PUCAI score, C reactive protein, erythrocyte sedimentation rate and fecal calprotectin were significantly decreased in 14 and 30 weeks of IFX treatment compared with before treatment (<i>P</i><0.05), and hemoglobin and albumin were significantly improved (<i>P</i><0.05). At 14 weeks,8 cases achieved mucosal healing,6 cases reduced severe mucosal inflammation to moderate inflammation, 4 cases reduced moderate inflammation to mild inflammation, and 2 cases showed no improvement in mucosal inflammation.The incidence of IFX infusion reactions was 43%(9/21),including acute infusion reactions,delayed infusion reactions,and transaminase elevation.Infections were the most common during treatment, with an incidence of 38% (8/21).<b>Conclusion</b>  IFX is effective on UC in children, However, we should be alert to the occurrence of adverse events during the treatment.]]></description>
<pubDate>2024/6/11 10:53:53</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[ZHU Liping<sup>1</sup>, WEI Xuxia<sup>1</sup>, HAO Lina<sup>1</sup>, XUE Ning<sup>1</sup>, LI Xia<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHU Liping<sup>1</sup>, WEI Xuxia<sup>1</sup>, HAO Lina<sup>1</sup>, XUE Ning<sup>1</sup>, LI Xia<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202405015&flag=1]]></guid><cfi:id>25</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Clinical application evaluation of cetuximab based on real-world data]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202404015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To conduct a clinical application evaluation of cetuximab based on real-world data, explore the content and methods of the clinical comprehensive evaluation of antitumor drugs, and provide a basis for rational clinical use and drug-related decision-making.<b>Methods</b>  According to the guidelines of a clinical application evaluation, through real-world data, Cetuximab was evaluated in six dimensions.<b>Results</b>  The evaluation results of various dimensions showed that most adverse reactions of cetuximab were not significantly different from bevacizumab and common chemotherapy regimens, but the incidence of rash was significantly higher than the others. In terms of efficacy,there is no significant difference between cetuximab and bevacizumab, but the remission rate of 5% is much lower than the clinical trial results. After propensity score matching, there was no significant difference in the total cost of the bevacizumab regimen, but it was significantly higher than the total cost of the common chemotherapy regimen. Cetuximab can be used for head and neck squamous cell carcinoma which can fill the clinical treatment gap and meet the clinical requirements. It is similar to other similar anti-tumor drugs and has no obvious advantages over the current suitability, but availability and affordability of cetuximab in Shandong is relatively poor. <b>Conclusion</b> Compared with bevacizumab, cetuximab has no significant difference in safety, efficacy, economy, and suitability, and has advantages in innovation and slightly poor accessibility.]]></description>
<pubDate>2024/5/20 16:36:51</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[LUAN Yali<sup>1</sup>, WANG Yuanming<sup>2</sup>, GAO Tiantian<sup>1</sup>, WANG Xiaojun<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LUAN Yali<sup>1</sup>, WANG Yuanming<sup>2</sup>, GAO Tiantian<sup>1</sup>, WANG Xiaojun<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202404015&flag=1]]></guid><cfi:id>24</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Meta-analysis of sacubitril-valsartan versus renin-angiotensin-aldosterone system inhibitors in the treatment of elderly refractory heart failure]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202404016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To systematically evaluate the efficacy and safety of sacubitril-valsartan(ARNI) compared to angiotensin converting enzyme inhibitors/angiotensin II receptor antagonists(ACEI/ARB)in the treatment of elderly refractory heart failure patients.<b>Methods</b>  The literatures were obtained in The Cochrane Library, Embase, PubMed, Web of science and Chinese databases (CNKI, VIP ,WanFang and CBM). After literature screening and data extraction, the quality of the included literature was evaluated using the Cochrane bias risk assessment tool. Meta analysis was conducted using RevMan and Stata software.Results A total of 10 literatures were included, with a total of 1 118 elderly refractory heart failure patients including. Meta-analysis results showed that the N-terminal proBNP(NT-proBNP)(MD=-282.61，95%CI -344.56~ -220.66，<i>P</i>﹤0.05), the left ventricular end-diastolic diameter(LVEDD)(MD=-3.48，95%CI -4.58~ -2.39，<i>P</i>﹤0.05) in the study group were lower than those in the control group; the left ventricular ejection fraction (LVEF)(MD=6.13, 95%CI 5.15~7.11, <i>P</i><0.05) and effective rate (OR=2.548, 95%CI 2.058~3.154, P<0.05) were significantly higher than those in the control group, respectively. The left ventricular ejection fraction (LVEF) (MD=6.35，95%CI 4.65~8.06，<i>P</i>﹤0.05) and effective rate (OR=2.449，95%CI 1.851—3.241，<i>P</i>﹤0.05) were significantly higher than those in the control group. In terms of adverse reactions, there was no difference in renal function damage, dizzy and hyperkalemia between the two groups, and the incidence of hypotension in the study group was lower than that in the control group.<b>Conclusion</b> Compared with ACEI/ARB, sacubitril-valsartan can significantly improve cardiac function, improve ventricular remodeling, and reduce myocardial tissue damage in elderly patients with refractory heart failure without significant adverse reactions.]]></description>
<pubDate>2024/5/20 16:36:52</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[MIAO Yiting<sup>1,2</sup>, GE Yalong<sup>3</sup>, HUANG Jing<sup>2</sup>, HE Xuemei<sup>2</sup>, ZHAO Xuan<sup>2,4</sup>, CHAI Chengcheng<sup>2</sup>, JIANG Dongyang<sup>2</sup>, LIANG Ying<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>MIAO Yiting<sup>1,2</sup>, GE Yalong<sup>3</sup>, HUANG Jing<sup>2</sup>, HE Xuemei<sup>2</sup>, ZHAO Xuan<sup>2,4</sup>, CHAI Chengcheng<sup>2</sup>, JIANG Dongyang<sup>2</sup>, LIANG Ying<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202404016&flag=1]]></guid><cfi:id>23</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Visualization analysis of GCP centers in hospitals in China based on bibliometrics]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202403013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To summarize the research status and development trends of clinical trial research centers in hospitals in China in the past 20 years.<b>Methods</b>  Using CNKI, VIP, and Wanfang databases, relevant literature from clinical trial research centers was searched. NoteExpress was used to process the literature, and CiteSpace 6.2.R3 software was used to visualize and analyze the journal sources, research authors, and keywords.<b>Results</b>  Including 4753 valid articles, and the magazine with the most articles included was "Chinese Journal of New Drugs" (111 articles). Analysis of literature author collaboration network shows that Hu Siyuan (40 articles) has the highest number of published articles in the research field of clinical trial research centers. The keywords in the top rankings show that the clinical trial research center mainly involves clinical trials (frequency 603), clinical efficacy (frequency 348), randomized controlled trials (frequency 241) and other related fields. <b>Conclusion</b>  In the past 20 years, clinical trial research centers have been conducting more and more drug trials. Establishing a standardized management model, accelerating the intelligent construction of clinical trial research centers, strengthening quality control of clinical trial research centers, standardizing the operational behavior of trial personnel, and improving the professional literacy of department members are important prerequisites for ensuring the safety of subjects and standardizing the trial process, as well as important guarantees for scientific, truthful, and reliable trial results.]]></description>
<pubDate>2024/4/19 14:40:51</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[YUAN Rukui<sup>1</sup>, WANG Mingli<sup>2</sup>, ZHOU Anqin<sup>3</sup>, CHEN Meijuan<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>YUAN Rukui<sup>1</sup>, WANG Mingli<sup>2</sup>, ZHOU Anqin<sup>3</sup>, CHEN Meijuan<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202403013&flag=1]]></guid><cfi:id>22</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Cost-effectiveness analysis of chemotherapy and chemotherapy combined with immunotherapy in the treatment of small cell lung cancer]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202403014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  Cost-effectiveness analysis was used to evaluate the economics of three regimens in the treatment of small cell lung cancer : chemotherapy (etoposide combined with carboplatin/cisplatin), chemotherapy combined with PD-L1 (atezolizumab/durvalumab) and chemotherapy combined with PD-1 (Serplulimab).<b>Methods</b>  The medical records of 94 patients with small cell lung cancer admitted to Shandong Provincial Hospital from January 2 020 to April 2 023 were retrospectively analyzed and divided into three groups according to the treatment regimen. The clinical efficacy of the three groups after four cycles of treatment was evaluated, adverse effects were recorded, and cost-effectiveness analysis was performed.<b>Results</b>  The objective response rates of the three groups were : chemotherapy group 56.25%, chemotherapy combined with PD-L1 group 63.33%, chemotherapy combined with PD-1 group 62.50%, the difference was not statistically significant(<i>P</i>>0.05). There was no significant difference in the incidence of leukopenia, thrombocytopenia and abnormal liver function among the three groups (<i>P</i>>0.05), and the incidence of gastrointestinal adverse reactions was 41.66 % in the chemotherapy group, 40.00 % in the chemotherapy combined with PD-L1 group, and 6.25 % in the chemotherapy combined with PD-1 group, the difference was statistically significant (<i>P</i><0.05). The objective response rate was used as the clinical efficacy index, and the cost-effectiveness ratios of the three groups were 480.88,2 026.80 and 1 001.47, respectively. The incremental cost-effectiveness ratios of chemotherapy combined with PD-L1 group and chemotherapy combined with PD-1 group were 14 309.06 and 5 686.81, respectively. The conclusion of sensitivity analysis is consistent with that of cost-effectiveness analysis. <b>Conclusion</b>  In the first-line treatment of extensive-stage small cell lung cancer, the ORR of chemotherapy alone was similar to that of combined immunization regimen, and the cost-effectiveness ratio of chemotherapy group was the best.]]></description>
<pubDate>2024/4/19 14:40:51</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[PEI Yihan<sup>1</sup>, WANG Shuping<sup>1,2</sup>, ZHANG Jindi<sup>1</sup>, BI Yunyan<sup>1</sup>, ZHANG Wen<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>PEI Yihan<sup>1</sup>, WANG Shuping<sup>1,2</sup>, ZHANG Jindi<sup>1</sup>, BI Yunyan<sup>1</sup>, ZHANG Wen<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202403014&flag=1]]></guid><cfi:id>21</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Effect of invigorating spleen and nourishing stomach on the level of tumor markers, immune function and long-term curative effect in elderly patients with advanced gastric cancer]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202402015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To explore the effects of invigorating the spleen and nourishing the stomach on the level of tumor markers, immune function and long-term efficacy in elderly patients with advanced gastric cancer. <b>Methods</b>  95 patients with advanced gastric cancer admitted to the gastroenterology department of our hospital from June 2019 to June 2022 were collected and randomly divided into control group (47 cases) and experimental group (48 cases). The control group was given FOLFOX4 regimen for chemotherapy, and the experimental group was given spleen-strengthening and stomach-nourishing method on the basis of the control group. Both groups were treated for 9 weeks. After treatment, TCM symptom scores, serum tumor markers, immune function indexes, gastrointestinal reactions and myelosuppression during treatment, and long-term survival rates were compared between the two groups.<b>Results</b>  After treatment, the clinical effective rate of experimental group was higher than that of control group (<i>P</i><0.05). After treatment, the scores of traditional Chinese medicine symptoms such as abdominal tightness, distention pain, poor appetite, loose stool and anesthesia in the 2 groups were reduced compared with before treatment. Compared with the control group, the scores of all TCM symptoms in experimental groups were lower (<i>P</i><0.05). After treatment, CEA, CA12-5, CA19-9 and CA72-4 were decreased compared with before treatment. Compared with the control group,CEA,CA12-5,CA19-9 and CA72-4 in experimental groups were lower (<i>P</i><0.05). After treatment, CD4<sup>+</sup>/CD8<sup>+</sup> and C3<sup>+</sup> increased, while IgG and IgM decreased in 2 groups compared with before treatment (<i>P</i><0.05). Compared with the control group, CD4<sup>+</sup>/CD8<sup>+</sup> and C3<sup>+</sup> in experimental groups were higher, while IgG and IgM were lower (<i>P</i><0.05). There was no significant difference in 6-month and 1-year survival rates between the two groups (<i>P</i>>0.05). The 3-year survival rate of experimental group was higher than that of control group (<i>P</i><0.05).<b>Conclusion</b>  Invigorating spleen and nourishing stomach has significant effect in the treatment of elderly patients with advanced gastric cancer, which can improve immune function and downregulate the level of tumor markers, and is suitable for clinical application.]]></description>
<pubDate>2024/3/21 14:35:15</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[CAO Shuang<sup>1</sup>, JIA Wenwen<sup>2</sup>, HU Jia<sup>3</sup>, TIAN Wei<sup>1</sup>, LIU Mei<sup>1</sup>, ZHU Jie<sup>4</sup>, CHENG Nian<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>CAO Shuang<sup>1</sup>, JIA Wenwen<sup>2</sup>, HU Jia<sup>3</sup>, TIAN Wei<sup>1</sup>, LIU Mei<sup>1</sup>, ZHU Jie<sup>4</sup>, CHENG Nian<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202402015&flag=1]]></guid><cfi:id>20</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Optimization of individualized tacrolimus dosing regimen after liver transplantation based on genetic testing and blood concentration monitoring techniques]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202402016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Tacrolimus, a widely used clinical calcium-modulated neural phosphatase inhibitor, is used as a first-line agent for the prevention and treatment of acute rejection after liver transplantation. However, in clinical applications, tacrolimus exhibits a narrow therapeutic window and large individual differences in pharmacokinetics, and low concentrations of tacrolimus in the early post-transplant period may induce rejection; whereas high concentrations of tacrolimus may lead to nephrotoxicity and/or neurotoxicity, so in-depth studies on the factors influencing the pharmacokinetics of tacrolimus are essential. In this article, we reviewed the clinical need for genetic testing and blood concentration monitoring in patients by searching the Chinese Network of Knowledge (CNKI), Wipro, Wanfang, and PubMed databases, and concluded that dosing based on genetic polymorphisms and the strategy of finding the optimal sampling point of the area under the curve at the time of substitution may be helpful to clinicians in predicting the optimal starting dosage of tacrolimus, which can help in the adjustment of the maintenance regimen, and is expected to reduce the incidence of adverse effects.]]></description>
<pubDate>2024/3/21 14:35:15</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[ZONG Huiying<sup>1,2</sup>, ZHANG Yundi<sup>1,2</sup>, LI Yue<sup>2</sup>, LI Yan<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZONG Huiying<sup>1,2</sup>, ZHANG Yundi<sup>1,2</sup>, LI Yue<sup>2</sup>, LI Yan<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202402016&flag=1]]></guid><cfi:id>19</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[The evolution of the wood soil relationship in chronic gastritis and its treatment with traditional Chinese and western medicine]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202412017&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Starting from the relationship between wood and soil, according to the pathogenesis evolution process of "wood" and "soil", this paper discussed the clinical diagnosis and treatment ideas and methods of wood without soil, wood with soil, wood with soil deficiency, and civil discapacity in chronic gastritis. It pays attention to the mixed symptoms, flexibly applies classical prescriptions, makes up for the defects of treating by syndrome differentiation and syndrome type alone, and gives full play to the advantages and characteristics of Chinese and western integrative treatment. Hope to provide a new clinical idea for the prevention and treatment of chronic gastritis.]]></description>
<pubDate>2025/1/9 14:34:37</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[DUAN Shuhang, SUN Jinhui]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>DUAN Shuhang, SUN Jinhui</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202412017&flag=1]]></guid><cfi:id>18</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[The impact of clinical pharmacists' involvement in the perioperative administration of tranexamic acid and anticoagulants in spinal surgery under the MTM model]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202412018&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To carry out pharmaceutical care based on the "patient-centered" approach under the MTM model, and explore the involvement of clinical pharmacists in the application of tranexamic acid and anticoagulants in spinal surgery perioperative period, in order to reduce blood loss, shorten hospitalization time, and ensure medical safety. <b>Methods</b>  A historical control study was conducted, including 135 cases of spinal surgery. By collecting patients' medical records, the types of anticoagulant drugs used, the rational use of tranexamic acid and anticoagulants, and the timing of drug use were analyzed to evaluate the effect of clinical pharmacist intervention.<b>Results</b>  After clinical pharmacists participated in pharmaceutical care, the qualified rate of tranexamic acid solvent selection, the correct rate of preoperative medication timing, and the qualified rate of anticoagulant drug use significantly increased, while the total blood loss decreased. The differences were statistically significant (<i>P</i><0.05). <b>Conclusion</b>  The participation of clinical pharmacists in the management of tranexamic acid and anticoagulants in spinal surgery perioperative period can improve the rationality of perioperative medication, achieve a balance between hemostasis and anticoagulation, and help improve the quality of medical management.]]></description>
<pubDate>2025/1/9 14:34:37</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[DI Huifeng, LIU Hui, HAN Jing, SHEN Lilin, YI Na, YAN Ying]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>DI Huifeng, LIU Hui, HAN Jing, SHEN Lilin, YI Na, YAN Ying</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202412018&flag=1]]></guid><cfi:id>17</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Survey on the use of intravenous infusion in 26 hospitals in Suzhou area]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202509015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To evaluate the current status of intravenous infusion in outpatient,emergency, and inpatient settings in Suzhou hospitals,providing evidence for standardized management. <b>Methods</b>  Data from 26 hospitals in Suzhou (2023) were collected and analyzed, including infusion rates in outpatient/emergency departments, antimicrobial usage,and inpatient infusion practices.<b>Results</b>  The outpatient and emergency infusion rates were 18.44% and 28.57% in primary hospitals, and 3.49% and 39.89% in secondary/tertiary hospitals,respectively.Respiratory diseases accounted for 80% (outpatient) and 60% (emergency) of the top infusion-related diagnoses. Antimicrobials were the most frequently used intravenous drugs, followed by glucocorticoids,expectorants,and antivirals. The inpatient infusion rate was 55.11% (antimicrobials 22.10%) in primary hospitals and 82.82% (antimicrobials 53.35%) in secondary/tertiary hospitals. <b>Conclusion</b>  While outpatient/emergency infusion rates show room for reduction, inpatient infusion management requires strengthening, with a focus on antimicrobial stewardship and rational use of glucocorticoids and other high-frequency intravenous medications.]]></description>
<pubDate>2025/10/14 16:33:21</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[HUANG Yan<sup>1</sup>, ZHU Zengyan<sup>1</sup>, MIAO Liyan<sup>2</sup>, ZHONG Wen<sup>1</sup>, ZHANG Xianming<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>HUANG Yan<sup>1</sup>, ZHU Zengyan<sup>1</sup>, MIAO Liyan<sup>2</sup>, ZHONG Wen<sup>1</sup>, ZHANG Xianming<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202509015&flag=1]]></guid><cfi:id>16</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Clinical efficacy of negative pressure wound therapy combined with rhEGF in the treatment of chronic non-healing wounds and its impact on wound healing factors]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202509016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To explore the clinical effect of negative pressure closed drainage (vacuum sealing drainage,VSD) combined with recombinant human epidermal growth factor (rhEGF) in the treatment of chronic refractory wounds and the influence of wound repair factors on patients. <b>Methods</b>  The study selected 80 patients with chronic non-healing wounds admitted to the burn department of our hospital from March 2022 to September 2023. They were randomly divided into a control group and a combination therapy group, with 40 patients in each group. All patients received conventional surgical treatment upon admission.The control group was treated with VSD on the basis of conventional treatment, while the combined treatment group was treated with VSD combined with rhEGF on the basis of conventional treatment. The clinical efficacy of the two groups after 2 weeks of treatment was observed and compared. Observe and compare the clinical efficacy of the two groups after 2 weeks of treatment, the pain score of the numerical rating scale (NRS) before and after treatment, the level of infection control, the positive bacterial culture of the wound surface, the level of wound repair factors, the complete healing time of the wound surface, the length of hospital stay and the hospitalization cost of the two groups, etc.<b>Results</b>  The comparison showed that the total effective rate of treatment in the combination therapy group was significantly higher than that in the control group (<i>P</i><0.05). After 2 weeks of treatment, the NRS pain score, serum CRP, WBC and ESR levels of both groups were significantly decreased compared with those before treatment (<i>P</i><0.05), and the NRS pain score and serum CRP, WBC and ESR levels of the combined treatment group were lower than those of the control group after 2 weeks of treatment (<i>P</i><0.05). The results showed that after 2 weeks of treatment, the positive rate of wound bacteria in both groups was lower than before treatment (<i>P</i><0.05), and the rate of wound bacteria turning negative in the combined treatment group (81.48%) was higher than that in the control group (48.00%) (<i>χ</i><sup>2</sup>=6.429, <i>P</i>=0.011). After 2 weeks of treatment, the levels of wound repair factors PDGF, EGF, VEGF and bFGF in both groups were significantly increased compared with those before treatment (<i>P</i><0.05), the levels of PDGF, EGF, VEGF and bFGF in the combined treatment group were significantly higher than those in the control group after 2 weeks of treatment (<i>P</i><0.05).The comparison showed that the wound healing time and hospital stay in the combined treatment group were shorter than those in the control group (<i>P</i><0.05), and the hospitalization cost was less than that in the control group (<i>P</i><0.05).<b>Conclusion</b>  The combination of VSD and rhEGF in the treatment of chronic non-healing wounds demonstrates significant efficacy, further improving the total effective rate of treatment, alleviating pain, enhancing infection control, promoting the expression of wound healing factors, accelerating healing, shortening hospital stay, and reducing costs. It is an efficient and economical treatment option.]]></description>
<pubDate>2025/10/14 16:33:21</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[FU Xiaoxiao, BIAN Chenghao, WANG Huiying, ZHAO Huanjun]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>FU Xiaoxiao, BIAN Chenghao, WANG Huiying, ZHAO Huanjun</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202509016&flag=1]]></guid><cfi:id>15</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Exploring the value of combining PD-1 inhibitor immunotherapy with Lenvatinib targeted therapy for unresectable hepatocellular carcinoma]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202507015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To investigate the efficacy of PD-1 inhibitor immunotherapy combined with targeted drug lenvatinib in the treatment of unresectable hepatocellular carcinoma (uHCC).<b>Methods</b> Fifty patients with unresectable hepatocellular carcinoma admitted to our hospital and Jinping County People's Hospital from March 1, 2022 to February 28, 2025 were selected as the study subjects. A simple randomized controlled trial was conducted, and 25 patients who received PD-1 inhibitor and Lenvatinib immunotherapy combined with targeted therapy were included in the combination group; 25 patients who received treatment with Lenvatinib alone were included in the control group. Maintain follow-up, evaluate efficacy using mRECIST criteria, and record the occurrence of adverse reactions and survival status.<b>Results</b>  After 12 months of medication, no patients in both groups achieved complete response (CR);The ORR and DCR rates in the combination group were higher than those in the control group (40.00%VS76.00%, 12.00%VS44.00%, <i>P</i><0.05). The median duration of PFS and OS in the combined group was 9.5 months and 18.9 months, respectively, while in the control group it was 5.4 months and 11.2 months, respectively. There was a statistically significant difference in the data comparison between the above indicators (<i>P</i><0.05). In terms of the total incidence of grade 3 and above adverse reactions, the combination group was 28.00%, while the control group was 25.00%. There was no statistically significant difference between the two groups (<i>P</i>>0.05). <b>Conclusion</b>  The combination of PD-1 inhibitor immunotherapy drugs and lenvatinib targeted drugs has shown significant advantages in efficacy and prolonged survival in the treatment of unresectable hepatocellular carcinoma. It can bring better and longer survival expectations to patients without significantly increasing the risk of adverse reactions, and is worth promoting in eligible patients.]]></description>
<pubDate>2025/8/8 8:41:35</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[ZHANG Cuipeng, YANG Yan, OU Beijin, PU Xueping, LIU Shikun, HU Keyu, ZHANG Youmei, LONG Yu]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Cuipeng, YANG Yan, OU Beijin, PU Xueping, LIU Shikun, HU Keyu, ZHANG Youmei, LONG Yu</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202507015&flag=1]]></guid><cfi:id>14</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Investigation of off-label drug use in emergency department of obstetrics and gynecology]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202506016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b> To investigate the application status of off-label drug use in emergency department of obstetrics and gynecology, and to analyze the risk factors of off-label drug use, so as to promote rational drug use to ensure drug safety of special patients.<b>Methods</b> The proportionate stratified random sampling was conducted to select medications in emergency department of obstetrics and gynecology in our hospital in 2022-2023. According to drug instructions, determine whether the medication was off-label. The incidence rates of off-label medications was analyzed between different group and categories of drugs. Meanwhile, the correlation between off-label drug use and whether to be pregnant and drug information (essential drugs, OTC drugs, high-alert drugs and pregnancy termination in early trimester drugs) was analyzed. <b>Results</b> A total of 4 268 prescriptions with 9 299 medications were extracted, including 98 kinds of drugs, the incidence rate of off-label drug use were 28.00% and 20.99%, respectively. Pregnant, essential drugs, prescription, high-alert drugs and pregnancy termination in early trimester drugs had a higher risk of off-label use (<i>P</i><0.05). <b>Conclusion</b> Off-label drug use is widespread in emergency department of obstetrics and gynecology, clinical application needs to strengthen management to ensure the rationality and safety of medication for special populations.]]></description>
<pubDate>2025/7/16 8:54:05</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[ZHAI Xin, LIU Zhenguo, CHANG Ying, ZHAO Kai]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHAI Xin, LIU Zhenguo, CHANG Ying, ZHAO Kai</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202506016&flag=1]]></guid><cfi:id>13</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Efficacy and safety of Donepezil Hydrochloride Tablets in the treatment of dementia: a network Meta-analysis]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202506017&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To assess the effectiveness and safety of both domestic and international donepezil in treating dementia via a network meta-analysis, offering a more dependable guide for clinical medication choices in managing dementia.<b>Methods</b>  An extensive search was performed across PubMed, Embase, Cochrane Library, CNKI, WanFang Data, and CBM databases to gather randomized controlled trials (RCTs) that evaluated domestic versus imported donepezil for dementia treatment, covering the period from January 1996 to January 2024.Two investigators separately reviewed the literature, collected data, and evaluated the potential for bias in the studies considered. A network meta-analysis was conducted utilizing Stata 17.0 software.<b>Results</b>  34 studies with a combined total of 3,43 participants were included. The outcomes of the network meta-analysis indicated that domestic donepezil (Surface Under the Cumulative Ranking curve, SUCRA =0.983) was more effective in treating dementia than imported donepezil (SUCRA =0.748). However, imported donepezil (SUCRA =0.855) showed better MMSE scores than domestic donepezil (SUCRA =0.640). The incidence of adverse reactions was slightly lower with imported donepezil (SUCRA =0.537) compared to domestic donepezil (SUCRA =0.499).<b>Conclusion</b>  Current evidence suggests that the overall efficacy and safety of imported and domestic donepezil are similar.Nonetheless, because the quantity and caliber of the studies included are restricted, additional large-scale, high-quality research is necessary to confirm these results.]]></description>
<pubDate>2025/7/16 8:54:05</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[GUAN Yuyao, WU Yubao, JI Jingchao, HAN Tongzhou, ZHENG Lei]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>GUAN Yuyao, WU Yubao, JI Jingchao, HAN Tongzhou, ZHENG Lei</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202506017&flag=1]]></guid><cfi:id>12</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Analysis of factors affecting hospital acquired infections andprognosis of carbapenem resistant <i>Pseudomonas aeruginosa</i>]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202503012&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To analyze the distribution characteristics, nosocomial infection and prognostic factors of carbapenem resistant <i>Pseudomonas aeruginosa</i> (CRPA) infection. <b>Methods</b>  A retrospective study was conducted to collect clinical data of patients first diagnosed with CRPA and carbapenem-sensitive <i>Pseudomonas aeruginosa</i> (CSPA) infection from 2021 to 2023 in the First Affiliated Hospital of Hebei North University, with CRPA as the case group (156 cases) and CSPA as the control group (156 cases). Patients with CRPA infection were divided into death group (37 cases) and survival group (119 cases) according to whether they died during hospitalization. SPSS 27.0 was used to analyze nosocomial infection of CRPA and prognostic factors, and to compare whether there were differences in in-hospital mortality and 30-day mortality between CRPA and CSPA.<b>Results</b> The most common type of infection in the CRPA and CSPA groups was respiratory infection, with CRPA concentrated in the intensive care unit (ICU) at 59.0% and CSPA concentrated in general internal medicine at 32.1%. The results of multivariate logistic regression analysis showed: Treatment history in two or more departments (OR=0.274,95%CI: 0.099-0.757,<i>P</i><0.05), use of β-lactamase inhibitors (OR=3.065,95%CI: 1.734-5.420,<i>P</i><0.01) and carbapenem antibiotics (OR=2.329,95%CI:1.217~4.456,<i>P</i><0.05) were the independent influencing factors of CRPA nosocomial infection. High serum creatinine [94.20 (63.50,282.40);OR=1.005,95%CI: 1.001-1.008,<i>P</i><0.01] was an independent factor for poor prognosis of CRPA nosocomial infection. In-hospital mortality and 30-day mortality were higher in the CRPA group than in the CSPA group (<i>P</i><0.01). Kaplan-Meier curve showed that the 30-day survival time in the CRPA group was shorter than that in the CSPA group (<i>P</i><0.01).<b>Conclusion</b> CRPA infection situation is serious, the most common type of infection is respiratory tract infection, and concentrated in ICU. Patients with a history of treatment in more than two departments, beta-lactamase inhibitors and carbapenems were more likely to be infected with CRPA, and higher serum creatinine was an independent factor for poor prognosis. In-hospital mortality and 30-day mortality were higher in the CRPA group than in the CSPA group, and 30-day survival was shorter in the CRPA group than in the CSPA group.]]></description>
<pubDate>2025/4/7 9:36:36</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[HAN Ping<sup>1</sup>, ZHANG Wei<sup>2</sup>, LEI Chunmei<sup>2</sup>, WANG Bu<sup>3</sup>, ZHAO Jianqing<sup>3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>HAN Ping<sup>1</sup>, ZHANG Wei<sup>2</sup>, LEI Chunmei<sup>2</sup>, WANG Bu<sup>3</sup>, ZHAO Jianqing<sup>3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202503012&flag=1]]></guid><cfi:id>11</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Real-world study of first-line chemotherapy in combination with bevacizumab for advanced non-small cell lung cancer]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202503013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To compare the safety and efficacy of domestic biological analogue Bevacizumab Injection (Ankeda) and the original research drug Bevacizumab Injection (Avastin) in the treatment of advanced non-small cell lung cancer patients.<b>Methods</b>  Total of 66 patients with advanced non-small cell lung cancer admitted to Weihai Municipal Hospital from January 2020 to December 2021 were selected, of which 28 patients were treated with the chemotherapy regimen "pemetrexed + platinum + bevacizumab (Avastin)" as the control group and the chemotherapy regimen was "pemetrexed+platinum+bevacizumab (Ankeda)" as the experimental group, with a total of 38 cases. The objective response rate (ORR) at week 12 was used as the primary endpoint, while objective response rates (ORR) at week 18, 24, duration of response (DOR), disease control rate (DCR), progression free survival (PFS), overall survival (OS), and safety assessment were used as secondary endpoints.<b>Results</b>  The median PFS was 16 weeks and median OS was 35 weeks in 66 patients; 28 patients in the Avastin group, of whom 22 had PFS, median PFS of 15 weeks, and median OS of 42 weeks; And 38 patients in the Ankeda group, of whom 15 had PFS, median PFS of 16 weeks, and median OS of 33 weeks. In the survival function of 66 patients, there was no significant difference in the effect of time to survival between the Ankeda and Avastin groups (<i>P</i>>0.05), and no significant association was found between sex, age, smoking history, tumor stage and metastatic site on PFS and OS in the COX one-way regression analysis (<i>P</i>>0.05). The main endpoint of the 12th week ORR study was 32.14% in the Avastin group and 65.79% in the Ankeda group（<i>P</i>=0.007）; The ORR of the secondary study endpoint at week 18 was 21.43% in the Avastin group and 44.74% in the Ankeda group (<i>P</i> =0.05); The ORR for the 24th week was 14.29% in the Avastin group and 23.68% in the Ankeda group(<i>P</i>=0.343). The patients in the Avastin group had an ORR of 3.57% and a DCR of 14.29% at the end of follow-up。And at the end of follow-up, patients in the Ankeda group had an ORR of 15.79% and a DCR of 5.26%, with no statistically significant difference between the two groups (<i>P</i>>0.05). Among the 66 patients, there were 24 cases of adverse reactions. And there was no statistically significant difference between the occurrence of adverse reactions in the Ankeda and Avastin groups. <b>Conclusion</b>  Bevacizumab Injection (Ankeda) has excellent clinical efficacy and survival advantages in the treatment of advanced non-small cell lung cancer with controlled and tolerable adverse effects.There is no statistically significant difference in clinical efficacy and safety compared to the reference drug bevaczumab injection (Avastin).]]></description>
<pubDate>2025/4/7 9:36:36</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[WANG Bing<sup>1</sup>, WANG Yuting<sup>1</sup>, LI Jinfeng<sup>1</sup>, LIU Fei<sup>2</sup>, WANG Ying<sup>1</sup>, CHEN Weina<sup>1</sup>, DONG Haozhen<sup>1</sup>, ZHANG Yuan<sup>1</sup>, SUN Tong<sup>3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WANG Bing<sup>1</sup>, WANG Yuting<sup>1</sup>, LI Jinfeng<sup>1</sup>, LIU Fei<sup>2</sup>, WANG Ying<sup>1</sup>, CHEN Weina<sup>1</sup>, DONG Haozhen<sup>1</sup>, ZHANG Yuan<sup>1</sup>, SUN Tong<sup>3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202503013&flag=1]]></guid><cfi:id>10</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Comparison of efficacy and safety of Pirarubicin and Epirubicin in neoadjuvant chemotherapy of triple negative breast cancer]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202501014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To compare the efficacy and safety of Pirarubicin and Epirubicin in neoadjuvant chemotherapy for triple-negative breast cancer.<b>Methods</b>  A retrospective analysis was conducted on the clinical data of triple-negative breast cancer patients who received complete neoadjuvant chemotherapy followed by surgery at Jiangsu Provincial Hospital of Traditional Chinese Medicine from January 2019 to September 2023. Patients were divided into two groups based on the drug used: the Pirarubicin group (<i>n</i>=91) and the Epirubicin group (<i>n</i>=95). The pathological complete response (pCR) rate, objective remission rate (ORR), Ki-67 index reduction, Miller-Payne grading, and incidence of adverse events were compared between the two groups. <b>Results</b>  The overall ORR in the Pirarubicin group was significantly higher than that in the Epirubicin group (89.0% vs 77.9%, <i>P</i>=0.042). In the subgroups with I-II stage tumors (91.4% vs 78.5%, <i>P</i>=0.048), tumors >2 cm (92.5% vs 78.5%, <i>P</i>=0.012), and patients with lymph node metastasis (90.0% vs 76.3%, <i>P</i>=0.028), the ORR was also higher in the Pirarubicin group, respectively, with statistically significant differences. Additionally, the incidence of bone marrow suppression was higher in the Pirarubicin group (27.5% vs 12.6%,<i>P</i>=0.011), while gastrointestinal reactions (16.5% vs 29.5%, <i>P</i>=0.036) and hair loss (19.8% vs 32.6%, <i>P</i>=0.047) were lower compared to the Epirubicin group.<b>Conclusion</b>  Pirarubicin can improve the ORR in neoadjuvant chemotherapy for triple-negative breast cancer compared to Epirubicin, and it reduces the incidence of gastrointestinal reactions and hair loss. However, it is associated with a higher rate of bone marrow suppression.]]></description>
<pubDate>2025/2/13 15:37:19</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[YIN Chenyan<sup>1</sup>, TANG Jie<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>YIN Chenyan<sup>1</sup>, TANG Jie<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202501014&flag=1]]></guid><cfi:id>9</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Establishing evaluation standards for the preventive use of antimicrobial drugs in class I incision orthopedic surgery and evaluating rationality and cost-effectiveness before and after volume-based procurement]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202501015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To establish evaluation criteria for the prophylactic use of antimicrobial drugs in Class I incision orthopedic surgeries and to assess the impact of volume-based procurement on the rationality and cost-effectiveness of such surgeries.<b>Methods</b>  Evaluation criteria were developed based on the Guidelines for Clinical Use of Antimicrobial Agents (2015 Edition), drug information leaflets, clinical guidelines, and expert consensus. Using the implementation of volume-based procurement of antimicrobials in October 2021 as a reference point, data from 270 archived cases of Class I incision orthopedic surgeries at a tertiary hospital in Anhui Province, spanning May 2019 to February 2024, were analyzed. These cases included 135 surgeries each from periods before and after the implementation of the procurement policy, and data were analyzed using the weighted TOPSIS (Technique for Order Preference by Similarity to Ideal Solution) method.<b>Results</b>  The Indicators with the highest weighting were appropriateness of indication, drug selection, timing of administration (preoperative, intraoperative, postoperative), and cost-effectiveness of selected drugs, with respective weights of 0.181, 0.170, 0.144, 0.076, 0.072, and 0.066. Post-policy implementation, the average cost of antimicrobials per case decreased by 77.67%. Rational drug use increased significantly from 70.37% (<i>C</i><sub>i</sub>≥0.6) before to 84.45% (<i>C</i><sub>i</sub>≥0.6) after volume-based procurement, with statistical significance (P<0.05).<b>Conclusion</b>  The weighted TOPSIS method is a feasible approach for evaluating the rationality and cost-effectiveness of prophylactic antimicrobial use in Class I incision orthopedic surgeries. Volume-based procurement not only reduces patient medication costs but also indirectly improves the rationality of drug use. Hospitals should strengthen oversight of irrational drug use to promote rational clinical prescribing practices.]]></description>
<pubDate>2025/2/13 15:37:19</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[WANG Jiangtao<sup>1</sup>, YANG Liyue<sup>1</sup>, SONG Junxing<sup>1</sup>, SUN Qingsong<sup>1</sup>, YE Ming<sup>1</sup>, FANG Jia<sup>1</sup>, HOU Ping<sup>2</sup>, DING Boping<sup>3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WANG Jiangtao<sup>1</sup>, YANG Liyue<sup>1</sup>, SONG Junxing<sup>1</sup>, SUN Qingsong<sup>1</sup>, YE Ming<sup>1</sup>, FANG Jia<sup>1</sup>, HOU Ping<sup>2</sup>, DING Boping<sup>3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202501015&flag=1]]></guid><cfi:id>8</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Clinical curative effect of continuous epidural analgesia combined with Shufeng Jiedu Decoction in herpes zoster neuralgia]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202609016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To explore clinical curative effect of continuous epidural analgesia (CEA) combined with Shufeng Jiedu Decoction in patients with herpes zoster (HZ) neuralgia.<b>Methods</b>  According to random number table method, 186 patients with HZ neuralgia were prospectively enrolled and divided into group A (CEA+Shufeng Jiedu Decoction), group B (CEA) and group C (Shufeng Jiedu Decoction, <i>n</i>=62), 62 cases/group. All were treated for 4 weeks and followed up for 3 months. Curative effect, immune function, pain mediators and inflammatory factors [Neuropeptide substance P (SP), β-endorphin (β-EP), neurokinin (NK)-1, interferon (IFN) -γ, interleukin-10(IL-10), IL-2], pain-related indexes, safety and incidence of postherpetic neuralgia were compared among the three groups.<b>Results</b>  After 4 weeks of treatment, curative effect of group A was better than that of groups B and C (<i>P</i>＜0.05). Compared with groups B and C, levels of CD3<sup>+</sup>, CD4<sup>+</sup>, CD4<sup>+</sup>/CD8<sup>+</sup>, β-EP, IFN-γ and IL-2 were higher, while levels of CD8<sup>+</sup>, SP, NK-1 and IL-10 were lower in group A (<i>P</i>＜0.05). Compared with groups B and C, scores of visual analogue scale (VAS) at different time points, frequency of 24 h breakthrough pain, remedial analgesia rate and score of sleep quality were lower, while analgesia satisfaction was higher in group A (<i>P</i>＜0.05). There was no significant difference in adverse reactions among the three groups (<i>P</i>＞0.05). After 3 months of follow-up, incidence of postherpetic neuralgia in group A was lower than that in groups B and C (<i>P</i>＜0.05). <b>Conclusion</b>  CEA combined with Shufeng Jiedu Decoction can effectively improve immune status, regulate pain and inflammatory factors, relieve pain and reduce the risk of postherpetic neuralgia in patients with HZ neuralgia, which has good safety.]]></description>
<pubDate>2026/10/19 8:53:41</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[WANG Kaiyun<sup>1</sup>, PENG Xiaoxing<sup>1</sup>, REN Dequan<sup>1</sup>, HE Yueyi<sup>1</sup>, HUANG Hua<sup>1</sup>, HAN Pengfei<sup>1</sup>, DENG Duping<sup>1</sup>, SU Long<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WANG Kaiyun<sup>1</sup>, PENG Xiaoxing<sup>1</sup>, REN Dequan<sup>1</sup>, HE Yueyi<sup>1</sup>, HUANG Hua<sup>1</sup>, HAN Pengfei<sup>1</sup>, DENG Duping<sup>1</sup>, SU Long<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202609016&flag=1]]></guid><cfi:id>7</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Analysis of off-label drug use in hospitalized children with macrolide-resistant mycoplasma pneumoniae]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202609017&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To retrospectively analyze off-label drug use in pediatric inpatients with macrolide-resistant <i>Mycoplasma pneumoniae</i>(MRMP) infection, aiming to provide a reference for managing off-label drug use in pediatric patients. <b>Methods<b/>  A total of 164 pediatric patients admitted to the Pediatrics Department of the Women and Children＇s Hospital of a tertiary general hospital in Shaanxi Province from January 2023 to December 2024 were enrolled. Off-label drug use for macrolide-resistant <i>Mycoplasma pneumoniae</i> infection was collected and statistically analyzed. <b>Results</b>  The 164 hospitalized patients comprised patients aged from 7 months to 15 years, with the highest prevalence among preschool and school-aged children. Off-label agents included levofloxacin, doxycycline, interferon, and budesonide. The primary categories of off-label drug use were: unapproved indications, unapproved patient populations, and unapproved routes of administration, with off-label drug use unapproved patient populations being the most prevalent. <b>Conclusion</b>  Off-label drug use for macrolide-resistant <i>Mycoplasma pneumoniae</i> infections is prevalent. Certain off-label drug uses carry safety and legal risks, necessitating urgent regulation of such practices. Multidisciplinary collaboration is recommended to mitigate medication risks. Establishing institution-wide systems for regulating off-label drug use can reduce medical disputes and promote rational drug use.]]></description>
<pubDate>2026/10/19 8:53:41</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[ZHAO Xu<sup>1</sup>, TIAN Tian<sup>1</sup>, GAO Lele<sup>2</sup>, HONG Shuxia<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHAO Xu<sup>1</sup>, TIAN Tian<sup>1</sup>, GAO Lele<sup>2</sup>, HONG Shuxia<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202609017&flag=1]]></guid><cfi:id>6</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Construction of a three-tier prevention system for <i>Helicobacter pylori</i> infection]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202606013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<i>Helicobacter pylori</i> (<i>H. pylori</i>) infection is the most significant modifiable risk factor for gastric cancer. However, escalating antibiotic resistance, uneven healthcare resource distribution, and post-eradication recurrence render antibiotic-centered strategies alone insufficient. Drawing on gastric cancer prevention frameworks and integrating the traditional Chinese medicine concept of “preventive treatment of disease” (Zhi Wei Bing), this paper proposes a three-tier prevention system for whole-process management of H. pylori infection. Guided by the One Health approach, primary prevention focuses on blocking transmission while designating the oral cavity as an intervention “sentinel”. Secondary prevention stratifies infected individuals into Category A (mandatory eradication) and Category B (“four no-kill” scenarios: unsuitable, deferred, resistant, and unwilling), shifting from eradication-centered to health-centered management. Tertiary prevention emphasizes post-eradication holistic recovery with dynamic re-stratification — recrudescence routes back to secondary prevention, while stable eradication returns to primary prevention. This system complements existing gastric cancer prevention as a strategic depth extension, providing a scientific, scalable framework for <i>H. pylori</i> prevention and control.]]></description>
<pubDate>2026/7/15 16:48:29</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[YAO Meicun]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>YAO Meicun</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202606013&flag=1]]></guid><cfi:id>5</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Real world study and comprehensive clinical evaluation of bevacizumab second-line treatment for non squamous non-small cell lung cancer]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202606014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To compare the efficacy and safety of the original bevacizumab (Avastin) and its biosimilar (Ankeda) in the second-line treatment of non-squamous non-small cell lung cancer (NSCLC) based on real-world clinical data, and to provide evidence for clinical decision-making.<b>Methods</b>  The clinical data of 82 patients with non-squamous non-small cell lung cancer who received bevacizumab injection (Avastin) or (Ankeda) in Weihai Municipal Hospital Affiliated to Shandong University from January 1, 2019 to January 31, 2021 were retrospectively analyzed. Kaplan-Meier method was used for univariate survival analysis, <i>χ</i><sup>2</sup> test was used to compare the clinical and treatment characteristics, short-term efficacy and adverse reactions between the two groups, Log-rank test was used to compare the differences between the two groups, and Cox regression method was used for multivariate prognostic analysis.<b>Results</b>  The 2-year OS and PFS were 63.3% and 60.0%, respectively. In the Avastin group: ORR was 33.3%, DCR was 87.5%; In the Anketa group, ORR was 27.6% and DCR was 96.6%. There was no significant difference in DCR (disease control rate) and ORR (objective response rate) between the two groups (<i>P</i>=0.147*; <i>χ</i><sup>2</sup>=0.271, <i>P</i>=0.603). There were no significant differences in PFS (<i>χ</i><sup>2</sup>=0.022, <i>P</i>=0.883) and OS (<i>χ</i><sup>2</sup>=0.041, <i>P</i>=0.840) between Avastin group and Anketa group. The clinical and treatment characteristics of the two groups did not show that the Avastin group was superior to the Anketa group. There was no significant difference in adverse reactions between the two groups (<i>P</i>>0.05). Cox multivariate analysis showed that no brain metastasis was an independent protective factor for OS (HR=0.446, <i>P</i>=0.042).<b>Conclusion</b>  There were no significant differences in DCR, ORR, PFS and OS between the two groups. There was no significant difference in adverse reactions between the two groups.No brain metastasis was an independent protective factor for OS.]]></description>
<pubDate>2026/7/15 16:48:29</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[WANG Bing<sup>1</sup>, WANG Yuting<sup>1</sup>, HUANG Huixuan<sup>2</sup>, TANG Huaying<sup>1</sup>, CUI Yingjie<sup>1</sup>, LI Yuhui<sup>1</sup>, LENG Jiawei<sup>3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WANG Bing<sup>1</sup>, WANG Yuting<sup>1</sup>, HUANG Huixuan<sup>2</sup>, TANG Huaying<sup>1</sup>, CUI Yingjie<sup>1</sup>, LI Yuhui<sup>1</sup>, LENG Jiawei<sup>3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202606014&flag=1]]></guid><cfi:id>4</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Meta-analysis of the efficacy and safety of NOACs versus Warfarin in the treatment of cerebral venous sinus thrombosis]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202605015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b> To systematically compare the efficacy and safety of non vitamin K antagonist (NOACs) and warfarin in the treatment of cerebral venous sinus thrombosis.<b>Methods</b> Randomized controlled trials (RCTs) and prospective cohort studies on the treatment of cerebral venous sinus thrombosis with NOACs and warfarin published at home and abroad were retrieved by computer. After the data were extracted, Review Manager 5.4 software was used for data processing.<b>Results</b>  According to the results of Meta-analysis, there were no significant statistical differences in the recurrence rate of venous thrombosis, partial recanalization rate of venous thrombosis, complete recanalization rate of venous thrombosis, mortality rate, incidence of major bleeding and incidence of intracranial hemorrhage between patients with cerebral venous sinus thrombosis treated with NOACs and those treated with warfarin for anticoagulation, but the good clinical outcomes of the NOACs group were better than those of the warfarin group.<b>Conclusion</b>  The efficacy and safety of NOACs are comparable to those of warfarin in the treatment of patients with cerebral venous sinus thrombosis (CVST).]]></description>
<pubDate>2026/6/15 15:35:39</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[CHANG Yuanyuan<sup>1</sup>, OU Yiyang<sup>2</sup>, YE Huirong<sup>1</sup>, WEN Enhui<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>CHANG Yuanyuan<sup>1</sup>, OU Yiyang<sup>2</sup>, YE Huirong<sup>1</sup>, WEN Enhui<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202605015&flag=1]]></guid><cfi:id>3</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Comprehensive clinical evaluation of a Bevacizumab biosimilar and the originator drug for advanced non-small cell lung cancer]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202601014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To conduct a comprehensive clinical evaluation of the bevacizumab biosimilar (Ankeda) and the originator drug (Avastin) for the treatment of advanced non-small cell lung cancer (NSCLC).<b>Methods</b>  According to the drug instructions, evidence-based guidelines and clinical research literature, Ankeda and Avastin were evaluated across six dimensions based on real-world data.<b>Results</b>  In terms of efficacy and safety, published studies demonstrated that Ankeda and Avastin were comparable. There were no significant differences in ORR (44.3% VS 39.2%), DCR (72.6% VS 82.1%), or the incidence of adverse reactions (45.3% VS 51.8%) between the two patient groups. Compared to Avastin, the Ankeda group showed advantages in economy, with a lower cost-effectiveness ratio (2 294.4 VS 3 125.0), a lower unit dose price (1 126 CNY VS 1 500 CNY), and a lower proportion of annual drug cost to residents' disposable income (57.80% VS 96.25%). The allocation and configuration of Ankeda was also found to be superior to that of Avastin in public medical institutions. In terms of suitability, Ankeda was highly consistent with Avastin in both critical quality attributes and clinical use. Furthermore, Ankeda has achieved significant optimization and innovation in its production process, and together with Avastin, has promoted the widespread clinical adoption and application of bevacizumab in China.<b>Conclusion</b>  Compared to Avastin, Ankeda shows no significant differences in efficacy, safety , suitability for the treatment of advanced NSCLC, while demonstrating significant advantages in economy and accessibility.]]></description>
<pubDate>2026/2/24 15:15:08</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[LIU Yanxin, LYU Xiaolin, YU Chen, LIU Anchang]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LIU Yanxin, LYU Xiaolin, YU Chen, LIU Anchang</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202601014&flag=1]]></guid><cfi:id>2</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Distribution and drug resistance of pathogenic microorganisms in dermatology patients
-taking Baoding No.1 Central Hospital as an example]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202601015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To analyze the distribution and antimicrobial resistance characteristics of pathogens in dermatology patients with skin and mucosal infections at Baoding First Central Hospital, in order to provide guidance for the diagnosis and treatment of clinical infections.<b>Methods</b>  Samples from 268 dermatology patients with infections between February 2021 and April 2023 were cultured and identified to analyze the distribution characteristics of pathogens and their resistance to antimicrobial agents. Traditional culture methods and Clinical and Laboratory Standards Institute (CLSI)-recommended antimicrobial susceptibility testing standards were used for detection and evaluation.<b>Results</b>  Among the 268 patients, Gram-positive bacteria were the main pathogens, with Staphylococcus aureus having the highest detection rate (25.4%). Among gram-negative bacteria, Pseudomonas aeruginosa had the highest detection rate (14.9%). The proportion of fungal infections was low, at only 1.1%. Antimicrobial resistance analysis showed that Staphylococcus aureus had a resistance rate of 92.6% to penicillin G, and Pseudomonas aeruginosa had a resistance rate of 47.5% to ciprofloxacin.<b>Conclusion</b>  The types and resistance patterns of pathogens in dermatology infections are diverse, and individualized treatment should be conducted based on the specific pathogen type and antimicrobial susceptibility results. Strengthening the rational use of antibiotics and infection control measures is crucial to reducing the emergence and spread of resistant bacteria. Future research should focus on the application of novel molecular diagnostic techniques and multi-center, large-sample studies to better guide the prevention and treatment of skin infections.]]></description>
<pubDate>2026/2/24 15:15:09</pubDate>
<category><![CDATA[Clinical Pharmacy]]></category>
<author><![CDATA[LI Qian<sup>1</sup>, MENG Qingcai<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LI Qian<sup>1</sup>, MENG Qingcai<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202601015&flag=1]]></guid><cfi:id>1</cfi:id><cfi:read>true</cfi:read></item>
</channel>
</rss>